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9Outline and objectives  
of the thesis
— CHAPTER 1
Sub-Saharan Africa (SSA) has the highest rates of neonatal sepsis mortality 
worldwide, and Group B Streptococcus (GBS) and Escherichia coli are considered 
the main pathogens. These bacteria infect the neonate ascending from the va-
gina. Chapters 2 to 5 provide background information on (GBS) neonatal sep-
sis. Chapters 5 and 6 introduce the female reproductive tract and the vaginal 
microbiota.
 Objective 1 In SSA, epidemiological data on vaginal carriage of Group B Strep-
tococcus (GBS) and Escherichia coli, the most important risk factors of neonatal 
sepsis, are very limited, although they are necessary to design and implement 
neonatal	sepsis	prevention	strategies.	Therefore,	the	first	objective	of	this	the-
sis was to assess the prevalence of vaginal GBS and E. coli in	different	popula-
tions from SSA. This objective is addressed in Chapter 7.
 Objective 2 Prevention measures to reduce neonatal GBS sepsis are based on 
two main strategies: intrapartum antibiotic prophylaxis (IAP) and vaccination. 
Most GBS vaccines under development aim at eliciting protective antibodies 
against capsular polysaccharides (CPS), of which ten antigenically distinct CPS 
are	known.	Vaccines	under	development	are	serotype-specific	but	might	not	be	
effective	in	SSA	populations	because	of	different	serotype	distribution.	Only	a	
few studies have documented on GBS serotype distributions of vaginal isolates 
in SSA. Therefore, the second objective of this thesis was to assess the GBS sero-
type	distribution	in	different	populations	of	SSA.	This	objective	is	addressed	in	
Chapter 7.
 Objective 3 Vaccines are still under development and both IAP and vaccina-
tion	strategies	have	their	drawbacks.	IAP	is	not	effective	against	E. coli EOS and 
other adverse perinatal outcomes related to GBS. Furthermore, national guide-
lines	for	IAP	are	lacking	in	SSA	countries	and	are	difficult	to	implement.	There-
fore,	the	third	objective	of	this	thesis	was	to	identify	modifiable	risk	factors	for	
CH1 Outline and objectives 10
vaginal GBS and E. coli carriage that can be considered as prevention measures 
in public health recommendations to reduce neonatal sepsis. This objective is 
addressed in Chapter 7 and 8.
 Objective 4	 SSA	remains	the	most	heavily	HIV-affected	region	with	67%	of	
the global burden. HIV infection in women has been associated with increased 
rates of genital tract infections. Therefore, our fourth objective was to clarify to 
which extent HIV infection in women is associated with rectovaginal GBS. This 
objective is addressed in Chapter 8.
 Objective 5 Infants born to HIV-infected mothers have increased rates of in-
fectious morbidity and mortality compared to non-exposed infants, even if they 
remain	HIV-uninfected.	Since	the	first	study	reporting	an	increased	risk	of	GBS	
neonatal sepsis in HIV-exposed neonates, evidence for this association has 
been	accumulating.	Therefore,	the	fifth	objective	of	this	thesis	was	to	assess	to	
which extent neonates born to HIV-infected mothers were at increased risk for 
GBS neonatal disease by means of systematic review and meta-analysis. This 
objective is addressed in Chapter 8.
 Objective 6 Most current GBS vaccines aim to protect the fetus or neonate 
against neonatal GBS disease by immunoglobuline G (IgG) transferred transpla-
centally from maternal serum. However, fetal IgG concentrations increase with 
gestational age and might not be high enough to protect premature newborns, 
at	high	risk	for	EOS.	Vaginal	mucosal	immunity	to	GBS	is	an	important	first-line	
defense against GBS EOS and some GBS-related adverse perinatal outcomes, as 
vaginal	colonization	is	the	first	step	in	pathogenesis.	Therefore,	an	optimal	vac-
cine should also induce vaginal mucosal immunity. However, the human vagi-
nal mucosal immune response to GBS colonization of the vaginal tract remains 
to be elucidated. Therefore, our sixth objective was to characterize the vaginal 
mucosal cytokine pattern associated with vaginal GBS colonization in popula-
tions at the highest need for better prevention measures against neonatal GBS 
disease. This objective is addressed in Chapter 9.
Chapter	10	summarizes	the	objectives	and	main	findings	of	this	thesis.
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Neonatal sepsis 
— CHAPTER 2 
2.4 Introduction
The	incidence	of	overall	infection	is	the	highest	in	the	first	four	weeks	of	life	
[Isaacs et al.,1991]. The WHO estimates that every year four million neonatal 
deaths	occur,	of	which	three-quarters	take	place	in	the	first	week	of	life	[Lawn	
et al., 2005]. Although more than 99% of these deaths arise in low- and mid-
dle-income countries, most research focuses on the 1% deaths in high-income 
countries [Lawn et al., 2005]. Countries with the highest absolute numbers of 
neonatal deaths are mainly in South Asia, because of the large populations in 
this region, but the highest rates of neonatal mortality are found in sub-Saha-
ran Africa.
The direct causes of these neonatal deaths are asphyxia (23%), preterm 
birth (28%) and severe infections (36%), including neonatal sepsis (26%), tet-
anus (7%) and diarrhoea (3%) (Figure 1).
FIGURE 1 Direct causes of neonatal deaths.  
 Adapted from [Lawn, et al. 2005].
Neonational 
sepsis
26%
7%
7%
3%
7%
23%
27%
Tetanus
Diarrhoea Preterm birth
Asphyxia
Other Congenital
13
2.5 Pathophysiology of neonatal sepsis
Neonatal sepsis (neonatal septicemia) is a clinical syndrome caused by bacte-
ria accessing the blood circulation (bacteremia), leading to systemic signs and 
symptoms	of	infection	without	specific	localization	(sepsis)	or	with	a	predomi-
nant manifestation in the lungs (pneumonia) or the meninges (meningitis).
Neonatal sepsis has been categoriszed in early-onset sepsis (EOS) and 
late-onset	sepsis	(LOS),	with	EOS	occurring	in	the	first	seven	days	of	life	[Muk-
hopadhyay et al., 2012]. Among very-low birth weight infants (VLBW, birth 
weight	<	1500	grams),	the	cut-off	for	EOS	is	restricted	to	infection	occurring	in	
the	first	72	hours	of	life	[Mukhopadhyay et al., 2012].
EOS is typically caused by bacterial pathogens transmitted vertically from 
mother to infant before or during childbirth (vertical transmission), while in 
LOS, bacterial pathogens are acquired from the community or nosocomially 
(horizontal transmisison) or vertically [Nizet et al., 2011]. 
In EOS, the usual clinical presentation is pneumonia, and mortality rates vary 
from 3% to as high as 50% [Nizet et al., 2011]. In LOS, meningitis is the most 
frequent clinical presentation and the mortality rate is usually lower, varying 
from 2% to 40% [Nizet et al., 2011].
2.6 Etiology of neonatal sepsis
 Early-onset sepsis The spectrum of bacterial pathogens causing EOS is a 
chan ging landscape. In the 1970s, Streptococcus agalactiae (Group B Strepto-
coccus, GBS) emerged in the US as an important cause of EOS [Stoll et al., 2011] 
and has since then been considered a leading cause of EOS. The organisms most 
frequently involved in EOS of term and preterm infants are GBS and Escherichia 
coli, accounting for 70% of infections together [Simonsen et al., 2014]. 
Other pathogens to consider are other streptococci (most commonly viri-
dans group streptococci), Staphylococcus aureus, Enterococcus spp., Gram-neg-
ative bacilli such as Enterobacter spp., Haemophilus influenzae and Listeria 
monocytogenes [Simonsen et al., 2014]. 
Although intrapartum chemoprophylaxis has been shown to reduce GBS 
EOS in high-income countries [Figure 2] (see 3.2), in these populations, GBS 
remains the most frequent pathogen in term infants, and E. coli the most sig-
nificant	pathogen	in	preterm	infants	[Stoll et al., 2011; Simonsen et al., 2014]. 
Data on causative agents of EOS in low-income countries, especially SSA, are 
scarce. However, a recent study of the WHO documented that also in SSA, GBS 
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and E.  coli were the most common Gram-positive and Gram-negative bacteria 
isolated [Seale et al., 2009].
 Late-onset sepsis LOS can be divided in two distinct entities: disease occur-
ring in the otherwise healthy term infants in the community, and disease af-
fecting premature infants in the neonatal intensive care unit, often referred to 
as hospital-acquired sepsis, as the risk factors for LOS in these neonates are re-
lated to the necessities of their care such as the presence of catheters [Puopo-
lo et al., 2008]. In otherwise healthy term and near-term infants, LOS is largely 
caused by GBS and Gram-negatives such as E. coli and Klebsiella spp. [Puopolo 
et al., 2008]. In premature infants, coagulase-negative staphylococci (CoNS) are 
the predominant pathogens of LOS [Puopolo et al., 2008]. In high-income coun-
tries and middle- and low-income countries, studies attribute 53–78% and 36–
47% of all LOS cases to CoNS, respectively [Dong et al., 2015]. Candida spp. are 
increasingly important causes of LOS, occurring in 12 to 18% of extremely-low 
birth weight infants (birth weight < 1000 grams) [Puopolo et al., 2008; Dong et 
al., 2015].
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Neonatal GBS sepsis
— CHAPTER 3 
3.1 Introduction
Streptococcus agalactiae (Group B Streptococcus, GBS) is a non-motile, faculta-
tive anaerobic, Gram-positive coccus that forms small, grey-white colonies on 
solid medium and diplococci or chains in broth. The gastrointestinal tract is 
the natural reservoir for GBS and is likely the source for vaginal colonization 
[Schuchat et al., 1999; El Aila et al., 2011]. Among pregnant women, GBS car-
riage rate in the vagina and rectum ranges from 10% to 40% [Gray et al., 2007]. 
Colonization can be transient, intermittent or persistent and is commonly 
a symptomatic [Schuchat et al., 1999; Verani et al., 2010].
3.2 Prevention strategies for GBS EOS and/or LOS
To	prevent	GBS	disease	in	infants	and	pregnant	women,	huge	efforts	have	been	
made since the late 1980s. These are based on two strategies, intrapartum anti-
biotic prophylaxis (IAP) and vaccination [Melin et al., 2013]. 
 Intrapartum antibiotic prophylaxis IAP, usually with intravenous penicillin G 
or ampicillin [Verani et al., 2010], aims at reducing maternal GBS colonization 
and subsequent transmission to neonates. Several clinical trials have demon-
strated	the	efficacy	of	intravenous	or	intramuscular	injection	of	antimicrobioal	
agents after the onset of labor or rupture of the membranes in reducing neona-
tal GBS colonization [Schuchat et al., 1999]. In populations from high-income 
countries, IAP has been shown to reduce the incidence of EOS from 1.7 in 1993 
to 0.6 per 1000 live births in 1998 [Schrag et al., 2000].
There are two strategies to identify eligible women for IAP: a screening- 
based strategy and a risk-based strategy. According to a screening-based ap-
proach, all women are screened for the rectovaginal carriage of GBS during late 
pregnancy,	and	 IAP	 is	offered	to	carriers	 [Schrag et al., 2000]. According to a 
risk-based approach, women who present at the time of labor with risk factors 
such as prolonged ruptures of the membranes, prematurity or maternal fever 
are	offered	IAP	[Schrag et al., 2000].
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Most high-income countries have guidelines for the prevention of GBS perina-
tal disease, which, according to countries, are issued by public health author-
ities or by professional societies [Melin et al., 2013]. In the US, the guidelines 
issued by the CDC recommend universal screening at 35–37 weeks’ gestation 
and the use of IAP [Verani et al., 2010].
The Belgian guidelines, issued in 2003, recommend screening of all preg-
nant women at 35–37 weeks of gestation [Melin et al., 2011]. Women found 
positive for GBS or women with a previous infant with GBS invasive disease, or 
with GBS bacteriuria during current pregnancy, or delivering before 37 weeks 
of gestation, should receive IAP [Melin et al., 2011]. If case of no screening or 
incomplete/unknown	GBS	results,	the	presence	of	intrapartum	fever	(≥	38	°C)	
or the rupture of membranes for more than 18 h is indicative for IAP [Melin et 
al., 2011]. If amnionitis is suspected, GBS prophylaxis is recommended to be re-
placed by a broad-spectrum antibiotic therapy that includes an agent known to 
be active against GBS [Melin et al., 2011]. Similar screening based approaches 
are also recommended in France, Germany, Italy, Japan, Poland, Spain, Switzer-
land, whereas a risk-based approach is recommended in guidelines from the 
Netherlands, Australia, Denmark, UK and New Zealand [Melin et al., 2011]. In 
SSA, no screening- or risk-based guidelines exist or are implemented in most 
countries, if they exist in these countries, these guidelines are hardly followed.
FIGURE 2 Incidence of early- and late-onset GBS disease. ACOG, American College of Obste- 
 tricians and Gynecologists; AAP, American Academy of Pediatrics. On the Y-axis,  
 the incidence per 1000 live births is shown. Adapted from [Jordan et al., 2008].
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 Screening for GBS carriage Crucial elements in the screening are (i) the time 
of collection, (ii) the type of specimen, (iii) the transport conditions of the 
specimen and (iv) the microbiological procedures for detection of GBS [Melin et 
al., 2013]. 
(i) Rectovaginal GBS colonization is dynamic. Although early screening can 
be advantageous for prevention of GBS EOS in premature deliveries, the pre-
dictive value of early screenings has been shown to be very low [Verani et al., 
2010]. Late third trimester colonization has been suggested as a proxy for intra-
partum colonization at birth [Verani et al., 2010]. Currently, most guidelines rec-
ommend screening at 35–37 weeks of gestation [Melin et al., 2013]. However, it 
is important to realize that up to 30% of mothers that are positive for rectovag-
inal GBS carriage at delivery, have a negative screening, and that up to 25% 
of	women	identified	as	GBS	carriers	during	screening	are	no	longer	positive	at	
time of delivery [Schrag et al., 2002; Melin et al., 2013].
(ii) A rectovaginal swab increases the predictive value substantially com-
pared to a vaginal swab alone [Verani et al., 2010; Dillon et al., 1982; El Aila et 
al., 2010]. 
(iii) After obtaining the specimens, Amies or Stuart transport medium has 
been widely recommended for maintaining GBS viability [Melin et al., 2013], 
and it has been shown that prolonged time between collection and inoculation 
has a negative impact on the recovery of GBS [Rosa-Fraile et al., 2005]. 
(iv) The use of a selective enrichment broth improves GBS detection substan-
tially, as it has been shown that, when direct plating is used, as many as 50% of 
women who are GBS carriers have false-negative culture results [Baker et al., 
1977; Platt et al., 1995; El Aila et al., 2011]. Widely used enrichment broths are 
Todd-Hewitt broth supplemented with gentamicin (8 µg/ml) and nalidix acid 
(15 µg/ml) (known as TransVag broth), or supplemented with colistin (10 µg/ml) 
and nalidixic acid (15 µg/ml) (known as Lim Broth) [Fenton et al., 1979]. Addi-
tion of 5% sheep blood to these selective broths can further increase GBS re-
covery [Verani et al., 2010].
After enrichment, the broth is inoculated onto blood agar plates, and ß-hae-
molyic	colonies	are	presumptively	identified	by	conventional	tests	such	as	the	
CAMP	 test	 or	 are	 identified	 using	 latex	 agglutination	 test	with	GBS	 antisera	
[Verani et al., 2010], or more recently by means of matrix-assisted laser desorp-
tion/ionization	 –  	 time-of-flight	 (Maldi-TOF).	 On	 Granada	medium	 (known	 as	
Carrot medium in the US), β-hemolytic GBS strains are orange due to the expres-
sion produce an orange pigment. Expression of pigment and the β-haemolysin 
are genetically linked – both genes lie in the cyl operon (Rosa-Fraile et al., 2008) 
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– making Granada medium not 100% sensitive (a small percentage of GBS 
strains	are	non-haemolytic),	but	however,	100%	specific.	 In	cintrast,	on	chro-
mogenic agars, the selected characteristic is not related to β-hemolysin, but can 
be found in other species, making these agars possible more sensitive but less 
specific	[Melin	et al., 2008]. Besides these culture-based techniques, molecu-
lar methods for the detection of GBS, such as polymerase chain reaction (PCR), 
have been described. Currently, quantitative PCR (qPCR) assays for the detec-
tion of GBS have been shown to be as sensitive or more sensitive compared to 
culture-based methods [El Aila et al., 2011; Bergeron et al., 2000; Davies et al., 
2004]. Despite their availability and proven sensitivity, their use is currently 
not widespread, even not in high-income countries. An important improvement 
of this technique would be the combined detection of GBS and genes associat-
ed with clindamycin resistance, to guide appropriate IAP for penicillin-allergic 
women at high risk of anaphylaxis [Melin et al., 2013].
 IAP has it drawbacks Although IAP for women with heavy GBS colonization 
may prevent part of the cases of LOS, the stable incidence of LOS during a peri-
od	when	use	of	IAP	was	increasing	suggests	that	this	intervention	is	not	effec-
tive	against	LOS	(see	Figure	2).	Furthermore,	IAP	is	not	effective	against	adverse	
perinatal outcomes related to GBS such as stillbirth or miscarriage. IAP has re-
duced the burden of GBS EOS in high-income countries (see Figure 2). However, 
it has been shown that up to 82% of term infants with EOS were born to wom-
en who had negative GBS cultures at screening [Van Dyke et al., 2009; Puopolo 
et al., 2005], suggesting that inaccurate screening, lack of communiation of re-
sults, improper implementation of IAP and antibiotic resistance contribute to 
ongoing disease [Melin et al., 2011]. 
IAP has been related to the increase of the incidence of E. coli neonatal dis-
ease [Joseph et al., 1998] and ampicillin-resistance isolates in E. coli neonatal 
disease [Bizzarro et al.,	2008],	but	this	increase	has	not	been	confirmed	in	one	
other study [Bauserman et al., 2013] and an increase in ampicillin-resistant E. 
coli might	merely	reflect	the	increased	communitywide	resistance	[Al-Hasan et 
al., 2009].
Finally, neonatal antibiotic exposure through IAP has been shown to strongly 
influence	the	development	of	the	neonatal	intestinal	microbiota	[Aloisio et al., 
2014; Tanaka et al.,	2016],	which	is	essential	for	the	differentiation	of	epitheli-
um and the gut-associated lymphoid tissue (GALT) [Gritz et al.,	2015].	This	effect	
has been shown to pertain even at 12 months of age [Azad et al., 2015]. 
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 Vaccination Some of the above-mentioned IAP-related problems may be cir-
cumvented by maternal vaccination against GBS. Given the rapid onset and pro-
gression	within	hours	of	birth	as	well	as	the	deficiencies	in	IAP	strategies	and	
absence of a solution for preventing LOS, it is clear that administration of a suit-
able vaccine in pregnancy could provide a better solution in all settings [Heath 
et al., 2016].
The observations that laboratory animals were passively protected from bacte-
rial challenge with GBS by antibodies against GBS CPS, and that infants with EOS 
and LOS were more likely than healthy infants (born to GBS colonized mothers) 
to	have	low	levels	of	CPS	specific	IgG,	prompted	research	on	GBS	CPS	antigens	
and their potential use as targets for vaccination [Schuchat et al., 1999]. 
In contrast to IAP, vaccination might prevent a broad range of GBS associat-
ed diseases besides EOS, such as GBS LOS, miscarriage, stillbirth and maternal 
infection.
During	the	last	two	decades,	the	first	generations	of	vaccines	targeting	CPS	
have been extensively studied and phase I and phase II clinical trials in healthy 
adults have demonstrated safety and immunogenicity of monovalent or multi-
valent, uncoupled CPS or conjugated vaccines against serotypes Ia, Ib, II, III and 
V, but these are not yet licensed [Heath et al., 2016].
Because	these	vaccines	are	serotype	specific	and	serotype	distribution	dif-
fers according to population, a vaccine suitable for high-income populations 
might not be suitable for populations in SSA [Johri et al., 2006]. To overcome 
this problem, new generations of vaccines that target conserved surface pro-
teins are considered [Melin et al., 2013]. C5a peptidase and Sip, expressed at 
the	surface	of	all	GBS	strains	were	identified	as	possible	candidates	[Melin et 
al.,	2013].	Reverse	vaccinology,	where	antigen	candidates	are	identified	using	
genomic analysis, bioinformatics and molecular biology [Johri et al., 2006], has 
identified	pilus-like	structures	on	GBS	as	potential	candidates	 [Maione et al., 
2005], which could be useful in preventing colonization by inhibiting bacterial 
adhesion [Pezzicoli et al., 2008]. Table 1 gives an overview of the status of the 
current vaccine candidates.
 Other strategies A less invasive approach to the interruption of perinatal 
transmission of GBS is the use of vaginal disinfectants when labor begins. The 
use of vaginal wipes with the antibacterial chlorhexidine has been explored 
during	labor	but	failed	to	show	a	beneficial	effect	[Cutland	et al., 2009].
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Developer Candidate name/identifier
NIH TT-CPS conjugates (M, B) 
CRM197–CPS-conjugate (M) 
P
Novartis/GSK CRM197-CPS conjugates (M, T) P
Minervax Rib surface proteins and 
AlphaC surface proteins
Novartis/GSK Pilus proteins
Various academic 
groups
Other proteins and/or 
Protein-CPS conjugates
TABLE 1 Development status of current vaccine candidates.  
 Adapted from [Heath et al., 2016].
POC, proof-of-concept; M, monovalent; B, bivalent; T, trivalent; P, trials in pregnant 
women; dark grey, progress of clinical trials of the candidate vaccine. CRM197 
is a non-toxic mutant of diphtheria toxin, currently used as a carrier protein for 
polysaccharides and haptens to make them immunogenic.
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Pathogenesis of GBS EOS
— CHAPTER 4
4.1 GBS virulence factors 
 Capsular polysaccharide (CPS) GBS strains are typically encapsulated by cap-
sular polysaccharides belonging to one of the ten capsular serotypes (Ia, Ib, II to 
IX) [Rajagopal et al., 2009]. CPS is considered a major virulence factor and the 
overwhelming majority of GBS isolated from invasive disease are encapsulated 
[Spellerberg et al., 2000]. CPS are polymers which in GBS are composed of dif-
ferent arrangements of four monosaccharides, ie. glucose, galactose, N-acetyl-
glucosamine and sialic acid (N-acetylneuraminic acid), except for serotype III 
that has rhamnose instead of N-acetylglucosamine and for serotype VI that 
lacks N-acetylglucosamine [Spellerberg et al., 2000]. 
Because GBS strains are decorated with sialic acid, which is present as the 
most distant sugar moiety on all GBS CPS but also on glycans of vertebrate cells, 
GBS cells are masked (molecular mimicry) and impair the host to recognize GBS 
as nonself. Consequently, the sialylated CPS prevents binding of factor C3b of 
the complement system to the capsule of GBS, thereby preventing the activa-
tion of the alternative complement pathway [Marques et al., 1992]. The com-
plement pathway is a crucial element of the host innate immune system and 
consists of serum proteins that can be activated by an enzymatic cascade mech-
anism. Activation of the complement system leads to the production of opson-
ins, such as C3b, which attach to bacteria, tagging them for destruction, and to 
the production of chemokines that recruit immune cells to sites of infection 
[Mitchell et al., 2003].
The	 importance	 of	 CPS	 in	 adaptive	 immunity	 against	 GBS	 has	 been	 first	 de-
scribed by Baker and coworkers [Baker et al., 1976], who demonstrated that pla-
cental transfer of maternal antibodies against CPS was associated with protec-
tion from invasive GBS infection. 
 β-hemolysin/cytolysin (β-H/C) (CylE) The β-H/C is responsible for the β-he-
molytic phenotype of GBS, a characteristic zone of clearing around the colonies 
of GBS when grown on blood agar plates (β-hemolysis), which is a useful di-
agnostic characteristic in the clinical microbiology laboratory [Rajagopal et al., 
2009;	Pritzlaff	et al., 2001].
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The GBS β-H/C was recognized as early as the 1930s [Todd et al., 1934], 
whereas early 1980s research provided insights in its mechanism of erythro-
cyte lysis and 1990s research showed a virulence factor with a broad spectrum 
of cytolytic properties [Liu et al., 2006].
The surface-associated β-H/C is expressed by the vast majority of strains 
[Rajagopal et al., 2009] and promotes bacterial invasion across epithelial and 
endothial walls, including the blood-brain barrier [Landwehr-Kenzel et al., 
2014]. Furthermore, β-H/C is associated with damage to lung epithelial and en-
dothelial cells, brain epithelial cells and macrophages [Mitchell et al., 2003]. 
GBS strains that are β-H/C	deficient	have	shown	impaired	virulence	in	various	in 
vivo models of pneumonia, sepsis and meningitis [Margarit et al., 2009; Doran 
et al., 2002a; Bebien et al., 2012]. At sublytic concentrations, β-H/C has been 
shown	 to	 induce	 the	 expression	 of	 the	 anti-inflammatory	 cytokine	 interleu-
kin-10 (IL-10) and inhibits both IL-12 and nitric oxide synthase (NOS2) expres-
sion in GBS-infected macrophages [Bebien et al., 2012]. 
 Christie, Atkins, Munch and Peterson (CAMP) factor The CAMP factor is a se-
creted protein that oligomerizes and forms discrete pores in susceptible tar-
get membranes. Besides its membrane-damaging activity, the CAMP factor has 
been shown to interact with the Fc portion of human IgG and IgM [Jurgens et 
al., 1987]. In vivo	studies	have	shown	that	injected	purified	CAMP	factor	was	
lethal to rabbits, and that co-administration of the CAMP factor with a sub-
lethal dose of GBS induced septicemia and death in murine models [Jurgens 
et al., 1987; Skalka et al., 1981], stressing the importance of the CAMP factor in 
pathogenesis. 
 C5a peptidase (ScpB) The C5a peptidase is a serine protease and surface pro-
tein present on all strains of GBS [Johri et al., 2006] and inactivates the com-
plement factor C5a by cleavage. As C5a is an anafylatoxine that is important 
for	the	inflammatory	response,	including	the	recruitment	of	neutrophils,	C5a	
peptidase induces an impaired innate immune reaction at the site of infection 
[Rajagopal et al., 2009; Chmouryguina et al., 1996; Takahashi et al., 1995]. Fur-
thermore, C5a peptidase has been shown to be involved in host colonization. 
Many GBS-host-cell interactions involve binding of GBS to the extracellular ma-
trix of these host cells. By binding to molecules of this extracellular matrix, such 
as	fibronectin,	laminin	and	fibrinogen,	which	in	turn	bind	host	cell-surface	pro-
teins such as integrin, GBS can enhance colonization. Independent of its pepti-
dase	activity,	C5a	peptidase	has	been	shown	to	bind	to	fibronectin	[Maisey	et 
al., 2008; Rajagopal et al., 2009]. 
25
Immunization of mice with C5a peptidase alone or conjugated with CPS 
showed an enhanced clearing of GBS from the lung, emphasizing the impor-
tance of C5a peptidase in the pathogenesis of GBS infection [Cheng et al., 2002].
 C antigen The C antigen of GBS is a protein complex consisting of two distinct 
and independently expressed components, the α C protein and the β C protein 
[Spellerberg et al., 2000]. C proteins are expressed in 40–60% of clinical iso-
lates [Hickman et al., 1999; Johnson et al.,	1984]	and	in	different	animal	models,	
vaccination with both the α C protein and the β C protein have been shown to 
elicit protective immunity [Spellerberg et al., 2000]. 
The α C protein is commonly expressed on the surface of GBS serotypes Ia, Ib 
and II [Rajagopal et al., 2009]. Equivalent proteins have been described in se-
rotypes III and V [Stalhammar-Carlemalm et al., 1993; Lachenauer et al., 1996]. 
The surface-anchored α C protein promotes invasion of human cervical epithe-
lial cells through α1β1-integrin binding or glycosaminoglycan binding in an ac-
tin-dependent manner [Bolduc et al., 2007; Glaser et al., 2002]. The importance 
of the α C protein as a virulene factor has been documented in a murine neona-
tal model of GBS infection, where GBS mutants lacking the protein were less vir-
ulent [Bolduc et al., 2007; Li et al., 1997]. 
By binding to IgA antibodies, the β C protein is thought to interfere with op-
sonophagocytosis of GBS [Spellerberg et al., 2000; Jerlstrom et al., 1991]. Fur-
thermore, β C protein binds to the human serum protein factor H, which de-
grades complement factor C3b [Mitchell et al., 2003]. Finally, the β C protein 
has been shown to bind sialic-acid-recognising immunogloblulin superfamily 
lectins (Siglecs), a family of cell-surface receptors with intracellular domains 
that send inhibitory signals to limit host cell activation. GBS binds Siglec-5 on 
macrophages and neutrophils, thereby downregaluting their immune function 
(see Figure 3) [Carlin et al., 2009].
 Pili	 Pili	 are	 filamentous	 cell-surface	 appendages	 better	 characterized	 in	
Gram- negative bacteria, where they facilitate adhesion and colonization of the 
host or other bacteria [Sauer et al., 2000]. Pili were only recently described in 
GBS [Lauer et al., 2005] and have been shown to promote colonization of epi-
thelial	cell	surfaces,	support	biofilm	formation,	mediate	GBS	resistance	to	an-
timicrobial proteins and enhance translocation across the blood-brain barrier 
[Konto-Ghiorghi et al., 2009; Dramsi et al., 2006; Pezzicoli et al., 2008; Maisey 
et al., 2007; Maisey et al., 2008b]. Interestingly, antibodies raised against im-
munogenic pilin subunits have been shown not only to elicit opsonophagocytic 
killing and protection from sepsis, but also to inhibit adherence, suggesting the 
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promise	of	a	pilus-based	vaccine	that	workins	at	two	different	levels	[Nuccitelli	
et al., 2011; Margarit et al., 2009].
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FIGURE 3 Pathogenesis of GBS EOS. 
Panel A. Colonization. Interactions of GBS with epithelial cells as viewed by 
scanning electron microscopy. Streptococcal chain adhering to the epithelial cell 
surface [Valentin-Weigand et al., 1997].  
Panel B. Invasion. Left image: association of group B Streptococcus (GBS) with the 
perimeter of epithelial cervical cells. Red, GBS stained with mouse polyclonal 
antisera against serotype V; green, tight junctions visualised with polyclonal anti-
ZO-1 antibodies; yellow, colocalisation of GBS and tight juntions. GBS preferentially 
transverses cervical epithelial cells via the paracellular route [Soriani et al., 2006]. 
Right images: transcytosis of GBS through a monolayer of chorion cells. Top image, 
apical surface of chorion cell engulfing two GBS cells; middle image, several GBS 
cells within a single intracellular vacuole; bottom image, two intracellular GBS cells 
near the apical surface of a chorion cell. Adherent and intracellular GBS cells are 
indicated by the arrows [Winram et al., 1998].  
Panel C. Pneumonia. Ultrastructural of GBS hemolysin-associated epithelial cell 
injury: scanning electron micrographs shows pneumocytes exposed to wild-type 
GBS (top image) and a hyperhemolytic mutant strain (bottom image) shows loss of 
microvillus architecture and bleb formation on the cell surface [Nizet et al., 1996].  
Panel D. Meningitis. Top image: neuroimaging of fatal GBS meningitis, transverse 
view of magnetic resonance imaging showing diffuse necrotizing encephalomalacia 
and formation of parenchymal abscesses or cysts [Doran, 2002b]. Bottom image: 
Gram stain of murine brain tissue infected with WT GBS [Doran et al., 2005].  
Panel E. Immune evasion. Green, GBS; blue, nuclei of macrophages; red, siglec-5 
on cell surface; bar, 5 µm. Left images: GBS cells expressing β protein colocalize 
with siglec-5 on macrophages, increasing bacterial attachment but impairing 
phagocytosis. Right images: mutant GBS strain not expressing β protein does not 
colocalize [Carlin et al., 2009].
 Extracellular-matrix binding proteins GBS is able to enhance its coloniza-
tion	by	binding	to	the	host	extracellular	matrix.	FbsA	and	FbsB	are	two	fibrin-
ogen-binding proteins expressed by GBS [Schubert et al., 2002; Jacobsson et 
al., 2003]. While FbsA promotes adhesion, FbsB facilitates invasion into host 
cells [Landwehr-Kenzel et al., 2014]. Furthermore, GBS is able to bind host-cell 
laminin by means of its laminin-binding protein Lmb. GBS strains lacking Lmb 
showed decreased adherence to human brain microvascular endothelial cells 
[Spellerberg et al., 1999a; Tenenbaum et al., 2007].
$
CH4 Pathogenesis of GBS EOS 28
 Hyaluronate lyase GBS is able to secrete a protease known as hyaluronate 
lyase (HlyB), important for GBS pathogenesis [Lin et al., 1994; Gase et al., 1998]. 
Hyalurons, chief components of the extracellular matrix of human tissue, are 
found at higher concentrations in placental and lung tissue and in amniotic 
fluid	[Lindahl	et al., 1978; Li et al., 2001]. As hyaluronate lyase is able to cleave 
hyaluron [Li et al., 2001; Pritchard et al., 1994; Akhtar et al., 2006], hyaluronate 
lyase is thought to engage in pathogenesis by promoting tissue invasion of GBS. 
 Superoxide dismutase Phagocytes such as neutrophils and macrophages kill 
engulfed bacterial pathogens by the production of reactive oxygen species 
(ROS). To counteract this attack, GBS is able to produce a superoxide dismutase, 
SodA [Rajagopal et al., 2009]. Superoxide dismutases convert harmful singlet 
oxygen or superoxide anions (O2ˉ)	 into	harmless	molecular	oxygen	 (O2) and 
harmful H2O2, which, in turn, is metabolized by catalases and/or peroxidases 
[Rajagopal et al., 2009].
In vitro, a GBS sodA	mutant	was	found	to	be	significantly	more	susceptible	to	
oxidative stress and in a murine model, this mutant showed increased suscep-
tibility to bacterial killing by macrophages and impaired survival in the blood-
stream and brain [Poyart et al., 2001]. 
4.2 Pathogenesis of GBS EOS
Using its plethora of virulence factors, GBS has to undertake several crucial 
steps for neonatal GBS disease to occur (see Figure 3).
(i) Colonization of the vaginal mucosa 
The presence of GBS in the maternal genital tract at delivery determines wheth-
er or not a newborn is at risk for invasive disease. Among infants born to col-
onized women, the risk of EOS is 30-fold compared to infants born to women 
with a negative culture-based screening result [Boyer et al., 1985]. A direct re-
lationship has been shown between vaginal GBS load, the risk of vertical trans-
mission and the likelihood of serious disease in neonates [Ancona et al., 1980; 
Pass et al., 1979]. Therefore, a crucial step, if not, a prerequisite, in the patho-
genesis is the colonization of the vaginal mucosa.
To establish a successful colonization of the vagina, GBS must adhere to the 
vaginal	epithelium.	GBS	has	been	shown	 to	bind	efficiently	 to	exfoliated	hu-
man vaginal epithelial cells or to vaginal tissue culture cells [Sobel et al., 1982; 
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Jelinkova et al., 1986] with maximal adherence at acidic pH characteristic of the 
vagina [Zawaneh et al., 1979; Tamura et al.,	1994].	High-affinity	interactions	of	
GBS are facilitated by binding of bacterial FbsA, Lmb, C5a peptidase and pili to 
host	extracellular	matrix	components	such	as	fibrinogen,	fibronectin	and	lami-
nin, which in turn interact with host cell-anchored proteins such as integrins. 
(ii) Invasion across host epithelial barriers  
to infect amniotic fluid
GBS can reach the fetus in utero through ascending infection of the amniot-
ic	fluid,	or	alternatively,	the	newborn	may	become	contaminated	with	GBS	on	
passage through the birth canal. The pivotal role of the ascending route in EOS 
has been underpinned by several observations. A direct relationship exists be-
tween the duration of membrane rupture before delivery and infection rate 
for EOS [Stewardson-Krieger et al., 1978]. Stewardson-Krieger and coworkers 
demonstrated that when duration of membrane rupture was 18 hours or less, 
the infection rate was 0.7 per 1000 live births, when it was more than 30 hours, 
it increased to 18.3 per 1000 live births [Stewardson-Krieger et al., 1978]. Fur-
thermore, most neonates with EOS GBS disease show symptoms of pneumo-
nia or sepsis at birth, suggesting that infection did take place in utero and not 
during passage through the birth canal. Histological examination of placentas 
from	women	with	GBS	chorioamnionitis	showed	bacterial	 infiltration	along	a	
choriodecidual route, implying that ascending infection may be a primary trig-
ger in many instances of premature rupture of the membranes [Evaldson et al., 
1982].
GBS	 is	 thought	 to	 infect	 the	 amniotic	 fluid	 after	 the	 rupture	 of	 the	mem-
branes, but has also been shown to cross intact chorioamnionitic membranes 
[Galask et al., 1984], for which crossing of chorion cells, amnion cells and the 
placental basement membrane is necessary. Transversion of chorion cell mono-
layers by GBS has been shown without disruption of intracellular junctions 
[Winram et al., 1998]. Hyaluronic acid, an important component of the extracel-
lular matrix that is abundant in placental tissues, can be degraded by the GBS 
hyaluron	lyase	to	facilitate	invasion	of	the	amniotic	fluid.	
Although	amniotic	fluid	has	antimicrobial	properties	[Espinoza	et al., 2003], 
it supports the growth and proliferation of GBS [Hemming et al., 1985], and a 
high GBS inoculum is thought to be delivered to the fetal lung, resulting in a 
continuum of intrapartum (stillbirth) to early postpartum infant death [Abbasi 
et al., 1987; Baker et al., 1978; Vollman et al., 1976; Ablow et al., 1976; Bergqvist 
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et al., 1978]. In contrast, when GBS is encountered on passage through the birth 
canal, a lesser inoculum is thought to be delivered to the neonate. 
(iii) Pulmonary entry, pneumonia and bloodstream entry
Through	 inhalation	of	 contaminated	 amniotic	fluid	by	 the	 fetus,	GBS	 can	en-
ter the fetal lung. Subsequently, entry into the bloodstream occurs when GBS 
crosses the pulmonary epithelial layer, basement membrane and the vascular 
endothelial layer.
Intracellular invasion of both alveolar epithelial and pulmonary endothe-
lial cells by GBS was demonstrated in newborn macaques following intra-am-
niotic challenge [Rubens et al.,	1991]	and	confirmed	in	human	tissue	culture	
lines for both cellular barriers [Rubens et al., 1992; Gibson et al., 1993], where 
GBS triggers host cytoskeleton changes, leading to endocytotic uptake within a 
membrane bound vacuole [Valentin-Weigand et al., 1997; Nizet et al., 1996]. Al-
though cellular invasion may play a principal role in bloodstream penetration, 
cellular damage to the lung barrier, largely due to the actions of the β-H/C, con-
tributes to the pathogenesis. Autopsies in fatal EOS cases reveal that 80% have 
histological evidence of lobar or multilobar pneumonia [Vollman et al., 1976; 
Hemming et al.,	1985],	characterized	by	dense	bacterial	infiltration,	epithelial	
cell	damage,	alveolar	hemorrhage	and	interstitial	inflammatory	exudate	[Ablow	
et al., 1976; Katzenstein et al., 1976]. GBS disease is rarely limited to the initial 
pulmonary focus, but spreads to the bloodstream and thereby to other organs 
and tissues.
(iv) Inflammatory activation and sepsis
When failure of the pulmonary epithelial and endothelial barrier function 
and of immunological clearance allows GBS to enter the bloodstream caus-
ing bacteremia, development of sepis may occur. In the acute phase, there is 
an	increase	in	inflammatory	markers	such	as	TNF-α, IL-1 and IL-6 [Maisey et al., 
2008a]. IL-12 has been shown to play an important role in regulating the sys-
temic	response	to	GBS	infection.	The	proinflammatory	effects	of	the	GBS	β-H/C 
also contribute to sepsis pathophysiology. Intravenous infusion of GBS in ani-
mal models produces similar pathophysiologic changes to those seen in human 
newborn infection, such as hypotension, persistent pulmonary hypertension, 
acidosis, tissue hypoxemia and multiple organ failure.
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(v) Crossing blood-brain barrier and meningitis
To	induce	meningitis,	the	predominant	clinical	finding	in	case	of	GBS	LOS,	GBS	
must penetrate human microvascular endothelial cells, the single-cell lay-
er constituting the blood-brain barrier. Intracellular invasion and transcytosis 
of human brain microvascular endothelial cell tissue culture monolayers have 
been shown in vitro [Nizet et al., 1997], and serotype III strains, accounting for 
most	of	the	isolates	causing	meningitis,	invade	more	efficiently	than	strains	of	
other serotypes. When GBS crosses the blood-brain barrier to enter the cere-
brospinal	fluid,	it	initiates	an	inflammatory	meningeal	reaction	in	the	subarach-
noid space, triggered through the sentinel function of the blood-brain barri-
er endothelium. Animal models suggest TNF-α has a pivotal role in the initial 
proinflammatory	reaction	[Ling	et al.,	1995],	which	contributes	significantly	to	
the pathogenesis of meningitis and the central nerve system injury. Following 
initial	inflammation,	the	cerebral	fluid	flow	is	altered,	and	cerebral	hyperemia	
and ischemia occur. 
(vi) Immune evasion
Following the entry of GBS into the lungs, blood and brain, normally considered 
sterile sites, the host attempts to clear the invading GBS mainly by the phago-
cytotic actions of neutrophils and macrophages [Spellerberg et al., 2000]. Ef-
fective phagocytosis of GBS relies upon opsonization through complement and 
serotype-specific	antibodies	[Remington	et al., 2010]. Neonates are particularly 
prone	to	invasive	disease	due	to	their	deficiencies	in	phagocytic	cell	function,	
specific	antibody	development,	and/or	classic	and	alternate	complement	path-
ways [Remington et al., 2010]. 
The	protective	effect	of	maternal	 antibodies	was	first	 recognized	 in	1976	
[Baker et al., 1976] and the complement system appears to play a central role in 
the	host	defense	against	GBS.	The	LD50	of	mice	deficient	in	either	complement	
C3 or C4 has been shown to be reduced 23–30-fold in comparison to controls 
[Wessels et al., 1995], suggesting that both the classical and alternative path-
ways contribute to immunity. 
GBS is equipped with virulence factors that thwart key components of ef-
fective opsonophagocytosis. Chief among these is the sialylated CPS that in-
hibits deposition of complement component C3b and thereby the activation of 
the alternative complement pathway [Platt et al., 1994; Edwards et al., 1993]. 
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Furthermore, the CAMP factor and the β-C protein presumably render antibod-
ies	ineffective	for	opsonization	by	binding	to	the	Fc	portion	of	immunoglobu-
lins and C5a peptidase impairs recruitment of neutrophils to sites of infection 
through cleavage of the chemotactic complement component C5a.
After phagocytosis, neutrophils and macrophages seek to kill the engulfed 
bacteria by the production of reactive oxygen species and other antimicrobial 
substances [Remington et al., 2010]. Although streptococci are often thought of 
as extracellular pathogens, they can survive for prolonged periods within the 
phagolysosome of macrophages [Cornacchione et al., 1998]. GBS superoxide 
dismutase can neutralize the actions of the reactive oxygen species thereby 
enhancing intracellular survival. Furthermore, the GBS β-H/C can induce direct 
cytolytic injury to macrophages. With highly hemolytic strains or with a large 
bacterial inoculum, killing of the phagocyte seems to outpace the phagocyte’s 
microbicidal mechanisms, allowing bacterial proliferation, as was shown in an 
in vitro murine model [Remington et al., 2010].
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Histology and anatomy  
of the vagina and cervix
— CHAPTER 5 
The female reproductive tract (FRT) can be divided into external genitalia (vul-
va) and internal genitalia, located in the pelvic cavity. The internal genitalia 
consist of the vagina, the cervix, the uterus, the Fallopian tubes and the ovaries 
(Figure 4). 
The vagina is an elastic, muscular canal lined with a mucosa and has an im-
portant role in reproduction as the penile recipient, the conduit for the men-
strual	flow	and	the	birth	channel	during	delivery.	The	vagina	connects	the	uter-
us – the organ receiving the embryo, sheltering the fetus during pregnancy and 
delivering the newborn – to the outside world: the vulva forms the entrance 
and the cervix, that protrudes into the vagina, forms the interior end.
The cervix forms a mucosa-lined canal, the endocervix, which opens in the 
vagina and the uterine cavity via the external and internal os, respectively. The 
ectocervix is the part of the cervical channel that protrudes into the vagina.
FIGURE 4 Anatomy of the female reproductive tract.
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The	vaginal	mucosa	consists	of	a	stratified	squamous	non-keratinizing	epitheli-
um, beneath which is a vascular aglandular connective tissue layer, the lamina 
propria. Under the lamina propria, a layer of smooth muscle and an adventitia 
are located. 
The	stratified	vaginal	epithelium	is	made	up	of	a	basal	layer	of	a	single	row	
of	columnar	cells,	a	parabasal	 layer	of	 two	to	five	cuboidal	cells,	an	 interme-
diate	layer	of	variable	thickness	that	contains	flattened	cells	and	a	superficial	
layer	that	consists	of	flat	epithelial	cells,	which	are	constantly	exfoliated	(Fig-
ure	5).	The	vaginal	mucosa	is	continuous	with	the	ectocervical	stratified	squa-
mous epithelium.
The endocervix is lined by a single cell layer of columnar epithelial cells 
(some of which contain cilia) that secerete mucus under estrogen regulation. 
The surface of the endocervical epithelium is increased by the deep invagina-
tions of the tubular glands, thereby increasing the mucus-secreting capacity. 
The	secreted	mucus	covers	the	external	os	and	fills	the	cervical	canal,	acting	as	
a protective barrier against ascending infections from the vagina into the uter-
ine cavity. 
The area where the squamous multi-layered epithelium of the ectocervix 
meets the single-layered columnar epithelium of the endocervix is called the 
squamocolumnar junction (SCJ, or transformation zone) and its location on the 
cervix is variable and dependent on age.
41
columnar	  
epithelial	  
	  cells	  
basal	  layer	  	  
superficial	  
layer	  
lumen	  
parabasal	  layer	  	  
intermediate	  
layer	  
lamina	  
propria	  
lamina	  	  
propria	  
lumen	  
FIGURE 5 Histology of the vaginal and cervical mucosa. 
Top panel: the four layers of the stratified squamous epithelium, located on 
top of the lamina propria. The left arrows indicate an exfoliated squamous 
epithelial cell; the right arrow indicates a nucleus of an epithelial cell.  
Bottom panel: the single layered columnar epithelium of the endocervix. 
The left arrow indicates cilia of an epithelial cell; the right arrow indicates 
the nucleus of an epithelial cell.
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The vaginal microbiota
— CHAPTER 6 
6.1 Introduction
We are not just single individuals walking the planet, we are walking ecosys-
tems.	And	like	our	planet,	the	human	body	harbors	many	different	ecosystems	
containing microorganisms. 
A human body hosts more bacterial cells than it has human cells, and en-
codes a 100-fold more unique genes than our own genome [Ley et al., 2006]. 
Different	sites	in	our	body	harbor	different	microbial	communities,	termed	mi-
crobiota,	that	differ	in	composition	and	dynamics.	
Microbiota exist in a mutualistic relationship with their human host [Deth-
lefsen et al., 2007; Turnbaugh et al., 2007; Ley et al., 2006]. Disease might be 
caused by opportunistic pathogens, members of the microbiota that only un-
der certain circumstances – such as a compromised immune system – cause dis-
ease; by true pathogens that are normally not part of microbiota; or by dysbio-
sis, the disturbance of the delicate balance of the microbiota.
The complex and dynamic nature of our microbiota only became clear during 
the	 last	decade	 thanks	 to	 the	advances	and	affordability	of	high-throughput	
DNA sequencing technologies, and we are only starting to understand the enor-
mous impact of our microbiota on human health and disease [Eloe-Fadrosh et 
al., 2013].
The human vagina and the associated vaginal microbiota are an example of a 
finely	balanced	mutualistic	association,	and	disturbances	of	this	balance	have	a	
major impact on reproductive health and disease [Ma et al., 2012]. 
6.2 The vaginal microbiota from Döderlein to DGGE  
– the classical paradigm
In	1892,	German	gynecologist	Döderlein	was	the	first	to	describe	an	organism	
named Döderlein’s bacillus, later renamed Lactobacillus, isolated from a vagi-
nal specimen of healthy pregnant women [Martin et al., 2012]. In 1899, Menge 
and Kronig described, in addition to Lactobacillus, the isolation of other anaer-
obic organisms from the human vagina [Menge et al., 1899]. In the 1920s, a 
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vaginal discharge syndrome described by Curtis, termed ‘white discharge syn-
drome’, was linked with a microscopy- and culture-proven deprivation of Lacto-
bacillus and with the presence of curved anaerobic motile rods, anaerobic cocci, 
and Gram-variable diphtheroidal rods [Martin et al., 2012].
Thus, nearly 100 years ago, a symptomatic vaginal discharge syndrome was 
already	 known	 to	 be	 associated	 with	 significant	 shifts	 in	 the	 vaginal	 micro-
biota. At that time, investigators believed that bacterial-associated diseases or 
syndromes were caused by a single organism, providing fertile ground for the 
strong association found by Gardner and Duke between a Gram-variable cocco-
bacillus, named Haemophilus vaginalis and later renamed Gardnerella vaginalis, 
and	the	white-discharge	syndrome,	at	that	time	renamed	nonspecific	vaginitis	
[Gardner et al.,	1955].	Despite	the	fact	that	Koch’s	postulates	were	not	fulfilled, 
G. vaginalis was	believed	to	be	the	cause	of	nonspecific	vaginitis,	reflected	in	
the term ‘Gardnerella vaginitis’, frequently used to describe the syndrome.
In the 1980s, a group of researchers from the University of Washington revi-
talized	 the	 research	on	nonspecific	vaginitis.	 They	 reported	quantitative	 cul-
ture-based	findings	that	nonspecific	vaginitis	was	not	only	associated	with	in-
creased abundance of G. vaginalis but also with striking increases of genital 
mycoplasmas and a number of anaerobic species such as Bacteroides spp. and 
Peptococcus spp. [Spiegel et al., 1980; Spiegel et al., 1983a; Spiegel et al., 1983b; 
Hillier et al.,	1993].	Based	on	this	seminal	work,	nonspecific	vaginitis	was	re-
named ‘bacterial vaginitis’. Later the designation ‘bacterial vaginosis’ (BV) was 
proposed	because	of	the	microscopical	observation	of	only	few	inflammatory	
cells	in	the	vaginal	fluids	of	women	with	BV.	The	same	group	described	clinical	
markers to diagnose BV, now known as the Amsel criteria [Amsel et al., 1983] 
(see further) and Nugent and co-workers revised the Gram-stain criteria for BV 
described by Spiegel, and this revised scoring system became known as the Nu-
gent score (see further) [Nugent et al., 1991; Spiegel et al., 1983b]. Over the 
years, the Amsel criteria and Nugent score became the standard for diagnosing 
BV in routine clinical care and clinical research, respectively.
Until the revolution introduced by molecular studies, the vaginal microbio-
ta was further studied using culture-dependent and microscopical techniques. 
The vaginal microbiota paradigm (Figure 6) was that lactobacilli are associated 
with a healthy vaginal microbiota and that a deprivation of lactobacilli paral-
lelled with the presence of other (facultative) anaerobes is the hallmark of bac-
terial vaginosis (BV). 
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FIGURE 6 The vaginal microbiota of women of reproductive age – the classical paradigm
Panel A. Lactobacilli are thought to acidify the vaginal mucosa by production of 
lactic acid and deprivation of lactobacilli is associated with higher pH.  
Panel B. In women of reproductive age, the spectrum of the vaginal microbiota 
goes from one dominated by lactobacilli, generally associated with health, to a 
microbiota lacking lactobacilli and dominated with anaerobes such as the BV 
associated bacteria. In between, an intermediate microbiota is thought to be the 
transition between the latter two.  
Panel C. In the disturbed BV-associated microbiota, anaerobes break down the 
protective mucus layer and attach in large numbers to the vaginal epithelial cells, 
which are then called clue cells.  
Panel D. Gram-stained vaginal smears from women with normal vaginal microbiota 
(left), intermediate microbiota (middle), and BV (right).
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 Lactobacilli-dominated microbiota Lactobacillus spp. are keystone species of 
a healthy vaginal microbiota – with L. crispatus as the most prevalent amongst 
the vaginal lactobacilli – [Gupta et al., 1998; Martin et al., 1999; Sobel, 1999; 
Antonio et al., 1999] and play a major role in protecting the vaginal environ-
ment from nonindigenous and potentially pathogenic microorganisms, includ-
ing those responsible for BV, sexual transmitted infections and urinary tract in-
fections by the production of lactic acid, H2O2 and bacteriocines [Gupta et al., 
1998; Hillier et al., 1992; Sewankambo et al., 1997; Sobel, 1999; van De Wijgert 
et al., 2000]. 
 » Production of lactic acid	 Lactobacilli	benefit	the	host	by	producing	lactic	
acid	as	a	fermentation	product	that	lowers	the	vaginal	pH	to	∼3.5–4.5,	which	
is thought to be protective [Alakomi et al., 2000; Boskey et al., 1999]. 
 » Production of H2O2 Production of H2O2 is a well-known mechanism for 
bacterial antagonism, inhibiting growth of microorganisms via direct inter-
action or via human myeloperoxidase [Dahiya et al., 1968; Eschenbach et 
al., 1989]. In vitro studies have shown that H2O2 producing lactobacilli were 
able to inactivate genital pathogens like HIV-1, herpes simplex virus type 2 
(HSV-2), Trichomonas vaginalis, G. vaginalis, P. bivia and E. coli and clinical 
studies have associated H2O2-producing lactobacilli with a decrease in BV 
and	inflammatory	markers	[Hawes	et al., 1996; Mitchell et al., 2013]. How-
ever,	based	on	observations	that	cervicovaginal	fluid	has	H2O2 blocking ac-
tivity and the hypothesis that lactobacilli in vivo probably do not produce 
enough H2O2	to	be	effective,	the	in vivo	beneficial	effects	of	H2O2 produc-
ing strains are still a matter of discussion [O’Hanlon et al., 2010; O’Hanlon et 
al., 2011].
 » Bacteriocines Several Lactobacillus species produce antimicrobial com-
pouds named bacteriocines, low-molecular weight proteins that can inhib-
it the growth of a variety of bacteria including G. vaginalis, reinforcing the 
protective role of the lactobacilli [Alpay Karaoglu et al., 2002; Aroutcheva et 
al., 2001; Klaenhammer et al., 1988]. 
 Bacterial vaginosis Bacterial vaginosis is the most common vaginal condi-
tion of reproductive-age women and is (vaguely) characterized by a disruption 
of the equilibrium of the normal vaginal microbiota [Ma et al., 2012]. Clinical-
ly, symptomatic women complain of vaginal discharge, vaginal and/or perineal 
pruritus,	a	fishy	odor	and	dyspareunia.	
Clinical	studies	defining	BV	based	on	Amsel	criteria	and/or	Nugent	score	have	
shown that BV is an independent risk factor for a plethora of adverse health 
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outcomes like the acquisition of Neisseria gonorrheae, Chlamydia trachomatis, T. 
vaginalis  [Brotman et al., 2010a], HSV-2 [Cherpes et al., 2005], the acquisition 
and transmission of HIV [Cohen et al., 1995; Coleman et al., 2007; Cu-Uvin et 
al., 2001; Martin et al., 1999; Spear et al., 2007; Taha et al., 1998], urinary tract 
infections [Harmanli et al., 2000; Hillebrand et al.,	2002],	pelvic	inflammatory	
disease [Srinivasan & Fredricks, 2008], preterm labor [Leitich et al., 2003], low 
birth weight [Hauth et al., 2003], preterm rupture of membranes [Benedetto et 
al., 2004], late miscarriage, spontaneous abortion [Hay et al., 1992], chorioam-
nionitis [Rezeberga et al., 2008], intra-amniotic infections [Gravett et al., 1986], 
preterm birth [Hauth et al., 2003] and postpartum maternal infections [Leitich 
et al., 2003]. Preterm birth is the leading cause of neonatal mortality, and Lawn 
and coworkers have estimated that 27% of the direct causes of the 4 million 
neonatal deaths in 2000 can be attributed to preterm birth [Lawn et al., 2005] 
(Figure 1).
Among the strongest risk factors for BV are the vaginal presence of menstru-
al blood, a new sexual partner, vaginal douching and smoking [Ma et al., 2012].
Common species traditionally isolated from women with BV by culture-de-
pendent techniques are anaerobes such as G. vaginalis, Prevotella spp., Mobi-
luncus spp., Mycoplasma hominis and Ureaplasma urealyticum. Historically, G. 
vaginalis has been considered the most important contributor to BV.
Clinically, BV is diagnosed when at least three of the four Amsel criteria are 
present, i.e. (i) a rate of at least 20% clue cells observed on wet mount micros-
copy, (ii)	a	‘fishy’	odour	elicited	after	mixing	vaginal	secretions	with	10%	KOH,	
(iii) vaginal secretions with an elevated pH of > 4.5 and (iv) a thin, white, skim-
milk-like homogeneous vaginal discharge. 
In research settings, BV is usually diagnosed by Nugent scoring of Gram-
stained vaginal smears. Upon microscopic examination, the presence and 
semi-quantification	 of	 three	 bacterial	 cell	 morphology	 types	 (Lactobacillus 
morphotypes, small Gram-variable Gardnerella and Bacteroides spp. cell mor-
phology types, and curved Gram-variable rods) is assessed (Figure 6). A score 
of 0–3 is considered as normal, a score of 4– 6 as an intermediate vaginal mi-
crobiota,	and	a	score	of	7–	10	as	BV-positive.	Further	refinements	of	the	Nugent	
score have been described and have improved our understanding of the vagi-
nal microbiota [Ison et al., 2002; Verhelst et al., 2005]. The sensitivity and spec-
ificity	of	the	Amsel	criteria	are	70%	and	94%,	respectively,	when	compared	to	
the Nugent score [Schwebke et al., 1996]. Compared to the Amsel criteria, the 
Nugent score allows for assessment of the alteration in the vaginal microbiota 
in a continuous way rather than a dichotomous way.
47
In summary, classical bacterial culture methods and the use of a rather simple 
microscopical assessment of the vaginal microbiota have resulted in knowl-
edge on the role of the vaginal microbiota in (reproductive) health and disease. 
Much has been learned about the epidemiology of BV and its plethora of ad-
verse health outcomes. However, issues such as the etiology of BV remained un-
resolved. In addition, observations such as (i) responders versus non-respond-
ers to treatment in symptomatic BV, (ii) the failure of preventive trials that aim 
to reduce preterm birth incidence in pregnant women by treating BV, (iii) symp-
tomatic	versus	asymptomatic	women	with	BV	defined	by	Nugent	score	and	(iv) 
asymptomatic	women	without	lactobacilli	remained	unexplained.	Better	defi-
nitions of the vaginal microbiota were needed to try to resolve these enigmas.
6.3 The composition of the vaginal microflora  
– the molecular era
During the last two decades, our knowledge of diversity of the vaginal micro-
biota has expanded enormously through the use of molecular approaches that 
circumvented the need to cultivate. Indeed, it was found possible to extract 
DNA	from	microbiota	and	to	amplify	specific	regions	of	the	bacterial	16S	rRNA	
genes containing phylogenetic information by means of polymerase-chain re-
action	 (PCR).	 After	 PCR,	 the	 amplified	 fragments	 –	amplicons	–	 represent	 all	
bacterial members of a sampled microbiota. Individual amplicons can be sepa-
rated	using	different	techniques,	such	as	the	construction	of	clone	libraries,	de-
naturating gradient gel electrophoresis (DGGE), and terminal restriction frag-
ment length polymorphism (T-RFLP). Sequencing of the individual amplicons 
yield	identification,	resulting	in	accurate	descriptions	of	the	bacterial	composi-
tion of microbiota. 
 Pioneer molecular research Using above-mentioned approaches, important 
new insights soon emerged [Verhelst et al., 2004; Burton et al., 2003]. Detec-
tion of Lactobacillus iners	in	vaginal	microbiota	was	a	novel	finding	[Burton	et 
al., 2003; Verhelst et al., 2004]. L. iners,	a	species	that	is	difficult	to	cultivate,	
does not grow on traditional media nor has the typical characteristics of lacto-
bacilli, appeared to be present in vaginal microbiota of women with and with-
out BV. Importantly, a 16S cloning study showed that Atopobium vaginae, previ-
ously an unknown member of the vaginal microbiota, was strongly associated 
with BV [Verhelst et al., 2004]. A. vaginae now appears to be a hallmark of BV 
and even stronger associated with BV than G. vaginalis. Other species detected 
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in BV-associated microbiota were Megasphaera spp., Leptotrichia spp., and un-
designated bacteria named BV-associated bacterium-1 (BVAB-1) and BVAB-3, 
belonging to the phylum Clostridium [Fredricks et al., 2005]. Of interest, it was 
shown	 that	women	with	BV	had	different	DGGE	profiles	 indicating	heteroge-
neity in the composition of vaginal microbiota of women with BV [Burton et al., 
2003].
Undoubtedly, these pioneer molecular studies were of utmost importance 
for our further understanding of the vaginal microbiota, but still they were lim-
ited in that the number of amplicons that could be sequenced by traditional 
Sanger sequencing was too low to allow all member species of the vaginal mi-
crobiota,	especially	the	low	abundant	species,	to	be	detected	and	identified.
 Next-generation sequencing technologies The call for a high-throughput 
sequencing technology that could provide thousands of sequences per speci-
men	at	costs	affordable	in	clinical	research	was	answered	by	Roche,	introducing	
its pyrosequencing technology on the 454 sequencing platform. Costs further 
tumbled by the rise of competing technologies. Collectively, these new tech-
nologies are referred to as next-generation sequencing (NGS).
Several	NGS	studies	have	analysed	vaginal	microbiota	in	different	study	pop-
ulations in both cross-sectional and longitudinal design [Ravel et al., 2013; 
Schellenberg et al., 2009; Gajer et al., 2012] and revealed compositions of the 
vaginal microbiota with unprecedented taxonomic resolution. Species shown 
previously to be associated with a healthy microbiota respectively with a dis-
turbed BV-associated microbiota are consistenly found together with a long list 
of minority species, previously unknown to be present in the vaginal microbio-
ta [van de Wijgert et al., 2014].
Some authors introduced the name community state, referring to the compo-
sition of the individual vaginal microbiota. Bioinformatic analyses of commu-
nity	states	of	different	women	allows	to	group	women	with	similar	community	
states	into	different	clusters,	named	community	state	types	(CST),	each	with	a	
markedly	different	bacterial	species	composition	[Ravel	et al., 2011]. 
Although L. crispatus was long thought to be the most common Lactobacillus 
spp. [Antonio et al., 1999], there is now emerging consensus that L. iners is the 
most prevalent vaginal species, including in women with BV and that L. crispa-
tus is mostly present in women with a healthy vaginal microbiota [Zhou et al., 
2004; van de Wijgert et al., 2014]. 
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6.4 The classic vaginal microbiota paradigm revisited
Numerous studies have shown that women with high vaginal concentrations of 
lactobacilli such as L. crispatus, L. gasseri, L. jensenii and/or L. vaginalis species 
do not have symptomatic BV, but the corollary that women whose vaginal mi-
crobiota are deprived in lactobacilli also have BV or an ‘unhealthy’ microbiota 
is faulty logic [Santiago et al., 2012; Jespers et al., 2015; Ravel et al., 2011; Zhou 
et al., 2004; Ma et al., 2012]. As much as 20–30% of asymptomatic and healthy 
women harbor vaginal microbiota reduced in lactobacilli and composed of a 
diverse array of facultative/strictly anaerobic bacteria that are associated with 
a somewhat higher pH (5.3–5.5), including members of the genera Atopobium, 
Corynebacterium, Anaerococcus, Peptoniphilus, Prevotella, Gardnerella, Sneath-
ia, Eggerthella, Mobiluncus and Finegoldia [Ravel et al., 2011; Zhou et al., 2004; 
Zhou et al., 2007; Zhou et al., 2010; Hyman et al., 2005]. 
Indeed, although NGS studies undeniable revealed valuable information on the 
composition of the vaginal microbiota, there is still a big gap of knowledge to 
be	filled	on	the	functional	characteristics	of	these	vaginal	microbiota	that	drive	
the	 interactions	with	 the	host	 in	health	and	disease.	Of	 interest,	 in	 the	field	
studying gut microbiota, enterotypes – the counterparts of CSTs – are not de-
fined	by	the	species	composition	or	the	presence	of	a	core	set	of	species,	but	by	
a core set of genes that are involved in critical metabolic pathways [Turnbaugh 
& Gordon, 2009].
6.5 The vaginal microbiota is highly dynamic
 A lifetime of vaginal bacteria The composition of the vaginal microbiota 
changes profoundly during lifetime driven by estrogen levels [Cribby et al., 
2008]. After birth, the neonatal vagina is normally sterile but is very soon colo-
nized with corynebacteria, staphylococci, and nonhemolytic streptococci most-
ly derived from the maternal vaginal microbiota [Mandar et al., 1996]. Of inter-
est, the maternal vaginal microbiota has recently been shown to play in a key 
rol in the colonization of neonates, as vaginally delivered infants harbored bac-
teria resembling those of the maternal vaginal microbiota, whereas neonates 
delivered by caesarean section harbored bacteria resembling those of the ma-
ternal skin microbiota [Dominguez-Bello et al., 2010].
During the early stage of infancy, maternal residual estrogen is still present 
in the neonatal circulation and induces thickening of the vaginal epithelium 
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and deposition of glycogen in epithelial cells. Glycogen – a polysaccharide of 
glucose – is released upon exfoliation of these epithelial cells and is fermented 
by glucose-fermenting bacteria [Boskey et al., 1999]. The presence of glyco-
gen in the vaginal mucosa favors the colonization glucose-fermenting bacteria, 
mainly lactobacilli. The fermentation of glycogen by lactobacilli and the pro-
duction of lactic acid as it’s end product is thought to be the main mechanism 
for lowering the vaginal pH. 
When the maternal estrogen levels in infants drop, the reverse cascade takes 
place: the vaginal mucosa thins, the glycogen levels drop, the lactobacilli disap-
pear and the vaginal pH increases. This changed physiology is associated with 
a vaginal microbiota composed of species of the genera Actinomyces, Bacteroi-
des, Bifidobacterium, Fusobacterium, Peptococcus, PeptoStreptococcus, Propion-
ibacterium, Staphylococcus and Veillonella. Importantly, no bacteria associated 
with a normal or BV-associated vaginal microbiota of women of reproductive 
age, such as lactobacilli, G. vaginalis, P. bivia or M. hominis are present in prepu-
bertal girls [Hill et al., 1995; Dei et al., 2010; Randelovic et al., 2012].
At menarche, the production of estrogen leads to a thickened mucosa and a 
glycogen deposit in the vaginal mucosa, and the vaginal microbiota changes to 
one typical of women of reproductive age, dominated by lactobacilli [Hillier et 
al., 1997; Marrie et al., 1980]. The composition of the vaginal microbiota and 
its correlates has been most studied during this stage of life and is discussed 
above. 
When menopause sets in, women develop a vaginal microbiota deprived in 
lactobacilli that resembles that of BV but without symptoms [Cauci et al., 2002; 
Gustafsson et al., 2011; Petricevic et al., 2012].
 Temporal dynamics of the vaginal microbiota Most studies have assessed 
the composition of the vaginal microbiota in a cross-sectional study designs 
in which samples are obtained from individuals at a single time point, or with 
weeks to months between sampling points. Although of major importance for 
our knowledge of the species composition of the vaginal microbiota and its cor-
relates, these studies yielded little insight into the temporal dynamics of these 
vaginal microbiota.
Microscopic	 studies	 documented	 daily	 or	 two-weekly	 fluctuations	 in	 the	
composition of the vaginal microbiota [Brotman et al., 2010b; Schwebke et al., 
1999], but it’s truly dynamic composition became only fully clear after pioneer-
ing studies that assessed the diversity of the vaginal microbiota on a daily ba-
sis using molecular techniques [Santiago et al., 2012; Ravel et al., 2013]. Some 
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women were shown to harbor vaginal microbiota that changed markedly even 
on a day time, eg. some species with a nearly 100% relative abundance disap-
peared completely ‘overnight’ in order to reappear a day later [Santiago et al., 
2012; Ravel et al., 2013]. In contrast to these highly dynamic microbiota, some 
women were found to have relatively stable microbiota, even if in the absence 
of Lactobacillus spp. [Santiago et al., 2012; Ravel, 2013]. 
Longitudinal	studies	have	revealed	factors	 influencing	 the	stability	of	 the	
vaginal	microbiota.	One	of	the	major	influencing	factors	is	the	menstrual	cycle.	
Over the course of the menstrual cycle, hormonal and glycogen levels in the va-
gina	fluctuate,	and	menstrual	blood	increases	the	vaginal	pH	and	offers	a	new	
niche	for	bacteria.	Menses	have	been	shown	to	have	a	negative	effect	on	the	
stability of the vaginal microbiota [Santiago et al., 2012], with a prominent in-
crease of L. iners, A. vaginae and G. vaginalis and a decrease of L. crispatus. 
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study of vaginal carriage of  
group B streptococci (GBS) and  
Escherichia coli in resource-poor  
settings: prevalences and risk factors
— CHAPTER 7 
7.1 Abstract
Background
One million neonates die each year in low- and middle-income countries be-
cause of neonatal sepsis; group B Streptococcus (GBS) and Escherichia coli are 
the leading causes. In sub-Saharan Africa, epidemiological data on vaginal GBS 
and E. coli carriage, a prerequisite for GBS and E. coli neonatal sepsis, respec-
tively, are scarce but necessary to design and implement prevention strategies. 
Therefore, we assessed vaginal GBS and E. coli carriage rates and risk factors 
and the GBS serotype distribution in three sub-Saharan countries.
Methods
A total of 430 women from Kenya, Rwanda and South Africa were studied 
cross-sectionally. Vaginal carriage of GBS and E. coli, and GBS serotype were as-
sessed	using	molecular	techniques.	Risk	factors	for	carriage	were	identified	us-
ing multivariable logistic regression analysis. 
Results
Vaginal carriage rates in reference groups from Kenya and South Africa were 
20.2% (95% CI, 13.7–28.7%) and 23.1% (95% CI, 16.2–31.9%), respectively 
for GBS; and 25.0% (95% CI, 17.8–33.9%) and 27.1% (95% CI, 19.6–36.2%), 
respectively for E. coli. GBS serotypes Ia (36.8%), V (26.3%) and III (14.0%) 
were most prevalent. Factors independently associated with GBS and E. coli 
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carriage were Candida albicans, an intermediate vaginal microbiome, bacteri-
al vaginosis, recent vaginal intercourse, vaginal washing, cervical ectopy and 
working as a sex worker. GBS and E. coli carriage were positively associated.
Conclusions
Reduced vaginal GBS carriage rates might be accomplished by advocating be-
havioral changes such as abstinence from sexual intercourse and by avoidance 
of vaginal washing during late pregnancy. It might be advisable to explore the 
inclusion of vaginal carriage of C. albicans, GBS, E. coli and of the presence of 
cervical ectopy in a risk- and/or screening-based administration of antibiotic 
prophylaxis. Current phase II GBS vaccines (a trivalent vaccine targeting sero-
types Ia, Ib, and III, and a conjugate vaccine targeting serotype III) would not 
protect the majority of women against carriage in our study population.
7.2 Introduction 
One million children die each year in low- and middle-income countries in the 
first	4	weeks	of	 life	because	of	neonatal	sepsis	 [Lawn	et al., 2005]. Early-on-
set	neonatal	sepsis	 (EOS),	occurring	 in	 the	first	week	of	 life,	accounts	 for	ap-
proximately 80% of cases, and is caused by bacteria that are transmitted ver-
tically from the genital tract of the mother to infant before or during delivery 
[Hornik et al., 2012]. Late-onset neonatal sepsis (LOS) occurs between week 1 
and month 2 to 3 of life and may be caused by bacteria acquired vertically or 
horizontally [Schuchat 1998]. Because the transfer of a single species from the 
maternal genitourinary tract to the neonate before or during delivery is a pre-
requisite for EOS [Cutland et al., 2009], there are unique opportunities for pre-
vention of EOS.
At present, Streptococcus agalactiae (Group B Streptococcus, GBS) and Escherichia 
coli are the leading causes of EOS worldwide [Simonsen et al., 2014]. Further-
more, GBS and E. coli are associated with preterm birth, very-low-birth-weight 
delivery and puerperal sepsis [Krohn et al., 1997; Acosta et al., 2014], which 
cause substantial morbidity and mortality in sub-Saharan Africa (SSA) [Hornik et 
al., 2012; Beck et al., 2010; Khan et al., 2006]. 
To	prevent	EOS,	efforts	have	been	focusing	mainly	on	GBS	and	high-income	
countries, based on two strategies, namely the screening- or risk-based admin-
istration of intrapartum antibiotic prophylaxis (IAP) and the development of 
vaccines [Melin and Efstratiou 2013].
59
IAP has been shown to reduce the incidence of GBS EOS from 1.7/1000 to 
0.6/1000 in the US [Schrag et al.,	2000],	but	is	not	effective	against	E. coli EOS, 
LOS, and adverse perinatal outcomes related to GBS [Regan et al., 1996; Ohls-
son et al., 2014]. Furthermore, according to the current universal guidelines 
(Centers for Disease Control and Prevention, CDC), IAP should be administered 
to women found positive for GBS at 35–37 weeks of gestation [Verani et al., 
2010]. However, these guidelines are not followed in most health-care facilities 
in low-income countries. The use of intravaginal washes with chlorhexidine (a 
wide-spectrum microbicide) during labour and neonatal wipes with chlorhex-
idine, has been explored in low- and middle-income countries, but is unlikely 
to prevent vertically acquired neonatal infections in any setting or population 
[Cutland et al., 2009].
Most GBS vaccines under development aim at eliciting protective antibod-
ies against capsular polysaccharides (CPS), the most important GBS virulence 
factor of which ten antigenically distinct CPS are known [Melin and Efstratiou 
2013], and are attractive as some of the IAP-related problems may be circum-
vented [Melin and Efstratiou 2013]. However, these vaccines might not be ef-
fective	 in	 low-income	 countries	 because	 of	 different	 serotype	 distribution	
[Johri et al., 2006].
Although SSA has the highest rates of neonatal sepsis mortality worldwide, 
epidemiological data on vaginal GBS and E. coli carriage are very limited but 
necessary to develop and implement prevention strategies [Capan et al., 2012; 
Stoll et al., 1998]. Therefore, in this multi-country cross-sectional study, we as-
sessed the vaginal GBS and E. coli carriage prevalence, risk factors for GBS and E. 
coli carriage, and GBS serotype distribution in populations from three countries: 
Kenya, Rwanda and South Africa.
7.3 Patients and methods 
Study design and population
In 2010–2011, we conducted a multi-country follow-up study entitled ‘‘Char-
acterisation of novel microbicide safety biomarkers in East and South Africa’’. 
The main aim of that project was to characterise the vaginal microbiome and 
the cervicovaginal mucosal immune system in African women and to assess 
changes of these over time [Gautam et al., 2015; Jespers et al., 2014; Jespers 
et al., 2015; Kyongo et al., 2015]. In that study, 430 women were recruited at 
three study sites, i.e. the International Centre for Reproductive Health Kenya 
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(ICRHK) in Mombasa, Kenya (170 women); the non-governmental organisation 
Rinda Ubuzima (RU) in Kigali, Rwanda (60 women), and the Wits Reproductive 
Health and HIV Institute (Wits RHI) in Johannesburg, South Africa (SA) (200 
women).	The	women	were	recruited	into	6	predefined	study	groups:	a	reference	
group of 219 women (adult, non-pregnant, HIV-negative women at average risk 
of HIV), 60 pregnant women (up to 14 weeks of gestational age as determined 
by abdominal ultrasound at recruitment), 60 adolescent girls (16–17 years), 31 
HIV-negative women engaging in vaginal practices (usage of cloth, lemon juice, 
or detergents to clean, dry or tighten the vagina on a regular basis), 30 self-ac-
knowledged female sex workers (FSW), and 30 HIV-positive women (on antiret-
roviral treatment for at least 6 months, asymptomatic and with a CD4 count of 
more than 350 cells/µl) (Table 2). Participants were eligible for inclusion if they 
were in good physical and mental health, able and willing to participate in the 
study as required by the protocol, able and willing to give written informed con-
sent (including written parental or guardian consent for adolescents). Women 
were excluded if they had never had penetrative vaginal intercourse, if they 
had a history of hysterectomy or other genital tract surgery in the three months 
prior to the screening visit, if external and/or internal genital warts were found, 
if they were enrolled in HIV prevention trials involving investigational products, 
if they were less than 6 months post-partum at the time of enrolment, if they 
were HIV-positive (unless for inclusion in the HIV-positive women group), or if 
they were pregnant (unless for inclusion in the pregnant women group). The 
study population, followed up for approximately eight months per person over 
8 visits, is described in detail by Jespers and coworkers [Jespers et al., 2014]. 
TABLE 2 Study population and vaginal GBS and E. coli carriage rates.
City, Country Group n
GBS prevalence % 
(95% CI)
E. coli prevalence % 
(95% CI)
Mombasa, Kenya Reference group 110 20.2 (13.7–28.7) 25.0 (17.8–33.9)
Mombasa, Kenya Pregnant women 30 14.3 (5.7–31.5) 14.3 (5.7–31.5)
Mombasa, Kenya Adolescents 30 3.6 (0.6–17.7) 28.6 (15.3–47.1)
Kigali, Rwanda FSW 30 20.0 (9.5–37.3) 70.0 (52.1–83.3)
Kigali, Rwanda HIV+ women 30 0.0 (0.0–11.4) 20.0 (9.5–37.3)
Johannesburg, SA Reference group 109 23.2 (16.2–31.9) 27.1 (19.6–36.2)
Johannesburg, SA Pregnant women 30 10.0 (3.5–25.6) 33.3 (19.2–51.2)
Johannesburg, SA Adolescents 30 0.0 (0.0–11.4) 13.3 (5.3–29.7)
Johannesburg, SA Vaginal practices 31 25.8 (13.7–43.2) 30.0 (16.7–47.9)
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The current study presents one of the tertiary objectives of the above-men-
tioned study, namely to document the vaginal carriage rates of the main patho-
gens associated with EOS (GBS and E. coli) and the risk factors for their carriage. 
These	analyses	are	based	on	the	screening	visit	and	the	first	visit	(scheduled	
soon after the last day (day 9 ± 2 days) of the menstrual period) from the fol-
low-up study. 
Study procedures
At the screening visit, blood, vaginal, endocervical and urine samples were tak-
en for diagnostic testing of HIV, HSV-2, syphilis, Neisseria gonorrheae (NG), Chla-
mydia trachomatis (CT), Trichomonas vaginalis (TV), urinary tract infection (UTI), 
pregnancy, cervical dysplasia (by Pap smear), bacterial vaginosis (BV) (Amsel 
criteria), and vaginal candidiasis. Treatment was provided according to national 
guidelines,	voluntary	HIV	counseling	was	offered,	and	condoms	were	provided	
free-of-charge.
At	visit	1,	two	sterile	Copan	flocked®	vaginal	swabs	(Copan	Diagnostics,	Inc.,	
Murrieta, CA), to be used for the molecular detection of GBS and E. coli, were 
brought into the vaginal vault by the study clinician, rotated against the vag-
inal wall at the midportion of the vault, gently dipped in the posterior fornix 
and carefully removed to prevent contamination with the microbiome of the 
vulva and introitus. The swab heads were collected into two 1.5 ml cryovials, 
labelled	and	immediately	frozen	at	-80	°C	until	shipment	to	the	central	labo-
ratory at the Institute of Tropical Medicine (ITM, Antwerp, Belgium) using tem-
perature-monitored	dry	shippers	filled	with	liquid	nitrogen.	One	Amies	swab	
(Copan Diagnostics, Inc.) for culturing was taken in a likewise manner, placed in 
the	Amies	tube,	and	transported	at	4	°C	in	a	temperature-monitored	cooler	to	
the local laboratory, where it was processed immediately. At both visits, women 
were interviewed during face-to-face interviews about their general and sexual 
health, vaginal habits and sociodemographic characteristics. A physical exam-
ination including speculum and bimanual pelvic examination was carried out 
by a clinician. At each visit, participants were compensated for their time and 
transportation.
Diagnosis of genital infections
At the local laboratories, tests for HIV, HSV-2, syphilis, CT and NG were per-
formed. For immediate detection of Candida cells and hyphae, TV, and clue cells, 
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wet mount microscopy was used. For the purpose of this study, a commercial-
ly available TV InPouchTM system (BioMed Diagnostics, White City, Oregon) was 
used. For this, a vaginal swab was inoculated according to the manufacturer’s in-
structions and InPouch cultures were monitored on a daily basis. InPouch bags 
with	no	growth	at	the	end	of	five	days	were	considered	negative.	BV	diagnosed	
according to the Amsel criteria was used for immediate treatment. For research, 
vaginal smears were made and sent to ITM for Gram staining and Nugent scor-
ing,	a	scoring	system	to	diagnose	BV.	Briefly,	smears	from	vaginal	swabs	were	
prepared	by	rolling	the	swab	onto	a	glass	slide.	Slides	were	air-dried	and	fixed	
using	70%	ethanol.	For	the	Gram-staining	at	ITM,	the	fixed	smear	was	covered	
with	crystal	violet	for	1	minute,	washed	with	water,	flooded	with	Lugol’s	iodine	
for 1 minute, washed with water, and then decolorized with acetone-alcohol for 
2–3 seconds. The smears were rinsed quickly under running water to stop the 
decolorisation and then counterstained with safranin for 1 minute. All reagents 
were from Becton Dickinson (BD). All smears were examined microscopically 
with the 40x objective to check the staining and the distribution of the material, 
and	then	assessed	under	oil	immersion	objective	(1000x	magnification)	using	
the grading system described by Nugent and co-workers [Nugent et al., 1991]. 
The Nugent score is calculated by assessing for the presence of Lactobacillus 
cell types, small Gram-variable coccobacilli, and curved Gram-variable rods. A 
score of 0–3 is considered as normal (BV-negative); a score of 4–6 as an inter-
mediate vaginal microbiome; and a score of 7–10 as BV-positive.
DNA extraction
For the molecular detection of GBS and E. coli, DNA extraction from the two Co-
pan swabs of each subject was carried out at ITM by thawing the swabs at room 
temperature for 30 minutes. After adding 1200 µL of diluted PBS, each swab 
was gently vortexed for 15 seconds, and 1 mL of each swab suspension was 
pooled	into	a	final	volume	of	2	mL.	An	aliquot	of	250	μL	was	extracted	using	
the Abbott m24sp automated extraction platform (Abbott, Maidenhead, UK), ac-
cording to the manufacturer’s instructions, and 200 µl of eluted DNA – to be 
used	in	the	quantitative	PCR	(qPCR)	assays	–	was	stored	at	-80	°C.
For the construction of qPCR standard curves, DNA was extracted from over-
night cultures of S. agalactiae LMG 14694T on TSA + 5% sheep blood, E. coli 
ATCC 25922 grown on TSA + 5% sheep blood, and C. albicans ATCC 90028 
grown on Sabouraud agar (all BD). All growth was harvested from the plate and 
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resuspended in 1 ml of saline. DNA of this suspension was extracted using the 
High Pure PCR Template Preparation Kit (Roche Applied Science, Basel, Switzer-
land) according to the manufacturer’s instructions. 
For capsular genotyping of GBS, 1 ml of inoculated Lim Broth medium (see 
Microbiological culturing) was used for DNA extraction using the High Pure 
PCR Template Preparation Kit (Roche), according to the the manufacturer’s 
instructions.
Streptococcus agalactiae qPCR
To detect S. agalactiae in vaginal DNA extracts, a S. agalactiae specific	qPCR	was	
carried out, using primers previously described [Bergh et al., 2004]. The qPCR 
reactions for S. agalactiae	were	performed	in	a	final	volume	of	10	µl, contain-
ing 5 µl	of	LightCycler	480®	SYBR	Green	I	Master	(Roche),	0.5	µM of both for-
ward primer Sip1 (5’-ATCCTGAGACAACACTGACA-3’) and reverse primer Sip2 
(5’-TTGCTGGTGTTTCTATTTTCA-3’), 0.3 µM of probe (5’- 6-FAM–ATCAGAAGAGT-
CATACTGCCACTTC–TAMRA-3’) (Eurogentec, Liège, Belgium) and 2 µl of DNA ex-
tract or 2 µl of HPLC water (as negative template control). Cycling conditions 
were	as	follows:	95	°C	for	5	min;	40	cycles	of	95	°C	for	10	s,	58	°C	for	15	s	and	
72	°C	for	20	s.	For	the	standard	series,	DNA	concentration	of	the	extract	of	S. 
agalactiae	LMG	14694T	was	determined	using	the	Qubit®	Fluorometer	(Invit-
rogen, Auckland, New Zealand) and the genomic concentration was calculated 
based on the GC% content and genome size of the type strain. A tenfold dilu-
tion standard series of S. agalactiae LMG 14694T DNA was prepared by dilution 
of the DNA stock in HPLC grade water. All standard tenfold dilution series and 
samples	were	run	in	duplicate.	Amplification,	detection	and	quantification	were	
carried	out	using	the	LightCycler480®	platform	and	the	LightCycler®	480	Soft-
ware Version 1.5 (Roche). 
Escherichia coli qPCR
To detect E. coli in vaginal DNA extracts, an E. coli	specific	qPCR	was	carried	out,	
using primers targeting the β-glucuronidase encoding gene uidA, previously 
described [Chern et al.,	2011].	The	qPCR	reactions	were	performed	in	a	final	vol-
ume of 10 µl, containing 5 µl	of	LightCycler	480®	SYBR	Green	I	Master	(Roche),	
0.3 µM of both forward primer EcoliFW (5’-CAACGAACTGAACTGGCAGA-3’) and 
reverse primer EcoliRV (5’- CATTACGCTGCGATGGAT -3’) (Eurogentec) and 2 µl of 
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DNA extract or 2 µl of HPLC water (as negative template control). Cycling condi-
tions	were	as	follows:	50	°C	for	2	min,	95	°C	for	10	min;	40	cycles	of	95	°C	for	15	
s	and	60	°C	for	1	min.	A	standard	series	(using	E. coli ATCC 25922 grown on TSA + 
5% sheep blood (BD)), was constructed as described for S. agalactiae. 
Candida albicans qPCR
To detect C. albicans in vaginal DNA extracts, a C. albicans	specific	qPCR	was	car-
ried out, using primers targeting the ITS-1 gene (adapted from [25]). The qPCR 
reactions	were	performed	in	a	final	volume	of	10	µl, containing 5 µl of LightCy-
cler	480®	SYBR	Green	I	Master	(Roche),	0.3	µM of both forward primer CA_FW 
(5’-CAACGAACTGAACTGGCAGA-3’) and reverse primer CA_RV (5’- CATTACGCT-
GCGATGGAT -3’) (Eurogentec) and 2 µl of DNA extract or 2 µl of HPLC water (as 
negative	template	control).	Cycling	conditions	were	as	follows:	50	°C	for	2	min,	
95	°C	for	10	min;	40	cycles	of	95	°C	for	15	s	and	60	°C	for	1	min.	A	standard	se-
ries (using C. albicans ATCC 90028 grown on Sabouraud agar (BD)), was con-
structed as described for S. agalactiae. 
Microbiological culturing
At the local laboratories, the Amies swab was inoculated on in-house TMBplus 
plates (a medium supporting growth of anaerobes and allowing assessment of 
hydrogen peroxide production of strains) [26], after which the plates were in-
cubated anaerobically as described previously [Verhelst et al., 2004]. After 48–
72 h, depending on the growth, all biological material of the culture plate was 
harvested using sterile cotton swabs and stored in cryovials with 1 ml of tryp-
tic	soy	broth	+	5%	glycerol	at	-80	°C	until	shipment.	After	shipment	to	the	ITM,	
bacteria from the cryovial were inoculated in commercial Lim Broth medium 
(BD) – a selective enrichment medium for GBS – according to the manufactur-
er’s instructions (5% CO2	at	35°C	for	24	hours).	The	latter	procedure	was	per-
formed only for women found to be positive for vaginal GBS carriage by means 
of qPCR. DNA extracts of inoculated Lim Broth medium was used for direct mo-
lecular capsular typing of GBS.
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S. agalactiae molecular capsular typing
To	determine	the	GBS	serotype,	we	used	a	flowchart	described	by	[Yao	et al., 
2013], based on the multiplex PCRs with primers as described by Poyart and 
co-workers and Imperi and co-workers [Poyaert et al., 2007; Imperi et al., 2010]. 
The multiplex PCRs were performed directly on DNA extracted from the inocu-
lated	Lim	Broth	medium.	The	reactions	were	performed	in	a	final	reaction	mix-
ture of 20 µl, containing 10 µl of FastStart PCR Master Mix (Roche), 0.2 µM of 
each primer, and 2 µl of DNA template. Using a Veriti 96-well thermal cycler 
(Applied Biosystems, Foster City, CA), the following PCR program was run: 94 
°C	for	5	min,	3	cycles	of	45	s	at	94	°C,	2	min	at	50	°C,	1	min	at	72	°C,	and	30	cy-
cles	of	20	s	at	94	°C,	1	min	at	50	°C	and	1	min	at	72	°C,	with	a	final	extension	at	
72	°C	for	7	min.	PCR	amplification	products	were	visualised	under	UV	light	after	
electrophoresis on 1% agarose gels (30 minutes at 10 V/cm) and staining with 
ethidiumbromide.	Twenty-five	control	strains	(covering	all	GBS	serotypes	and	
provided by the Belgian Streptococcus agalactiae reference center (Dr. Pierette 
Melin, University of Liège, Belgium)) were used as a positive control.
Physiological parameters
Vaginal pH was measured during the speculum examination by pressing com-
mercial pH strips (pH Fix 3.6–6.1, Machery-Nagel) against the vaginal wall. De-
tection	of	prostate-specific	antigen	(PSA),	a	marker	for	sexual	intercourse	with-
in the past 24 hours [Macaluso et al.,	1999]	in	vaginal	swab	fluid	was	performed	
using	a	chromatographic	immune	assay	(the	Seratec®	PSA	SemiQuant	Cassette	
Test, Seratec, Gottingen, Germany) according to the manufacturer’s instructions. 
Pregnancy was assessed by testing urine with a rapid hCG test (QuickVue One-
Step hCG Test (Kigali, Johannesburg) or Unimed First Sign hCG test (Mombasa)). 
Leucocytes and erythrocytes in urine were detected using dipsticks according 
to	the	manufacturer’s	instructions	(Siemens	Multistix	10	sg	in	Kigali,	Mission®	
urinalysis strips in Mombasa, and Neotest 4 Urine Dipstick in Johannesburg).
Statistical analysis
Data were analyzed with SPSS software version 22 (SPSS Inc.). Prevalences were 
reported	with	their	95%	confidence	interval.	Outcomes	for	this	analysis	were	
vaginal GBS carriage and vaginal E. coli carriage, as determined by a positive 
qPCR. 
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Independent variables considered were study site, sociodemographic char-
acteristics, reproductive health characteristics, sexual behavioural factors, vag-
inal practices characteristics, cervicovaginal signs and symptoms and micro-
biological characteristics. Variables were analyzed using logistic regression 
in univariable and multivariable ways, with p-values < 0.05 indicating sig-
nificance.	 In	order	not	 to	overfit	our	multivariable	models,	variables	were	re-
stricted in proportion to the number of cases positive for GBS and E. coli, i.e. 
maximum one degree of freedom per 10 cases [Babyak et al., 2004]. Variables 
included in the models were selected as follows [Wakkee et al.,	2014]:	firstly,	
only	variables	found	to	be	significantly	associated	with	GBS	or	E. coli carriage 
in univariable analysis were considered for inclusion the multivariate GBS or 
E. coli model, respectively. Subsequently, of correlated variables (e.g. ‘having 
had recent vaginal intercourse’ and a positive PSA test), only one was kept for 
further	consideration	to	avoid	collinearity.	The	final	selection	of	variables	was	
based on literature and clinical expertise/relevance. The multivariable mod-
els were controlled for possible confounding variables and were validated with 
bootstrap analysis.
Ethics statement 
Written information and consent forms in the local language were provided to 
the women or to the Legally Authorized Representatives for their review. After 
the interview, the participants were asked to express their willingness to par-
ticipate in the study by signing (or thumb-printing in case they were illiterate) 
the consent form. In case they were of minor age (age below 18 in Kenya and SA, 
and below 21 in Rwanda), also the parents or guardians were asked to give con-
sent. The study was approved by the Kenyatta National Hospital Ethical Review 
Committee, Kenya; the Human Research Ethics Committee (Medical), Universi-
ty of the Witwatersrand, SA; the Rwanda National Ethics Committee, Rwanda; 
the Institutional Review Boards of the Institute of Tropical Medicine in Antwerp, 
of Ghent University, and of the University Teaching Hospital in Antwerp, Bel-
gium. In addition, the study was approved by the National Council on Science 
and Technology in Kenya, and the National AIDS Control Commission in Rwanda. 
The study is registered at the Trial Registration at the National Health Research 
Ethics Council South Africa (DOH2709103223) [Jespers et al., 2014].
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7.4 Results
Vaginal GBS and E. coli carriage and GBS serotype distribution 
Of the 430 women enrolled in the study, 424 and 421 vaginal swab DNA ex-
tracts were analysed for the presence of GBS and E. coli, respectively. The vagi-
nal GBS and E. coli	carriage	rates	in	the	different	study	groups	are	presented	in	
Table 1.
The GBS serotype distribution is presented in Table 3 and Fig 7. For 12 GBS 
carriers, the serotype could not be determined because samples were no lon-
ger available. Serotype distribution was largely comparable between sites. The 
most prevalent serotypes were Ia (27.3%), V (27.3%), and III (22.7%) in Kenya; 
Ia (34.5%), V (31.0%), and IV (13.8%) in SA; and Ia (83.3%) and II (16.7%) in 
Rwanda. 
FIGURE 7 Distribution of GBS capsular serotypes.  
 Left, Kenya (n=22);  
 Middle, Rwanda (n=6);  
 Right, South Africa (n=29).
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TABLE 3 Studies reporting GBS serotype distribution of (recto)vaginal isolates in SSA.
Country Year Population Ia Ib II III IV V VI VII VIII IX NT Reference
The Gambia 1994 P 19 28 6 3 38 [Suara et al., 1994]$
Malawi 2011
P, HIV+,  
HIV-
18.2 6.2 10.3 39.0 0.3 23.9 0.8 0.8 1.5 [Gray et al., 2011]
SA 2011 P 30.1 6.7 11.3 37.3 3.7 10.2 [ Madzivhandila et al., 2011]
SA 2014 P 36.2–41.4 3.5–4.6 7.2–7.5 31.3–34.9 2.0–4.0 10.3–15.6 0.0–3.3 [Kwatra et al., 2014]
Kenya 2015 P, NP 27.3 22.7 27.3 13.6 4.5 4.5 This study
Rwanda 2015 NP 83.3 16.7 This study
SA 2015 P, NP 34.5 10.3 13.8 31.0 6.9 3.4 This study
Europe 2010 N/A 18.2 12.4 14.4 28.1 3.7 14.9 0.6 0.6 0.6 [Ippolito et al., 2010]£
US 2010 N/A 26.8 8.1 10.9 24.8 1.0 15.0 0.3 0.0 0.2 [Ippolito et al., 2010]£
 
P, pregnant;  
NP, non-pregnant;  
$determined serotypes I-VI (no differentiation between Ia and Ib);  
N/A, not applicable (review);  
£data from meta-analysis but excluding isolates from non-sterile sites and from neonates 
were excluded. 
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TABLE 3 Studies reporting GBS serotype distribution of (recto)vaginal isolates in SSA.
Country Year Population Ia Ib II III IV V VI VII VIII IX NT Reference
The Gambia 1994 P 19 28 6 3 38 [Suara et al., 1994]$
Malawi 2011
P, HIV+,  
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18.2 6.2 10.3 39.0 0.3 23.9 0.8 0.8 1.5 [Gray et al., 2011]
SA 2011 P 30.1 6.7 11.3 37.3 3.7 10.2 [ Madzivhandila et al., 2011]
SA 2014 P 36.2–41.4 3.5–4.6 7.2–7.5 31.3–34.9 2.0–4.0 10.3–15.6 0.0–3.3 [Kwatra et al., 2014]
Kenya 2015 P, NP 27.3 22.7 27.3 13.6 4.5 4.5 This study
Rwanda 2015 NP 83.3 16.7 This study
SA 2015 P, NP 34.5 10.3 13.8 31.0 6.9 3.4 This study
Europe 2010 N/A 18.2 12.4 14.4 28.1 3.7 14.9 0.6 0.6 0.6 [Ippolito et al., 2010]£
US 2010 N/A 26.8 8.1 10.9 24.8 1.0 15.0 0.3 0.0 0.2 [Ippolito et al., 2010]£
 
P, pregnant;  
NP, non-pregnant;  
$determined serotypes I-VI (no differentiation between Ia and Ib);  
N/A, not applicable (review);  
£data from meta-analysis but excluding isolates from non-sterile sites and from neonates 
were excluded. 
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Univariable and multivariable analyses 
Tables 4 and 5 present the univariable associations of the sociodemographics, 
sexual behavior, vaginal practices, cervicovaginal signs and symptoms, and mi-
crobiological characteristics with vaginal GBS and E. coli carriage, respectively. 
Because of the low prevalence, CT, NG, TV, and syphilis were not considered for 
further analysis.
TABLE 4 Sociodemographic characteristics, reproductive health, sexual behavior,  
 vaginal practices, vaginal signs & symptoms, and microbiological associations  
 with vaginal GBS carriage (univariable analysis).
n GBS+ n (%) Crude OR (95% CI) p-value*
424 69 (16.3)
Sociodemographic characteristics
City (Country)
Mombasa (Kenya) 165 27 (16.4) 0.89 (0.51–1.53) 0.665
Kigali (Rwanda) 60 6 (10.0) 0.50 (0.20–1.26) 0.142
Johannesburg (SA) 199 36 (18.1) 1 -
Age (years)
<18 58 1 (1.7) 0.07 (0.01–0.50) 0.008
18–24 148 23 (15.5) 0.71 (0.41–1.23) 0.219
>24 218 45 (20.6) 1 -
Educational level
Higher educational level£ 189 39 (20.6) 1 -
Lower educational level££ 235 30 (12.8) 0.56 (0.33–0.95) 0.030
Marital status
Never married 242 34 (14.0) 1 -
Married 148 30 (20.2) 1.55 (0.91–2.67) 0.109
Separated/divorced/widowed 34 5 (14.7) 1.06 (0.38–2.91) 0.918
Socio-economic status#
Low 106 17 (13.0) 1 -
Medium 163 31 (19.0) 1.23 (0.64–2.36) 0.533
High 155 21 (13.5) 0.82 (0.41–1.64) 0.576
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Reproductive health
Pregnant
No 366 62 (16.9) 1 -
Yes 58 7 (12.1) 0.67 (0.29–1.55) 0.353
Parity
0 149 18 (12.1) 1 -
1–2 211 42 (19.9) 1.81 (1.00–3.29) 0.052
>2 64 9 (14.1) 1.19 (0.50–2.81) 0.690
Gravity
0 118 14 (11.9) 1 -
1–2 210 38 (18.1) 1.64 (0.85–3.17) 0.141
>2 96 17 (17.7) 1.60 (0.74–3.44) 0.230
Regular cycle
Yes 256 42 (16.4) 1 -
No/unknown 168 27 (16.1) 0.98 (0.58–1.66) 0.927
Menstrual cycle 
No cycle 194 33 (17.0) 1 -
With cycle 230 36 (15.7) 0.91 (0.54–1.51) 0.706
Contraceptive 
None 73 15 (20.5) 1 -
Condom only 108 10 (9.3) 0.40 (0.17–0.94) 0.035
Others (hormones/IUD/
sterilisation/pregnant)
243 44 (18.1) 0.86 (0.44–1.65) 0.639
Currently breastfeeding
No 390 64 (16.4) 1 -
Yes 34 5 (14.7) 0.88 (0.33–2.36) 0.796
Sexual behaviour
Age at first sexual encounter (years) 
<16 80 8 (10.0) 1 -
16–18 197 36 (18.3) 2.01 (0.89–4.5) 0.093
19–21 104 16 (15.4) 1.64 (0.66–4.04) 0.286
 >21 43 9 (20.9) 2.38 (0.85–6.71) 0.101
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Sexually active (last 3 months) 
No 55 4 (7.3) 1 -
Yes 369 65 (17.6) 2.73 (0.95–7.81) 0.062
Condom use (at last sexual encounter)@
No 229 47 (20,5) 1.75 (0.94–3.16) 0.050
Yes 140 18 (12.9) 1 -
Lifetime n° of sex partners
1 112 13 (11.6) 1 -
2–3 186 32 (17.2) 1.58 (0.79–3.16) 0,194
> 3 126 24 (19.0) 1.79 (0.86–3.71) 0,117
N° of sex partners in the last 3 months
0 25 0 (0.0) 1 -
>=1 399 69 (17.3) N/A 0.010
Recent vaginal sex% 
No 343 49 (14.3) 1 -
Yes 81 20 (24.7) 2.73 (0.95–7.81) 0.024
Sexual risk taking€
Low 167 25 (15.0) 1 -
Medium 155 30 (19.4) 1.36 (0.76–2.44) 0.297
High 102 14 (13.7) 0.90 (0.45–1.83) 0.779
Estimated frequency of sexual encounters in last 3 months@, &
0 55 4 (7.3) 1 -
< 10 times 137 18 (13.1) 1.93 (0.62–5.98) 0.255
11–30 times 129 24 (18.6) 2.91 (0.96–8.84) 0.059
> 30 times 98 23 (23.5) 3.91 (1.27–11.98) 0.017
HIV status partner@
HIV positive 38 3 (7.9) 1 -
HIV negative 250 52 (20.8) 3.06 (0.91–10.36) 0.072
Unknown 79 10 (12.6) 1.69 (0.44–6.54) 0.447
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Estimated frequency of unprotected sex in last 3 months
No sexual contacts 55 4 (7.3) 1 -
Never unprotected 104 12 (11.5) 1.66 (0.51–5.42) 0.399
< 10 times 88 14 (15.9) 2.41 (0.75–7.75) 0.139
>= 10 times 177 39 (22.0) 3.60 (1.23–10.59) 0.020
New partner (within 3 months)
No 378 60 (15.9) 1 -
Yes 46 9 (19.6) 1.29 (0.59–2.81) 0.523
Circumcision status partner@
Circumcised 240 38 (15.8) 1 -
No/don’t know Not circumcised/
don’t know
129 27 (20.9) 1.41 (0.81–2.43) 0.222
Female sex worker
Yes 30 6 (20.0) 1 -
No 394 64 (16.2) 1.03 (0.38–2.97) 0.952
Vaginal practices
Washing inside the vagina when bathing 
No 176 15 (8.5) 1 -
Yes 248 54 (21.8) 2.99 (1.63–5.49) <0.001
Drying the vagina before sex
Yes 10 4 (40.0) 1 -
No 414 65 (15.7) 3.58 (0.98–13.04) 0.053
Washed inside the vagina recently (morning or evening before study visit)
No 231 28 (12.1) 1 -
Yes 193 41 (21.2) 1.96 (1.16–3.30) 0.012
Products to wash/clean/dry/tighten the vagina
None 153 13 (8.5) 1 -
Water/fingers	only	or	water/soap 211 44 (20.9) 2.84 (1.47–5.48) 0.002
Cloth 48 9 (18.8) 2.49 (0.99–6.24) 0.053
Lemon juice/detergents 12 3 (25.0) 3.59 (0.86–14.92) 0.079
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Cleaning the vagina after sexual intercourse
No 227 28 (12.3) 1 -
Yes 197 41 (20.8) 1.87 (1.11–3.16) 0.019
Cervicovaginal signs and symptoms
Ectopy¶
No 226 34 (15.0) 1 -
Yes 197 34 (17.3) 1.18 (0.70–1.98) 0.536
Degree of ectopy¶ 
Absent 226 34 (15.0) 1 -
Small 53 8 (15.1) 1.00 (0.44–2.32) 0.993
Moderate 139 24 (17.3) 1.18 (0.67–2.09) 0.573
Large 5 2 (40.0) 3.77 (0.61–23.4) 0.155
Colposcopic findings§, ¶
No 380 59 (15.5) 1 -
Yes 43 10 (23.3) 1.65 (0.77–3.53) 0.197
Cervical mucus
No 270 39 (14.4) 1 -
Mild to moderate 140 28 (20.0) 1.48 (0.87–2.53) 0.151
Abundant 14 2 (14.3) 0.99 (0.21–4.58) 0.987
Reported abnormal discharge
No 399 64 (16.0%) 1 -
Yes	 25 5 (20%) 1.31 (0.47–3.61) 0.604
Vaginal discharge on speculum
No 332 52 (15.7) 1 -
Yes 92 17 (18.5) 0.82 (0.45–1.50) 0.518
Vaginal epithelial abnormalities
No 419 67 (16.0) 1 -
Yes 5 2 (40.0) 3.50 (0.57–21.36) 0.174
Cervical epithelial abnormalities
No 379 64 (16.9) 1 -
Yes 45 5 (11.1) 0.62 (0.23–1.62) 0.325
75
Red blood cells in urine
No 358 58 (16.2) 1 -
Yes 66 11 (16.7) 1.03 (0.51–2.10) 0.925
White blood cells in urine
No 328 56 (17.1) 1 -
Yes 96 13 (13.5) 0.76 (0.40–1.46) 0.411
Microbiological factors
BV visit 1 (Amsel criteria)
No BV 346 61 (17.6) 1 -
BV 78 8 (10.3) 0.53 (0.24–1.17) 0.116
BV (Nugent) ¶ 
No BV (Nugent 0–3) 217 37 (17.1) 1 -
Intermediate (Nugent 4–6) 29 6 (20.7) 1.30 (0.60–2.83) 0.507
BV (Nugent 7–10) 137 13 (9.5) 0.29 (0.12–0.70) 0.006
Reproductive tract infection (RTI) 
No RTI 352 60 (17.0) 1 -
1 or more RTI 60 8 (13.3) 0.75 (0.34–1.66) 0.475
>1 RTI 12 1 (8.3) 0.44 (0.06–3.50) 0.439
Syphilis
No 415 69 (16.6) 1 -
Yes 9 0 (0.0) N/A 0.001
Chlamydia trachomatis
No 382 62 1 -
Yes 42 7 1.03 (0.44–2.43) 0.942
Neisseria gonorrhoeae
No 415 69 (16.6) 1 -
Yes 9 0 (0.0) N/A 0.001
Trichomonas vaginalis
No 390 66 (16.9) 1 -
Yes 26 3 (11.5) 0.64 (0.19–2.20) 0.478
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Candida albicans (qPCR)
No 375 50 (13.3) 1 -
Yes 46 17 (37.0) 3.81 (1.95–7.44) <0.001
Escherichia coli (qPCR)
No 354 89 (25.1) 1 -
Yes 67 29 (43.3) 2.27 (1.33–3.90) 0.003
HSV-2 serology
No 276 42 (15.2%) 1 -
Yes 147 27 (18.4%) 1.25 (0.74–2.13) 0.404
Vaginal pH
< 4.4 126 15 (11.9) 1 -
4.4 – 5.3 240 42 (17.5) 1.57 (0.83–2.96) 0.163
5.4 and more 58 12 (20.7) 1.93 (0.84–4.44) 0.122
PSA present
No 233 31 (13.3) 1 -
Yes 181 38 (21.0) 1.73 (1.03–2.91) 0.039
Systemic antibiotics visit 1
No 341 62 (18.1) 1 -
Yes 83 7 (8.4) 0.41 (0.18–0.94) 0.036
Systemic antibiotics screening visit
No 391 68 (17.4) 1 -
Yes 33 1 (3.0) 0.15 (0.02–1.11) 0.063
 
*bold: significant at the 5% level; £completed secondary school, or post-secondary school;  
££Primary school (completed or not), secondary school but not completed;  
#Socio-economic-status was constructed from total income, type of housing, type of toilet;  
@with partners within three months prior to enrolment;  
&missing data for 5; %sex morning or evening before visit;  
&, €low risk: 1 or no partners in last year and did not have any partner (in the last 3 months) 
with multiple partners and age first sex at least 15 years; medium risk: 2 partners last year or 
had at least one sexual partner (in the last 3 months) who had multiple partners; high risk: 
sex worker or at least 3 partners last year or at had at least one sexual partner with HIV in the 
last 3 months or age first sex less than 15 years; N/A, no odds ratio due to no cases in one 
category;  
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¶data missing for 1 (ectopy, colposcopic findings, HSV-2 serology), 3 (C. albicans, E. coli), 8 (T. 
vaginalis), 41 (BV Nugent, unreadable slides); §petechiae (6 GBS cases/20), abrasion (2 GBS 
cases/5), erythema (1 GBS case/10), laceration (1 GBS case/4); BV, bacterial vaginosis; IUD, in-
trauterine device.
TABLE 5 Sociodemographic characteristics, reproductive health, sexual behavior,  
 vaginal practices, vaginal signs & symptoms, and microbiological associations  
 with vaginal E. coli carriage (univariable analysis).
n E. coli + n (%) Crude OR (95% CI) p-value*
421 118 (28.0)
Sociodemographic characteristics
City (Country)
Mombasa (Kenya) 164  39 (23.6)  0.87 (0.54–1.41) 0.569
Kigali (Rwanda) 60 27 (45.0)  2.28 (1.25–4.15) 0.007
Johannesburg (SA) 197 52 (26.5) 1 -
Age (years)
<18 58 12 (20.7) 0.73 (0.36–1.47) 0.376
18–24 147 49 (33.3)  1.40 (0.88–2.20) 0.154
>24 216 57 (26.4) 1 -
Educational level
Higher educational level£ 187 56 (29.9) 1 -
Lower educational level££ 234 62 (26.5) 0.84 (0.55–1.29) 0.434
Marital status
Never married 240 71 (29.6) 1 -
Married 147 37 (25.2) 0.80 (0.50–1.27) 0.348
Separated/divorced/widowed 34 10 (29.4) 0.99 (0.45–2.18) 0.984
Socio-economic status#
Low 106 27 (25.5) 1 -
Medium 163 46 (28.2) 1.15 (0.66–2.00) 0.620
High 152 45 (29.6) 1.23 (0.70–2.15) 0.467
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Reproductive health
Pregnant
No 363 104 (28.7) 1 -
Yes 58 14 (24.1) 0.79 (0.42–1.51) 0.478
Parity
0 149 35 (23.5) 1 -
1–2 209 62 (29.7) 1.37 (0.85–2.22) 0.196
>2 63 21 (33.3) 1.63 (0.85–3.11) 0.139
Gravity
0 118 25 (21.2) 1 -
1–2 208 63 (30.3) 1.62 (0.95–2.75) 0.077
>2 95 30 (31.6) 1.72 (0.93–3.19) 0.087
Regular cycle
Yes 254 65 (25.6) 1 -
No/unknown 167 54 (33.3) 1.42 (0.92–2.18) 0.111
Menstrual cycle 
No cycle 194 58 (29.9) 1 -
With cycle 227 60 (26.4) 0.84 (0.55–1.29) 0.430
Contraceptive 
None 72 20 (27.8) 1 -
Condom only 106 28 (26.4) 0.93 (0.48–1.83) 0.841
Others (hormones/IUD/
sterilisation/pregnant)
243 70 (28.8) 1.05 (0.59–1.89) 0.865
Currently breastfeeding
No 387 106 (27.4) 1 -
Yes 34 12 (35.3) 1.45 (0.69–3.03) 0.327
Sexual behaviour
Age at first sexual encounter (years) 
<16 79 29 (36.7) 1 -
16–18 197 52 (26.4) 0.62 (0.35–1.08) 0.090
19–21 103 26 (25.2) 0.58 (0.31–1.10) 0.096
 >21 42 11 (26.2) 0.61 (0.27–1.40) 0.224
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Sexually active (last 3 months) 
No 55 16 (29.1) 1 -
Yes 366 102 (27.9) 0.94 (0.50–1.76) 0.851
Condom use (at last sexual encounter) 
No 283 68 (24.0) 1.80 (1.16–2.79) 0.009
Yes 138 50 (36.2) 1 -
Lifetime n° of sex partners
1 110 28 (25.5) 1 -
2–3 185 42 (22.7) 0.86 (0.50–1.49) 0.591
> 3 126 48 (38.1) 1.80 (1.03–3.15) 0.039
N° of sex partners in the last 3 months
0 25 6 (24.0) 1 -
>=1 396 112 (28.3) 1.25 (0.49–3.21) 0.644
Recent vaginal sex% 
No 340 91 (26.8) 1 -
Yes 81 27 (33.3) 1.37 (0.81–2.30) 0.238
Sexual risk taking€
Low 167 44 (26.3) 1 -
Medium 152 37 (22.4) 0.90 (0.54–1.49) 0.681
High 102 37 (36.3) 1.59 (0.94–2.71) 0.086
Estimated frequency of sexual encounters in last 3 months@, &
0 55 16 (29.1) 1 -
< 10 times 135 31 (23.0) 0.73 (0.36–1.47) 0.376
11–30 times 128 43 (33.6) 1.23 (0.62–2.45) 0.550
> 30 times 98 27 (27.6) 0.93 (0.45–1.93) 0.839
HIV status partner@
HIV positive 38 11 (28.9) 1 -
HIV negative 247 63 (25.5) 0.84 (0.39–1.79) 0.653
Unknown 79 28 (35.4) 1.35 (0.58–3.12) 0.486
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Estimated frequency of unprotected sex in last 3 months
No sexual contacts 55 16 (29.1) 1 -
Never unprotected 102 34 (33.3) 1.22 (0.60–2.49) 0.586
< 10 times 87 19 (21.8) 0.68 (0.31–1.48) 0.330
>= 10 times 177 49 (27.7) 0.93 (0.48–1.82) 0.839
New partner (within 3 months)
No 375 96 (25.6) 1 -
Yes 46 22 (47.8) 2,66 (1.43–4.97) 0.002
Circumcision status partner@
Circumcised 238 62 (26.1) 1 -
 Not circumcised/don’t know 128 40 (31.3) 1.29 (0.80–2.07) 0.291
Female sex worker
No 391 97 (24.8) 1 -
Yes 30 21 (70.0) 7.07 (3.13–15.96) <0.001
Vaginal practices
Washing inside the vagina when bathing 
No 175 44 (25.1) 1 -
Yes 246 74 (30.1) 1.28 (0.83–1.98) 0.267
Drying the vagina before sex
No 411 114 (27.3) 1 -
Yes 10 4 (40.0) 1.74 (0.48–6.27) 0.399
Washed inside the vagina recently (morning or evening before study visit)
No 229 64 (27.9) 1 -
Yes 192 54 (28.1) 1.01 (0.66–1.55) 0.968
Products to wash/clean/dry/tighten the vagina
None 153 40 (26.1) 1 -
Water/fingers	only	or	water/
soap
210 59 (28.1) 1.10 (0.69–1.77) 0.680
Cloth 46 16 (34.8) 1.51 (0.74–3.05) 0.255
Lemon juice/detergents 12 3 (25.0) 0.94 (0.24–3.65) 0.931
Cleaning the vagina after sexual intercourse
No 226 61 (27.0) 1 -
Yes 195 57 (29.2) 1.12 (0.73–1.71) 0.610
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Cervicovaginal signs and symptoms
Ectopy¶
No 224 49 (21.9) 1 -
Yes 196 69 (35.2) 1.94 (1.26–2.99) 0.003
Degree of ectopy¶
Absent 224 49 (21.9) 1 -
Small 52 22 (42.3) 2.62 (1.39–4.94) 0.003
Moderate 139 46 (33.1) 1.77 (1.10–2.84) 0.019
Large 5 1 (20.0) 0.89 (0.10–8.17) 0.920
Colposcopic findings§, ¶
No 377 102 (27.1) 1 -
Yes 43 16 (37.2) 1.60 (0.83–3.09) 0.163
Cervical mucus
No 269 67 (24.9) 1 -
Mild to moderate 138 47 (34.1) 1.56 (1.00–2.44) 0.052
Abundant 14 4 (28.6) 1.21 (0.37–3.97) 0.758
Reported abnormal discharge
No 396 112 (28.3) 1 -
Yes 25 6 (24.0) 0.80 (0.31–2.06) 0.644
Vaginal discharge on speculum
No 331 85 (25.7) 1 -
Yes 90 33 (36.7) 1.68 (1.02–2.75) 0.041
Vaginal epithelial abnormalities
No 416 116 (27.9) 1 -
Yes 5 2 (40.0) 1.72 (0.28–10.45) 0.554
Cervical epithelial abnormalities
No 377 105 (27.9) 1 -
Yes 44 13 (29.5) 1.09 (0.55–2.16) 0.813
Red blood cells in urine
No 355 101 (28.5) 1 -
Yes 66 17 (25.8) 0.87 (0.48–1.59) 0.655
CH7 Vaginal GBS and E. coli in SSA 82
White blood cells in urine
No 325 81 (24.9) 1 -
Yes 96 37 (38.5) 1.89 (1.17–3.06) 0.010
Microbiological factors
BV visit 1 (Amsel criteria)
No BV 344 99 (28.8) 1 -
BV 77 19 (24.7) 0.81 (0.46–1.43) 0.469
BV visit 1 (Nugent) ¶
No BV (Nugent 0–3) 217 60 (27.6) 1 -
Intermediate (Nugent 4–6) 29 15 (51.7) 2.80 (1.28–6.16) 0.010
BV (Nugent 7–10) 137 33 (24.1) 0.83 (0.51–1.36) 0.459
GBS
No 354 89 (25.1) 1 -
Yes 67 29 (43.3) 2.27 (1.33–3.90) 0.003
Reproductive tract infection (RTI) 
No RTI 349 96 (27.5) 1 -
1 or more RTI 60 19 (31.7) 1.22 (0.68–2.21) 0.508
>1 RTI 12 3 (25.0) 0.88 (0.23–3.31) 0.848
Syphilis
No 412 117 (28.4) 1 -
Yes 9 1 (11.1) 0.32 (0.04–2.55) 0.279
Chlamydia trachomatis
No 379 107 (28.2) 1 -
Yes 42 11 (26.2) 0.90 (0.44–1.86) 0.780
Neisseria gonorrhoeae
No 412 114 (27.7) 1 -
Yes 9 4 (44.4) 2.09 (0.55–7.93) 0.278
Trichomonas vaginalis¶
No 387 105 (27.1) 1 -
Yes 26 11 (42.3) 1.97 (0.88–4.43) 0.101
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Candida albicans (qPCR) 
No 375 102 (27.2) 1 -
Yes 46 16 (34.8) 1.43 (0.75–2.73) 0.282
HSV-2 serology¶
No 274 80 (29.2) 1 -
Yes 146 38 (26.0) 0.85 (0.54–1.34) 0.492
Vaginal pH
< 4.4 125 34 (27.2) 1 -
4.4 – 5.3 237 65 (27.4) 1.01 (0.62–1.65) 0.963
5.4 and more 58 19 (32.8) 1.30 (0.66–2.56) 0.441
PSA present
No 231 69 (29.9) 1 -
Yes 180 48 (26.7) 0.85 (0.55–1.32) 0.475
Systemic antibiotics visit 1
No 338 98 (29.0) 1 -
Yes 83 20 (24.0) 0.78 (0.45–2.36) 0.374
Systemic antibiotics screening visit
No 388 111 (28.6) 1 -
Yes 33 7 (21.2) 0.67 (0.28–1.59) 0.366
 
*Bold: significant at the 5% level; £completed secondary school, or post-secondary school;  
££Primary school (completed or not), secondary school but not completed;  
#Socio-economic-status was constructed from total income, type of housing, type of toilet;  
@with partners within three months prior to enrolment;  
&missing data for 5; %sex morning or evening before visit;  
€low risk: 1 or no partners in last year and did not have any partner (in the last 3 months) with 
multiple partners and age first sex at least 15 years; medium risk: 2 partners last year or had 
at least one sexual partner (in the last 3 months) who had multiple partners; high risk: sex 
worker or at least 3 partners last year or at had at least one sexual partner with HIV in the 
last 3 months or age first sex less than 15 years; N/A, no odds ratio due to no cases in one 
category;  
¶data missing for 1 (ectopy, colposcopic findings, HSV-2 serology), 8 (T. vaginalis), 38 (BV 
Nugent, unreadable slides); §petechiae (6 E. coli cases/20), abrasion (2 E. coli cases/5), 
erythema (3 E. coli cases/10), laceration (2 E. coli cases/4), ulcer (2 E. coli cases/6), 
ecchymosis (2 E. coli cases/6); BV, bacterial vaginosis.
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In	our	final	multivariable	GBS	model	 (Table	6),	BV	by	Nugent	score	remained	
significantly	negatively	associated	with	GBS	carriage	(AOR,	0.43;	95%	CI,	0.21–
0.88; p=0.022), and a positive association was observed for vaginal Candida al-
bicans carriage (AOR, 3.25; 95% CI, 1.50–7.06; p=0.003), vaginal E. coli carriage 
(AOR, 2.01; 95% CI, 1.10–3.80; p=0.023), recent vaginal intercourse (AOR, 2.63; 
95% CI, 1.35–5.15; p=0.005), and currently washing the vagina (AOR, 2.26; 
95% CI, 1.16–4.37; p=0.016). 
TABLE 6 Multivariable associations with vaginal GBS carriage.
n GBS+ (%) adjusted OR (95% CI) p-value$
424 69 (16.3)
Recent vaginal sex% 
No 343 49 (14.3) 1 -
Yes 81 20 (24.7) 2.63 (1.35–5.15) 0.005
Washing inside the vagina#
No 176 15 (8.5) 1 -
Yes 248 54 (21.8) 2.26 (1.16–4.37) 0.016
BV (Nugent)¶
No BV (Nugent 0–3) 217 37 (17.1) 1 -
Intermediate (Nugent 4–6) 29 6 (20.7) 0.93 (0.33–2.64) 0.898
BV (Nugent 7–10) 137 13 (9.5) 0.43 (0.21–0.88) 0.022
Candida albicans (qPCR)¶
No 375 50 (13.3) 1 -
Yes 46 17 (37.0) 3.25 (1.50–7.06) 0.003
Escherichia coli ¶
No 303 38 (12.5) 1 -
Yes 118 29 (24.6) 2.01 (1.10–3.80) 0.023
$bold, significant at the 5% level;  
#when having shower or bath;  
%morning or evening before study visit;  
¶data missing for 3 (C. albicans, E. coli), 41 (BV, unreadable slides).
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In our multivariable E. coli model, an intermediate Nugent score remained sig-
nificantly	negatively	associated	with	vaginal	E. coli carriage (AOR, 2.61; 95% 
CI, 1.15–5.94; p=0.023), and a positive association was observed with work-
ing as a FSW (AOR, 7.83; 95% CI, 2.88–21.30; p<0.001), vaginal GBS carriage 
(AOR, 2.05; 95% CI, 1.09–3.83; p=0.025), and cervical ectopy (AOR, 1.64; 95% 
CI, 1.01–2.68; p=0.046) (Table 7).
 
TABLE 7 Multivariable associations with vaginal E. coli carriage.
n E. coli + (%) adjusted OR (95% CI) p-value$
421 118 (25.2)
Condom use (at last sexual encounter)
No 283 68 (24.0) 1.53 (0.92–2.56) 0.104
Yes 138 50 (36.2) 1.0 -
Female sex worker
No 391 97 (24.8) 1 -
Yes 30 21 (70.0) 7.83 (2.88–21.30) <0.001
Ectopy ¶
No 224 49 (21.9) 1 -
Yes 196 69 (35.2) 1.64 (1.01–2.68) 0.046
Vaginal discharge on speculum
No 331 85 (25.7) 1 -
Yes 90 33 (36.7) 1.63 (0.92–2.88) 0.095
BV (Nugent)¶
No BV (Nugent 0–3) 217 60 (27.6) 1 -
Intermediate (Nugent 4–6) 29 15 (51.7) 2.61 (1.15–5.94) 0.023
BV (Nugent 7–10) 137 33 (24.1) 0.66 (0.38–1.15) 0.140
GBS
No 354 89 (25.1) 1 -
Yes 67 29 (43.3) 2.05 (1.09–3.83) 0.025
 
$bold, significant at the 5% level;  
¶data missing for 1 (ectopy), 38 (BV, unreadable slides). 
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7.5 Discussion
Group B streptococci (GBS) and E. coli account for the majority of EOS cases 
worldwide. Vaginal carriage of GBS and E. coli is considered a prerequisite for 
GBS or E. coli transmission to the neonate in GBS EOS and E. coli EOS, respec-
tively. However, epidemiological data of vaginal GBS and E. coli carriage, which 
are essential for the development and implementation of prevention strate-
gies, are very limited in sub-Saharan Africa (SSA) [Capan et al., 2012; Stoll and 
Schuchat 1998]. In this study, we aimed to present vaginal GBS and E. coli car-
riage	rates,	GBS	serotype	distribution	and	define	risk	factors	for	carriage	in	pop-
ulations from three SSA countries.
Vaginal GBS and E. coli carriage rates
We found a vaginal GBS carriage rate of 20.2% and 23.2% in the Kenyan and 
South African reference groups (adult, non-pregant, HIV-negative women at av-
erage risk of HIV), respectively. Compared to these reference groups, adoles-
cents in our study were found to have lower GBS carriage rates: 3.6% of the 
Kenyan and 0% of the SA adolescents carried GBS vaginally. Other studies re-
port	conflicting	associations	between	age	and	vaginal	GBS	carriage	[Kim	et al., 
2011; Regan et al., 1991; Hastings et al., 1986]. All of these studies (except for 
[Valkenburg-van den Berg et al., 2006]) report on pregnant women. Interest-
ingly,	when	we	compare	different	age	groups	 (<	18	years,	18–24	years,	>	24	
years) in our Kenyan and SA population, we see no age-group dependent GBS 
colonization in the pregnant women. However, we do see a statistically signif-
icant age-group dependent GBS association in the non-pregnant women, with 
the lowest and the highest GBS carrier rates in the youngest and the oldest age 
groups, respectively (Pearson Chi-Square test, data not shown). 
The pregnant women in our study population had vaginal GBS carriage rates 
of 14.3% and 10.0% in Kenya and SA, respectively. This is lower than most oth-
er studies reporting (recto)vaginal GBS carriage rates in SSA (see Table 8). Al-
though the CDC recommends rectovaginal sampling for detection of GBS in 
pregnant women, we only swabbed vaginally, to be able to study the interac-
tion of GBS with the vaginal immune system and vaginal microbiome (to be 
published). This vaginal sampling may (partly) explain the lower GBS carriage 
rates found by us, as rectovaginal sampling has been shown to yield higher GBS 
recovery rates compared to vaginal sampling alone [Gupta et al., 2004; El Aila et 
87
al., 2010]. Furthermore, in contrast to other studies (listed in Table 8) using cul-
turing techniques, we used qPCR without prior enrichment step to detect GBS. 
Although the CDC allows PCR for the detection of GBS (albeit recommending an 
enrichment	step),	this	difference	with	other	studies	probably	does	not	account	
(or to a lesser extent) for the lower rates found by us, as PCR (even without an 
enrichment step) has been shown to be more sensitive than culture [Verani et 
al., 2010; El Aila et al., 2011; Davies et al., 2004; Convert et al., 2005; Rallu et al., 
2006].	A	further	difference	with	other	studies	regards	the	fact	that	the	pregnant	
women in our study were up to 14 weeks of gestation, while the other studies 
listed in Table 7 sampled pregnant women at 35–37 weeks of gestation, which 
also	may	account	for	differences,	as	some	authors	have	reported	on	varying	GBS	
rates during pregnancy [Baker et al., 1975]. 
In the group of HIV positive women, we did not observe any GBS carriers, 
which is probably explained by the fact that most of the HIV positive women 
(26/30)	received	prophylactic	cotrimoxazole,	which	is	largely	effective	against	
GBS [Joachim et al., 2009].
TABLE 8 Studies reporting (recto)vaginal GBS carriage rates in SSA.
Country Year n Population % GBS Sample Detection Reference
Nigeria 1980 588 P, L 19 V SB+C [Onile 1980]
Nigeria 1983 225 P 20 V SB+C
[Dawodu  
et al., 1983]
Zimbabwe 1990 89 P 31 V SB+C
[Nathoo  
et al., 1990]
Togo 1991 106 P 4 V, R SB+C
[David-Prince  
et al., 1991]
Gambia 1994 136 P 22 V, R SB+C
[Suara  
et al., 1994]
Malawi 2005 97 P 16.5 V, R SA
[Dzowela  
et al., 2005]
Mozambique 2008 113 P 1.8 V, R SB+C
[de Steenwinkel 
et al., 2008]
Tanzania 2009 300 P 23.0 V, R SB+C
[Joachim  
et al., 2009]
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Zimbabwe 2010 780 P
47, 24, 
21#
V, R SB+C
[ Mavenyengwa 
et al., 2010 ]
Malawi 2011 1840
P, HIV+ 
and HIV-
21.2 V, R SB+C
[Gray  
et al., 2011]
South Africa 2014
661, 
621, 
595, 
521$
P
33.0, 
32.7, 
28.7, 
28.4$
V, R SA
[Kwatra  
et al., 2014]
DR Congo 2015 509 P 20.2 V SA
[Mitima  
et al., 2014]
L, women in labor; NP, non-pregnant women; P, pregnant women; V, vaginal swab;  
R, rectal swab; SB+C, selective broth and culturing; SA, selective agar; #week 20, 26,  
and delivery, respectively; $week 20–25, week 26–30, week 31–35, and week 37+, 
respectively.
Our reference groups from Kenya and SA had vaginal E. coli carriage rates of 
25.0% and 27.1%, respectively. Compared to other studies from SSA reporting 
vaginal carriage of E. coli, these prevalences are higher than the ones report-
ed by Karou and coworkers (2012) and Ekwempu and coworkers (1981), low-
er than the ones reported by Schellenberg and coworkers (2011) and Cutland 
and coworkers (2012), and comparable with the prevalence reported by Sagna 
and coworkers (2010) (See Table 9) [Karou et al., 2012; Ekwempu et al., 1981; 
Schellenberg et al., 2011; Cutland et al., 2012; Sagna et al., 2010]. Vaginal E. coli 
carriage	rates	in	Asia,	Europe,	North	and	South	America	appear	lower.	Different	
study populations, sampling and detection techniques might account for these 
differences.
Compared to the reference group in Kenya, pregnant women had a lower 
prevalence of vaginal E. coli carriage; compared to the reference group in SA, 
adolescent women had a lower prevalence of E. coli carriage. The FSW study 
group in Kigali had a very high prevalence of E. coli carriage, i.e. 70%, and will 
be discussed below (risk factors).
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TABLE 9 Studies reporting (recto)vaginal E. coli carriage rates. 
Country Year n Population % E. coli Sample Detection Reference
Africa (pooled prevalence 36.0% (2846/7912); range 9.1–46.5%)
Burkina 
Faso
2010 156 HIV+ 28.4 V C
[Sagna  
et al., 2010]
Burkina 
Faso
2012 2000 S 16.7 V C
[Karou  
et al., 2012]
Kenya 2011 44
HIV+, HIV-, 
HESN
40.1 V cpn60
[Schellen-
berg et al., 
2011]
Nigeria 1981 187 L 9.1 C C
[Ekwempu  
et al., 1981]
SA 2012 1347 P, HIV+ 42.3 V C
[Cutland  
et al., 2012]
SA 2012 3752 P, HIV- 46.5 V C
[Cutland  
et al., 2012]
Asia (pooled prevalence 5.3% (163/3072); range 0–25.8%)
Iraq 2011 90 S, NP 16.2 V C
[Razzak  
et al., 2011]
Iraq 2011 20 S, P 25.8 V C
[Razzak et al., 
2011]
Iran 2014 85 S, P 18.0 V C
[Mobasheri 
et al., 2014]
Japan 2002 2575 NP, P 3.4 V C
[Obata- 
Yasuoka	et al., 
2002]
Pakistan 2012 100 HC 28 V C
[Kazi et al., 
2012]
Pakistan 2012 100 H 6 V C
[Kazi et al., 
2012]
Turkey 2007 34 IUD 14.7 V C
[Ocak et al., 
2007]
Turkey 2007 34 HC 2.9 V C
[Ocak et al., 
2007]
Turkey 2007 34 H 0.0 V C
[Ocak et al., 
2007]
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Europe (pooled prevalence 13.4% (670/4980); range 3.1–51.2%)
Croatia 2011 114 IUD 25.5 V C
[Kaliterna et 
al., 2011]
Croatia 2011 122 H 8.2 V C
[Kaliterna et 
al., 2011]
Denmark 2014 668 P 11.7 V C
[Stokholm et 
al., 2014]
Germany 2007 166 H
16.3, 
51.2, 
25.9*
V C
[Chase et al., 
2007]
Greece 2008 1632 S 3.1 V C
[Iavazzo et 
al., 2008]
Lithuania 2012 970 P 19.9 V, R C
[Tameliene 
et al., 2012]
Spain 2002 623 P 27.0 V C
[Bayo et al., 
2002]
Spain 2011 321 P 15 E, V C
[Guiral et al., 
2011]
Spain 2011 327 NP 12 E, V C
[Guiral et al., 
2011]
Sweden 2008 37 H 5.4 V C
[Nikolai-
tchouk et al., 
2008]
North America (pooled prevalence 12.7% (430/3373); range 0–29.5%)
Canada 1983 495 H 12.3 V C
[Per-
cival-Smith 
et al., 1983]
US 1997 2646 P 13.0 V C
[Krohn et al., 
1997]
US 2001 44 H
18.2, 9.1, 
29.5, 6.8, 
6.8 #
V C
[Eschenbach 
et al., 2001]
US 2005 20 H 0 V 16S
[Hyman et al., 
2005]
US 2012 70 P 10 V C
[Ghartey et 
al., 2012]
US 2012 35 NP 23 V C
[Ghartey et 
al., 2012]
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US 2013 47 P
2.1, 2.2, 
5.6, 8.3£
V C
[Anderson et 
al., 2013]
US 2013 16 NP
6.3, 0, 
12.5, 20
V C
[Anderson et 
al., 2013]
South America (pooled prevalence 19.7% (135/684); range 14.3–23.0%)
Argentina 2013 259 P 14.3 V C
[Villar et al., 
2013]
Chile 2009 425 S 23.0 V C
[Lobos et al., 
2009]
 
The electronic bibliographic database PubMed was searched for articles using the search 
terms ‘(Escherichia) AND (coli) AND (vaginal)’ with no date or language restriction. Studies 
were included if the number of vaginal E. coli carriers and the total number of individuals 
tested were reported; studies were excluded if women were not of childbearing age.  
16S, deep sequencing of the 16S rRNA gene; cpn60, deep sequencing of the cpn60 gene;  
C, conventional culturing and identification; E, endocervial swab;  
FSW, female sex workers; H, healthy women; HC, women using hormonal contraception;  
HESN, HIV exposed seronegative women; IUD, women using an intrauterine device as 
contraception; L, women in labor; NP, non-pregnant women; P, pregnant women; Q, qPCR;  
R, rectal swab; S, women with vaginal symptoms or clinical diagnosis of infection;  
V, vaginal swab; *pre, mid, post cycle, respectively;  
# visit 1at 1 month before visit 2 and 19–24 days after cycle, 1–2 days before intercourse, 
8–12h after intercourse, 3–4 days after intercourse, 5–6 days after intercourse;  
£ <14weeks, between 14–28 weeks, >28weeks, postpartum.
To	our	knowledge,	this	is	the	first	study	to	determine	simultaneously	the	vag-
inal GBS and E. coli carriage rates in SSA populations using qPCR, known to be 
more sensitive than culture-based techniques. Moreover, vaginal carriage rates 
of GBS in Kenya and Rwanda and E. coli in Rwanda have not yet been described.
Risk factors for vaginal E. coli and GBS carriage
The presence of vaginal C. albicans, recent vaginal intercourse, working as a 
FSW, an intermediate vaginal microbiome, BV, washing the vagina and cervical 
ectopy were independent risk factors for vaginal GBS or E. coli colonization. 
Women carrying C. albicans were 3.6 times more likely also to carry GBS. 
Three	US	based	studies	have	shown	this	same	significantly	positive	association	
between GBS and Candida or yeast [Regan et al., 1991; Cotch et al., 1998; Beigi 
et al., 2004]. 
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Intravaginal practices, like e.g. cleaning inside the vagina beyond the in-
troitus or insertion of substances into the vagina to dry or tighten the vagina, 
are common in Africa and are associated with adverse outcomes including in-
creased risk for BV and for sexually transmitted infections [Low et al., 2011]. 
Our model showed that washing inside the vagina was an independent risk fac-
tor for vaginal GBS carriage: women were twice as likely to be colonized with 
GBS compared to women not washing inside the vagina. A study by van de Wij-
gert and coworkers [van de Wijgert et al., 2000] showed that women using sub-
stances	other	than	plain	water	to	finger-clean	or	wipe	inside	the	vagina	had	a	
GBS prevalence of 26.3% (n=99), whereas women not engaging in these prac-
tices	had	a	GBS	prevalence	of	14.7%	(n=70).	However,	their	findings	did	not	
reach	 significance,	 most	 probably	 because	 of	 the	 smaller	 sample	 size	 (169	
women compared to 424 women in our study). 
Women who had recent vaginal sex (the morning or evening before the study 
visit) were more than twice as likely to carry GBS vaginally than women who did 
not.	Accordingly,	a	positive	PSA	test	was	also	significantly	correlated	with	GBS	
carriage.	GBS	is	generally	not	considered	an	STI,	and	the	influence	of	sexual	be-
havior on vaginal GBS carriage or acquisition is a matter of debate [Foxman et 
al., 2008; Foxman et al., 2007; Honig et al., 2002]. Based on published literature 
and our own data, we hypothesize that sexual activity might lead to a brief tem-
poral GBS colonization of the vagina. This hypothesis is strengthened by a re-
cent longitudinal deep-sequencing study of the vaginal microbiome, where 25 
women were sampled on a daily basis over a 10 week period, revealing an aver-
age of 0.39 GBS episodes per week and an average GBS episode of 2.8 days (Fig 
1	and	additional	file	4	in	[Ravel	et al., 2013]), contrasting with earlier studies 
– where sampling occurred every 3 weeks – that report average GBS episodes of 
13.7 weeks [Foxman et al., 2006]. The brief colonization might explain why we 
and	other	authors	find	parameters	such	as	‘age	of	first	sexual	intercourse’	not	
to be associated with GBS carriage (they do not cover the recent aspect), while 
parameters such as ‘high frequency of intercourse during last month’ (as a con-
sequence, a higher chance of also having had recent intercourse) do correlate. 
Taken together, GBS should be considered as a potentially pathogenic micro-or-
ganism that can be sexually transmitted and whose vaginal presence can be en-
hanced by sexual activity. 
Cervical ectopy was an independent risk factor for vaginal E. coli carriage, 
21.9% of women without cervical ectopy were E. coli carriers as opposed to 
35.2% of women with cervical ectopy. Cervical ectopy has been associated 
with CT [Lee et al., 2006], HPV [Rocha-Zavaleta et al., 2004] and an increased 
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susceptibility to HIV infection [Venkatesh et al., 2013]. Although we could not 
determine	 the	cause-effect	 relation	of	 this	 association,	 it	 seems	biologically	
plausible that a niche is created by the glandular columnar epithelium of wom-
en with cervical ectopy that somehow – directly or indirectly – favors the col-
onization by E. coli. Some studies have e.g. related cervical ectopy with a re-
duced cell-mediated or changed humoral immunity [Kyongo et al., 2015; De 
Luca Brunori et al., 1994].
Working as a FSW was an independent risk factor for vaginal E. coli carriage. 
We could not explain this by any of the sexual behavioural or other parameters 
presented in Table 5. In our study, none of the participants, including the female 
sex workers, reported having had anal intercourse during the last 3 months. 
These percentages probably are underestimates, since stigma associated with 
anal intercourse often leads to reduced reporting [Veldhuijzen et al., 2011]. Fur-
thermore, Ghanem and coworkers [Ghanem et al., 2005] showed that regarding 
anal	intercourse,	significantly	more	women	reported	to	engage	in	these	prac-
tices when asked by means of computer assisted self-interviews compared to 
face-to-face interviews, which was used in our study. It is not unlikely that FSW 
engage more in anal intercourse, compared to the general population, and that 
in our FSW population, vaginal contamination with E. coli is higher by transfer of 
(peri)anal bacteria during anal/vaginal intercourse. Other studies from East-Af-
rica report anal intercourse prevalences in FSW of up to 40.8% [Schwandt et al., 
2006]. Interestingly, anal intercourse during pregnancy has been reported as a 
significant	risk	factor	for	neonatal	E. coli colonization [Tameliene et al., 2012].
Besides above-mentioned risk factors for GBS or E. coli carriage, we show for 
the	first	time	that	colonization	with	GBS	and	E. coli, the leading causes of EOS, 
are positively associated.
Above-mentioned risk factors can be translated and implemented into strat-
egies that aim to reduce the maternal carriage of GBS and E. coli. First, behavior-
al change by advocating abstinence from sexual intercourse and vaginal wash-
ing during late pregnancy, e.g. via counseling in family planning facilities, could 
help to reduce the risk of maternal GBS and E. coli colonization in resource-poor 
settings. Second, the extension of GBS screening with screening for C. albicans 
and E. coli – risk factors for vaginal GBS carriage – should be further investigat-
ed. Furthermore, the screening for E. coli itself also merits further investigation 
because of its role as a major EOS causative agent for which currently no pre-
vention measures are taken, nor in low-income, nor in high-income countries 
[Stoll et al., 2011]. In this context, the presence of cervical ectopy – a risk factor 
for vaginal E. coli carriage – should be further investigated.
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GBS serotype distribution
As	IAP	is	not	effective	against	LOS	and	culture-based	screening	and	administra-
tion of costly intravenous antibiotics might not be feasible in most low-income 
countries, an alternative and long-term solution lies in the development of ef-
fective GBS vaccines, that however would not cover for other micro-organisms 
causing EOS. As most GBS vaccines under development aim at eliciting protec-
tive	antibodies	against	capsular	polysaccharides,	the	principal	difficulty	in	de-
veloping	globally	effective	GBS	vaccines	is	the	existence	of	several	serotypes	
with	different	geographical	distributions.	In	our	study,	the	most	prevalent	GBS	
serotypes were Ia (27.3%), V (27.3%) and III (22.7%) in Kenya; Ia (34.5%), V 
(31.0%), and IV (13.8%) in SA; and Ia (83.3%) and II (16.7%) in Rwanda. Only 
few other studies have documented vaginal GBS serotype distribution in Africa 
and	these	are	largely	in	line	with	our	findings	(Table	3	and	Fig	7).	
Interestingly, compared to the low prevalences in Europe and the US, we 
found	relatively	high	prevalences	of	serotypes	IV,	VI,	VII	–	shown	for	the	first	
time in sub-Saharan Africa – and VIII in the Kenyan and South African popula-
tion (VI, 13.6%; VII, 4.5%; VIII 4.5% in Kenya, and IV, 13.8%; VI, 6.9%; VIII, 3.4% 
in SA) (Table 4). In contrast, we did not detect any serotype Ib, which has, ac-
cording to a recent meta-analysis, a prevalence of 8.1% in the US and 12.4% in 
Europe [Ippolito et al., 2010]. 
Differences	 in	 serotype	distribution	between	our	 study	and	other	 studies	
(Table	3)	might	be	explained	by	differences	 in	 study	populations,	most	 stud-
ies listed in Table 3 typed strains isolated from pregnant women whereas most 
of our GBS strains were isolated from non-pregnant women. Methodological 
differences	might	 also	 contribute.	Many	GBS	 capsular	 polysaccharide	 typing	
methods have been described, with the most commonly used method being a 
serological test, used by all studies listed in Table 3, except our study. We used 
a molecular capsular typing method, developed and applied by European (ref-
erence) laboratories [Joubrel et al., 2015; Afshar et al., 2011]. Brigtsen and co-
workers (2015) compared capsular typing of 426 GBS strains by a conventional 
latex agglutination test with PCR, and found that a substantial proportion of the 
strains were non-typeable by serotyping, but typeable by genotyping, and that 
an agreement between serotyping and genotyping was shown in 71.1% (of the 
isolates that were typeable by both methods) [Brigtsen et al., 2015]. Moreover, 
we used a molecular technique directly on DNA extracts from vaginal swabs 
(and not on DNA extracts from isolates), which could lead to the detection of 
certain serotypes that would not have been isolated by culture.
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Currently, there are two candidate vaccines in phase II clinical trials, i.e. a tri-
valent vaccine targeting serotypes Ia, Ib, and III, and a conjugate vaccine target-
ing	serotype	III	(www.clinicaltrials.gov).	In	theory,	the	first	vaccine	could	cover	
for 50.0%, 83.3% and 44.8% of vaginal GBS cases in our Mombasa, Kigali and 
Johannesburg population, respectively, but only a minority of women would be 
protected by the conjugate vaccine (22.7%, 0% and 10.3%, respectively). 
GBS, E. coli and the vaginal microbiome
Our results show that vaginal GBS and E. coli	carriage	were	significantly	associ-
ated with disturbances of the vaginal microbiome: compared to women with a 
normal vaginal microbiome, women with an intermediate vaginal microbiome 
were 2.61 times more likely to carry E. coli, whereas women with BV were 2.33 
less	likely	to	carry	GBS.	The	latter	finding	is	in	accordance	a	study	of	Hillier	and	
coworkers [Hillier et al.,	1992],	reporting	a	significant	negative	association	be-
tween GBS carriage and BV by Nugent scoring, studying 7,918 pregnant women. 
Two	other	studies	did	not	confirm	these	findings	[Honig	et al., 2002; Rocchetti 
et al., 2011]. In depth analysis of above-mentioned interdependencies of GBS, 
E. coli, C. albicans, BV and the vaginal microbiome will be published elsewhere.
Our study was limited by the fact that we used vaginal sampling instead of rec-
tovaginal sampling for the detection of GBS (as recommended by the CDC), 
which has been shown to have higher recovery rates for GBS. Furthermore, we 
did not use a selective broth enrichment prior to PCR, as recommended by the 
CDC. In our study, pregnant women were up to 14 weeks of gestation, and were 
not sampled at 35–37 weeks’ gestation as recommended by the CDC, which 
could have biased our results. Our study was further limited by the rather small 
sample size of our Rwanda study population.
In conclusion, vaginal GBS carriage rate and serotype distribution were similar 
to high-income countries, except for the higher prevalence of serotypes VI, VII 
and VIII. E. coli carriage rate was higher compared to high-income countries. We 
identified	risk	factors	for	GBS	or	E. coli carriage, ie. recent sexual intercourse, 
vaginal washing, C. albicans colonization and presence of cervical ectopy, that 
can be implemented in strategies to reduce maternal colonization. Immunopro-
phylaxis with current phase II candidate GBS vaccines would not protect the 
majority of women against vaginal GBS carriage in our study population. The 
most important causative agents of EOS, GBS and E. coli, both associated with 
disturbances of the vaginal microbiome, are positively associated.
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Role of HIV exposure and infection  
in relation to neonatal GBS disease  
and rectovaginal GBS carriage:  
a systematic review and meta-analysis
— CHAPTER 8 
8.1 Introduction
One	million	children	die	each	year	in	the	first	4	weeks	of	life	because	of	neo-
natal disease [Lawn et al., 2005]. Early-onset neonatal disease (EOD), which oc-
curs	in	the	first	week	of	life	and	most	often	within	24	hours	after	birth,	is	caused	
by bacteria that are transmitted from the genital tract of the mother before or 
during delivery [Hornik et al., 2012]. Late-onset neonatal disease (LOD) occurs 
between	the	first	week	and	the	third	month	of	life	and	may	be	caused	by	bacte-
ria acquired vertically or horizontally [Schuchat 1998]. 
Streptococcus agalactiae (Group B Streptococcus (GBS)), present in the vagi-
na and/or gastro-intestinal tract of 20 to 30 % of pregnant women, is the most 
common	infectious	agent	identified	in	case	of	EOD	[Stoll	et al., 2011] and an im-
portant pathogen in LOD [Dillon, Khare, and Gray 1987]. Although vaginal car-
riage of GBS usually remains asymptomatic, it has been associated with cho-
rioamnionitis	 [Yancey	et al., 1994], spontaneous abortion [Temmerman et al., 
1992; McDonald and Chambers 2000], premature labor [Allen et al., 1999], pre-
mature delivery [Regan et al., 1996], premature rupture of membranes [Mator-
ras et al., 1989] and puerperal sepsis [Acosta et al., 2014; Koenig and Keenan 
2009], causing substantial neonatal and maternal morbidity and mortality 
[Beck et al., 2010; Hornik et al., 2012; Khan et al., 2006; Lawn et al., 2005]. 
Infants born to HIV-infected mothers have increased rates of infectious morbid-
ity and mortality compared to non-exposed infants, even if they remain HIV-un-
infected [Madhi et al., 2011; Epalza et al.,	2010].	Since	the	first	study	reporting	
an increased risk of GBS neonatal disease in HIV-exposed neonates [Epalza et 
al., 2010], evidence for this association has been accumulating. 
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A possible explanation for these observations might be higher rectovaginal 
GBS carriage rates in HIV-infected women, as rectovaginal GBS carriage is a ma-
jor risk factor for GBS neonatal sepsis. 
Indeed,	HIV	might	 influence	 the	microbial	 composition	of	 the	 vagina,	 rec-
tum and colon [Spear et al., 2008; Schellenberg et al., 2011; Jespers et al., 2015; 
McHardy et al., 2013; Dillon et al., 2014] and HIV infection in women has been 
associated with increased prevalence of vaginal candidiasis and sexually trans-
mitted infections [Weiss et al., 2001; Vandepitte et al.,	2012].	However,	conflict-
ing results have been reported for the association between HIV infection and 
rectovaginal carriage of GBS [Mitima et al., 2014; El Beitune et al., 2006].
The objectives of this systematic review and meta-analysis were to assess to 
which extent HIV exposure of neonates is associated with GBS neonatal disease 
and to clarify to which extent HIV infection of women is associated with rec-
tovaginal GBS carriage, a major risk factor for GBS neonatal disease.
RESEARCH IN CONTEXT
 Evidence before this study Mother-to-child transmission of HIV is one of 
the great tragedies of the HIV pandemic. Although the number of HIV-in-
fected infants is declining due to interventions for the elimination of pe-
diatric HIV infection, the number of newborns that are HIV-uninfected but 
HIV-exposed through their HIV-infected mothers is on the rise. Interest in 
the health outcomes of these HIV-exposed infants has grown in the past de-
cade, and several studies suggest increased mortality rates and increased in-
fectious morbidity.
Neonatal sepsis causes one million neonatal deaths yearly, and Group B 
Streptococcus (GBS) is the leading cause. Since 2010, evidence has also been 
accumulating for an association between HIV-uninfected neonates born to 
HIV-infected mothers and neonatal sepsis caused by GBS. Regarding the as-
sociation between maternal vaginal GBS carriage – the single most import-
ant risk factor, if not, a prerequisite, for GBS neonatal sepsis – and HIV-infec-
tion	in	mothers,	conflicting	results	have	been	reported.
 Added value of this study This systematic review and meta-analysis is the 
first	to	examine	the	association	between	HIV-exposure	of	neonates	and	the	
risk for neonatal disease caused by GBS. We performed subgroup analysis to 
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further clarify the risk for the early-onset form of GBS neonatal sepsis, and 
the late-onset form. Furthermore, we performed a meta-analysis to assess 
the risk for maternal vaginal GBS carriage in HIV-infected compared to unin-
fected women. We present a framework the associations between neonatal 
HIV-exposure	and	early-and	late-onset	neonatal	sepsis,	offering	opportuni-
ties for the clinical practice and global health policy to reduce HIV-related 
neonatal morbidity and mortality rates.
 Implications of all the available evidence. Neonates born to HIV-infected 
mothers, but themselves uninfected, are at increased risk for GBS neonatal 
sepsis. Subgroup analysis showed that these neonates were four time more 
likely to have the GBS late-onset form, but were not at increased risk for the 
early-onset form. We found no association between maternal vaginal GBS 
carriage	and	HIV-infection,	but	these	studies	suffered	from	major	limitations.
The health needs of HIV-exposed, uninfected infants should be prioritized 
further. Particularly in sub-Saharan Africa, were 90% of new HIV infections 
occurs and the burden of neonatal mortality is the highest, public health 
interventions reducing neonatal mortality rates are urgently needed, and 
could be found in improved nutrition strategies.
8.2 Methods
 Protocol and registration We followed the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) guidelines [Moher et al., 2009] 
for carrying out and reporting this systematic review and meta-analysis, using 
an a priori	defined	protocol.	This	systematic	review	and	meta-analysis	has	been	
registered in PROSPERO under registration number CRD42016033414.
 Eligibility criteria We included studies that assessed the association between 
neonatal GBS disease and HIV-status of the mother and studies that assessed 
the association between rectovaginal GBS colonization and HIV status in adult 
women. We only included studies that reported a sample size and a measure 
of	effect	for	the	associations	assessed	or	provided	the	data	to	calculate	the	lat-
ter. There were no restrictions in terms of study design, manuscript language, or 
date of publication. We included papers that were published up to 1 November 
2015.
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Reviews, conference abstracts, comments, guidelines, case reports or case 
series, unpublished articles, multiple reports of the same data and in vitro and 
animal studies were not considered for inclusion. We excluded studies that had 
no clear description of the assessment of the HIV status of the women, of the 
HIV exposure of the neonates, or of the laboratory methodology to assess rec-
tovaginal	GBS	carriage.	GBS	neonatal	disease	was	defined	as	the	presence	of	
GBS	as	assessed	by	molecular	methods,	culture	from	blood,	cerebrospinal	fluid	
or	another	normally	sterile	site,	or	by	latex	agglutination	in	cerebrospinal	fluid,	
in neonates below 90 days of age.
 Search strategy We searched the MEDLINE (through PubMed), Web of Science, 
and EMBASE databases for bibliographic references. We used the combination 
of all of the following search terms (Streptococcus agalactiae, S. agalactiae, GBS, 
Group B Streptococcus, Group B streptococci, early-onset disease, early-onset 
sepsis, late-onset disease, late-onset sepsis, neonatal sepsis, neonatal septi-
cemia, neonatal pneumonia or neonatal meningitis) with all of the following 
search	terms	(human	immunodeficiency	virus,	HIV,	HIV-1,	or	AIDS).
The bibliographic references of the studies that were considered eligible 
were also hand searched. 
 Study selection Studies were selected in a two-stage process (Figure 8). First, 
all bibliographic references were screened to identify studies for full text eval-
uation by one reviewer (PC), on the basis of only the information present in the 
title and abstract. Subsequently, the full texts of those articles not excluded in 
the screening process were assessed for eligibility, using the aforementioned 
criteria, by two authors independently (PC and MV). Reasons for inclusion or ex-
clusion were recorded and categorized, and disagreements were resolved by 
consensus.
Selected studies were divided into two categories, i.e. studies reporting an 
association between HIV-exposure and GBS invasive neonatal disease in in-
fants (or providing data to calculate this), and studies reporting an association 
between HIV infection and rectovaginal GBS carriage in adult women (or pro-
viding data to calculate this).
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N	  =	  197
Web	  of	  Science
N	  =	  262
Embase
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  =	  381
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  alone
81	  manuscripts	  for	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Exclusion	  (63)
-­‐ Not	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  outcome/exposure	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  (9)
-­‐ Review,	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   to	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   of	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   (11)
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  published	  data	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Not	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17	  manuscripts	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  disease
FIGURE 8 Identification of studies included in the meta-analysis.  
 #, including two studies reporting on neonatal GBS disease;  
 ##, including two studies reporting on rectovaginal carriage. 
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 Data collection process	 A	 predefined	 data	 extraction	 form	 was	 pilot-test-
ed and used for data extraction. From each individual study, information was 
collected on authors, year of publication, journal, country where the study had 
been carried out, study design, sample collection period, study population, age 
of the participants, total number of study participants, total number of samples 
included in the analysis, HIV assessment and prevalence, GBS neonatal disease 
assessment and incidence, rectovaginal GBS carriage assessment and preva-
lence,	relevant	measures	of	effects,	statistics,	correction	for	confounding,	and	
epidemiological strengths and weaknesses. 
This procedure was performed for each article independently by two authors 
(PC, and TC, VJ, ES, JVDW or MV) and disagreements were resolved by discussion 
between	both	authors.	Further	information	or	clarification	from	manuscript	au-
thors was sought by PC on seven occasions. 
 Risk of bias in individual studies To assess the quality and risk of bias of the 
included studies, we developed a quality appraisal tool (Supplementary Ta-
ble 1), based on the Newcastle-Ottawa Scale [GA Wells 2013]. This scale is a 
bias assessment tool for observational studies, recommended by the Cochrane 
Collaboration [Higgins et al., 2011]. We adapted this tool to the content of the 
meta-analysis. For example, consideration was given to the methodology used 
to assess rectovaginal GBS carriage. 
Stars were assigned by PC for three broad criteria (representativeness of the 
study groups, comparability of the study groups, and quality of the outcome as-
sessment) in order to provide a measure of their quality. In this context, good 
representativeness	 is	 defined	 as	 those	 exposed/unexposed	 being	 similar	 to	
others	in	the	community	they	come	from,	and	good	comparability	is	defined	as	
the exposed and unexposed being similar in all respects other than their HIV or 
HIV exposure status. 
Studies that scored none or one, two or three, or four stars for representa-
tiveness	were	classified	as	having	respectively	a	high,	medium	or	low	risk	of	
bias for this criterion. Studies assigned none, one, or two stars for comparability 
or outcome were considered to have respectively a high, medium or low risk of 
bias for comparability and outcome. 
 Data analysis First, an odds ratio (OR) was calculated for studies that did not 
present them. We compared the odds of neonatal GBS disease in neonates born 
to HIV-infected mothers versus infants born to HIV-uninfected mothers, and the 
odds of rectovaginal GBS carriage in HIV-positive versus HIV-negative women, 
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using unadjusted counts. All neonates born from HIV-positive women were 
considered as HIV-exposed, regardless of their infection status. Rectovaginal 
GBS	carriage	was	defined	as	GBS	detected	in	the	vagina	and/or	rectum	and/or	
(peri)anal region by culture. While our protocol also included detection of rec-
tovaginal and neonatal GBS by molecular testing, none of the eligible studies 
used molecular testing, and the results reported in this manuscript are based 
on culture and latex agglutination results only. 
We reported the results of the meta-analyses obtained after pooling indi-
vidual	study	estimates	with	random	effects	model	as	ORs	with	95%	confidence	
interval (CI). The degree of heterogeneity between the studies was assessed 
using the I2 index, with percentages of 30 – 50%, 50–75% and 75–100% be-
ing indicative of moderate, substantial and considerable heterogeneity, respec-
tively [Higgins 2011].
A priori planned subanalyses were performed for GBS neonatal disease by 
considering early-onset and late-onset neonatal GBS disease separately, rely-
ing	on	the	authors’	own	classification	into	these	two	groups.	
To assess publication bias, funnel plots were created by plotting the natu-
ral logarithm of the ORs against the inverse of the standard error. The asymme-
try of the funnel plots was visually inspected and statistically checked using 
Egger’s regression test and Begg and Mazumdar’s rank correlation test [Begg 
and Mazumdar 1994; Egger et al., 1997]. All statistical analyses were carried out 
using the Comprehensive Meta-Analysis software package v3 (Biostat Inc., En-
glewood, NJ).
8.3 Results
 Manuscript and study selection A total of 546 unduplicated citations were 
identified,	we	selected	81	abstracts	for	full	text	evaluation	(Figure	8).	Of	these,	
32 manuscripts did not report results on GBS disease or carriage or HIV expo-
sure, seven were reviews, book chapters or letter to editors, nine did not in-
clude an HIV-negative or GBS-negative group, 11 did not present measures of 
effect	or	the	data	to	calculate	these,	four	reported	already	published	data,	and	
one paper could not be found.
Seventeen manuscripts reporting on 19 studies met the inclusion criteria. 
These included four studies reporting on neonatal GBS disease only, 11 stud-
ies reporting on rectovaginal carriage only, and two studies reporting both (Fig-
ure 8). A list of these studies and a digest of the extracted information is pre-
sented in the Supplementary Tables 2 and 3. 
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 Description of selected studies Six studies reported cases of infants with GBS 
neonatal disease born to HIV-infected mothers compared to infants with GBS 
neonatal disease born to HIV-uninfected mothers [Dangor, Lala, et al., 2015; 
Dangor, Kwatra, et al., 2015; Cutland et al., 2012; Cutland et al., 2015; Epalza et 
al., 2010; Frigati et al., 2014]. Five of these studies were conducted in South Af-
rica [Dangor, Lala, et al., 2015; Dangor, Kwatra, et al., 2015; Cutland et al., 2012; 
Cutland et al., 2015; Frigati et al., 2014] and one was performed in Belgium [Ep-
alza et al., 2010]. All infants included were born in a hospital. For the laborato-
ry diagnosis of GBS neonatal disease, all studies used the BacT/ALERT microbial 
detection	system	to	detect	bacteria	 in	blood	and/or	cerebrospinal	fluid	sam-
ples.	Positive	samples	were	subcultured	on	blood	agar	plates	and	identification	
was	subsequently	performed	using	standard	identification	methods.
For the second category, thirteen studies, representing a total of 10.105 
women, provided rectovaginal GBS carriage ratios of HIV-infected versus 
HIV-uninfected women [Cutland et al., 2012; Dangor, Kwatra, et al., 2015; Djig-
ma et al., 2011; El Beitune et al., 2006; Ernest et al., 2015; Gray et al., 2011; Joa-
chim et al., 2009; Mavenyengwa, Moyo, and Nordbø 2010; Mitima et al., 2014; 
Sebitloane, Moodley, and Esterhuizen 2011; Shah et al., 2011; Temmerman et 
al., 1992; Ulla et al., 1993]. Eleven of these studies were conducted in low-or-
middle income countries, i.e. three studies in South Africa [Cutland et al., 2012; 
Dangor, Kwatra, et al., 2015; Sebitloane, Moodley, and Esterhuizen 2011], two 
studies in Tanzania [Joachim et al., 2009; Ernest et al., 2015], and one study in 
Burkina Faso, Brazil, Democratic Republic Congo, Kenya, Malawi, and Zimbabwe 
[Djigma et al., 2011; El Beitune et al., 2006; Gray et al., 2011; Mavenyengwa, 
Moyo, and Nordbø 2010; Mitima et al., 2014; Temmerman et al., 1992] and two 
in a high-income country namely Spain and the US [Shah et al., 2011; Ulla et al., 
1993]. All these studies recruited pregnant women in a hospital setting, except 
for the study of Djigma and coworkers in Burkina Faso (2011), who recruited 
non-pregnant women, and the study of Ulla and coworkers in Spain (1993), who 
recruited female sex workers attending a family planning center. 
Rectovaginal	GBS	carriage	was	assessed	by	culture	in	all	studies:	five	stud-
ies performed rectovaginal sampling and culturing with the use of an enrich-
ment broth, as recommended by the Centers for Disease Control and Preven-
tion (CDC) guidelines [El Beitune et al., 2006; Gray et al., 2011; Joachim et al., 
2009; Mavenyengwa, Moyo, and Nordbø 2010; Shah et al., 2011], two studies 
only sampled vaginally with cultures performed according to the CDC guide-
lines [Cutland et al., 2012; Dangor, Kwatra, et al., 2015] and the remaining six 
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studies did not culture according to CDC guidelines or did not report the ex-
act culture methods used [Djigma et al., 2011; Ernest et al., 2015; Mitima et al., 
2014; Sebitloane, Moodley, and Esterhuizen 2011; Temmerman et al., 1992; 
Ulla et al., 1993]. 
Of the 19 studies described of the 17 manuscripts, three were retrospec-
tive [Epalza et al., 2010; Shah et al., 2011; Frigati et al., 2014], fourteen were 
cross-sectional [Dangor, Lala, et al., 2015; Dangor, Kwatra, et al., 2015; Cutland 
et al., 2012; Cutland et al., 2015; El Beitune et al., 2006; Ernest et al., 2015; Gray 
et al., 2011; Joachim et al., 2009; Mavenyengwa, Moyo, and Nordbø 2010; Miti-
ma et al., 2014; Sebitloane, Moodley, and Esterhuizen 2011; Temmerman et al., 
1992] and none were prospective.
One	 study	 reported	 two	 different	 analyses	 for	 rectovaginal	 GBS	 carriage	
in HIV-infected versus uninfected women, i.e. using the total cohort versus 
matched subsets [Cutland et al., 2012]. The analysis least prone to bias (i.e. 
the matched subsets) was used for this meta-analysis. The same study ana-
lyzed matched subsets for the association of HIV exposure of neonates and GBS 
neonatal disease and early-onset GBS neonatal disease, but not for late-onset 
GBS neonatal disease. Therefore, we used the total cohort analysis for these 
associations.
 Risk of bias within studies The results of the critical appraisals of the includ-
ed studies are shown in Figure 9 and Supplementary Table 4. All six studies ad-
dressing the relationship between HIV exposure of neonates and GBS neonatal 
disease were assessed as having a low risk of bias for representativeness [Dan-
gor, Lala, et al., 2015; Dangor, Kwatra, et al., 2015; Cutland et al., 2012; Cutland 
et al., 2015; Frigati et al., 2014; Epalza et al., 2010]. Two out of the six studies 
had a low risk of bias for comparability [Cutland et al., 2012; Dangor, Lala, et al., 
2015], two had a medium risk [Cutland et al., 2015; Dangor, Kwatra, et al., 2015] 
and two had a high risk [Epalza et al., 2010; Frigati et al., 2014]. For the GBS dis-
ease outcome assessment, four studies were assessed as having a low risk of 
bias [Cutland et al., 2012; Cutland et al., 2015; Dangor, Lala, et al., 2015; Frigati 
et al., 2014] and two had a medium risk [Dangor, Kwatra, et al., 2015; Epalza et 
al., 2010]. 
Of the studies on HIV infection and maternal GBS carriage only two out of the 
thirteen studies were assessed as having a low risk of bias for representative-
ness [Cutland et al., 2012; Gray et al., 2011], nine studies a medium risk [Dan-
gor, Kwatra, et al., 2015; El Beitune et al., 2006; Ernest et al., 2015; Joachim et al., 
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2009; Mavenyengwa, Moyo, and Nordbø 2010; Mitima et al., 2014; Sebitloane, 
Moodley, and Esterhuizen 2011; Temmerman et al., 1992; Ulla et al., 1993] and 
two studies a high risk [Djigma et al., 2011; Shah et al., 2011]. 
Three out of the thirteen studies were assessed as having a low risk of bias 
for comparability [Cutland et al., 2012; Gray et al., 2011; Shah et al., 2011], four 
a medium risk [Dangor, Kwatra, et al., 2015; Ernest et al., 2015; Joachim et al., 
2009; Sebitloane, Moodley, and Esterhuizen 2011], and six a high risk [Djig-
ma et al., 2011; El Beitune et al., 2006; Mavenyengwa, Moyo, and Nordbø 2010; 
Mitima et al., 2014; Temmerman et al., 1992; Ulla et al., 1993]. The risk of bias 
for	outcome	assessment	was	low	in	five	out	of	the	thirteen	studies	[El	Beitune	et 
al., 2006; Gray et al., 2011; Joachim et al., 2009; Mavenyengwa, Moyo, and Nord-
bø 2010; Shah et al., 2011]; medium in two studies [Cutland et al., 2012; Dan-
gor, Kwatra, et al., 2015] and high in six studies [Djigma et al., 2011; Ernest et al., 
2015; Mitima et al., 2014; Sebitloane, Moodley, and Esterhuizen 2011; Temmer-
man et al., 1992; Ulla et al., 1993]. 
 Association of maternal HIV status with GBS neonatal disease The meta- 
analysis of the association between HIV exposure of neonates and GBS neona-
tal disease showed that HIV-exposed neonates were more than twice as likely 
to have neonatal GBS disease compared to unexposed neonates (OR, 2.39; CI, 
1.31–4.38; p=0.005) (Figure 10). The crude OR in the individual studies ranged 
from 1.72 to 19.86, with three of the six individual studies showing a statistical-
ly	significant	association.	The	subanalyses	showed	that	HIV-exposed	neonates	
were not at increased risk for early-onset neonatal disease (OR, 1.31; 95% CI, 
0.84–2.04; p=0.240), but were 4.43 times more likely to have late-onset neona-
tal disease (95% CI, 1.81–10.85; p=0.001).
As recommended by Sterne and co-workers [2011] to only create funnel 
plots when the number of studies is ten or more, we did not create a funnel plot 
for this meta-analysis. 
 Association of HIV infection and rectovaginal GBS carriage In our meta-anal-
ysis of the association between HIV infection and rectovaginal GBS carriage, we 
found	no	 significant	 association	between	HIV	 infection	 status	 and	 rectovagi-
nal GBS carriage (OR 1.09; 95% CI 0.82–1.44; p=0.55) (Figure 11). The crude 
ORs in the individual studies ranged from 0.26 to 4.22, with only three studies 
reporting	a	statistically	significant	association	[Temmerman	et al., 1992; Miti-
ma et al., 2014; Cutland et al.,	2012].	Two	of	these	studies	found	a	significantly	
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higher rectovaginal carriage rate in HIV-positive women [Temmerman et al., 
1992; Mitima et al.,	2014],	whereas	one	study	found	a	significantly	lower	rate	
[Cutland et al., 2012].
The heterogeneity among these studies is substantial (I2 = 68.7%). Visual in-
spection of the funnel plot shows an asymmetrical distribution of studies, sug-
gesting publication bias (Figure 6), which is marginally supported by Egger’s 
regression intercept (0.94; 95% CI -0.48 -2.37; p=0.09), but not by the Begg 
and Mazumdar’s rank correlation test (Kendall’s tau = -0.10, one-tailed p-value 
= 0.313). Two studies [Mitima et al., 2014; Temmerman et al., 1992] fall outside 
the	pseudo	95%	confidence	interval,	providing	further	evidence	of	heteroge-
neity and bias.
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FIGURE 10 Forest plot of estimates of association between HIV exposure and GBS neonatal  
 disease. Studies are plotted alphabetically according to the last name of the first  
 author and followed by the publication year. Each study is represented by a black  
 square and a horizontal line, which corresponds to the OR and 95% CI, respectively.  
 The areas of the black squares reflect the weight of the study (determined by  
 random effects analysis) in the meta-analysis. The vertical line in the middle  
 corresponds to an OR of 1.0. The diamonds represent the overall summary  
 estimate for EOD, LOD and total GBS disease, respectively, with the 95% CIs  
 given by the width. In the columns on the right, the number of cases on the total  
 number of HIV-positive and of HIV-negative mothers is given, respectively,  
 for each study. a, Dangor, 2015, JID; b, Dangor, 2015, PONE; CI, confidence interval;  
 OR, odds ratio; //, 95% CI line exceeding OR 100.
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FIGURE 11 Forest plot of estimates of association between HIV infection and rectovaginal  
 GBS carriage. Studies are plotted alphabetically according to the last name of the  
 first author and followed by the publication year. Each study is represented by a  
 square and a horizontal line, which corresponds to the OR and the 95% CI,  
 respectively. The magnitude of the squares reflects the weight of the study  
 (determined by random effects analysis) in the meta-analysis. The vertical line  
 in the middle indicates the OR 1.0. The diamond at the bottom represents the  
 summary estimate, with its width indicating the 95% CI. The two columns on  
 the right document the number of GBS cases on the total of HIV-positive and of  
 HIV-negative women, respectively, for each study. a, Dangor, 2015, JID; CI,  
 confidence interval; OR, odds ratio; bold, p<0.05.
Cutland,	2012	 0.74	(0.63-0.86)	
Dangor,	2015a	 1.29	(0.66-2.53)	
Djigma,	2011	 0.79	(0.20-3.21)	
El	Beitune,	2006	 1.50	(0.72-3.12)	
Ernest,	2015	 0.43	(0.02-7.51)	
Gray,	2011	 0.87	(0.66-1.15)	
Joachim,	2009	 0.28	(0.06-1.15)	
Mavenyenga,	2010	 0.88	(0.55-1.43)	
MiJma,	2014	 4.22	(1.63-10.93)	
Sebitloane,	2011	 0.91	(0.38-2.22)	
Shah,	2011	 1.35	(0.86-2.12)	
Temmerman,	1992	 2.82	(1.19-6.71)	
Ulla,	1993	
	 0.26	(0.01-4.82)	
OVERALL	 1.09	(0.82-1.44)	
0.01	 0.1	 1 10	 100	
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FIGURE 12 Funnel plot to assess publication bias among studies evaluating the association  
 between HIV infection and rectovaginal GBS carriage. The circles represent the  
 estimates of the 11 included studies of association between HIV infection and  
 rectovaginal GBS carriage. The log of the odds ratio is plotted on the horizontal  
 axis, against the inverse of the standard error of the odds ratio on the vertical axis.  
 The vertical line in the funnel plot indicates the fixed-effects summary estimate  
 and the sloping lines indicate the expected 95% confidence intervals for a given  
 standard error. 
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8.4 Discussion
Group B streptococci (GBS) are a major cause of neonatal sepsis, which results 
in one million neonatal deaths every year [Lawn et al., 2005]. Also, studies have 
repeatedly shown that HIV-negative neonates that had been exposed to HIV 
during pregnancy are at increased risk for infectious morbidity and mortality 
(reviewed in [Afran et al., 2014]). In this systematic review and meta-analysis, 
we assessed the risk for GBS neonatal disease in HIV-exposed neonates. We 
also assessed the risk for rectovaginal GBS carriage in HIV-infected women, as 
rectovaginal carriage is a major risk factor for neonatal GBS disease. 
We found convincing evidence that HIV-exposed neonates were at high-
er risk for GBS neonatal disease. When analyzing cases of early-onset GBS and 
late-onset GBS disease separately, we found that this increased risk pertains to 
late-onset disease only. 
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FIGURE 13 Integrated model of factors influencing rectovaginal GBS carriage, EOD and LOD.  
 Overview of the different factors and their influence on early- and late-onset sepsis  
 in HIV- and HIV+ mothers.
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There are several factors associated with HIV infection in pregnant women or 
mothers that might explain why infants born to HIV-infected mothers are at in-
creased risk for late-onset, but not early-onset GBS disease. In the case of ear-
ly-onset GBS disease, the factors that increase or decrease the risk for early-on-
set GBS disease might be well-balanced, while in the case of late-onset GBS 
disease, the net result may be an enhanced risk (Figure 13).
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Factors that might decrease early-onset GBS disease rates  
in HIV-exposed neonates
First, HIV-infected pregnant women widely use antibiotic prophylaxis (co-tri-
moxazole), as recommended by the World Health Organization (WHO) [WHO 
2006].	Co-trimoxazole,	 largely	effective	against	GBS	[Joachim	et al., 2009], is 
likely to be responsible for lower GBS rectovaginal carriage rates in HIV-infect-
ed pregnant women. For instance, we previously showed, using GBS-specif-
ic quantitative PCR (qPCR), that none of 30 Rwandan HIV-infected women, of 
which 93.3% were on antibiotic prohylaxis, carried GBS [Cools et al., 2016]. As 
vaginal GBS carriage is a prerequisite for GBS early-onset disease, reduction of 
carriage rates might reduce the risk for the early-onset form, but not for the 
late-onset form, where GBS is considered to be more frequently community- or 
hospital-acquired. 
Second, the prevalence of EOD might be reduced by the practice of elective 
caesarean section. Elective caesarean section, i.e. caesarean delivery before la-
bor and before rupture of membranes, has been shown to reduce the risk of 
mother-to-child transmission of HIV by 80% (60% to 70% of mother-to-child 
transmissions occur during labor and vaginal delivery [Chama and Morrupa 
2008; Jamieson et al., 2007]. This has led to dramatically increased ECS rates in 
HIV-infected women in some countries [Jamieson et al., 2007]. Because in EOD, 
GBS is transmitted to the neonate when passing the birth channel or, more com-
monly in utero after rupture of the membranes, ECS might reduce the risk for 
EOD. Interestingly, Hook and colleagues [Hook et al., 1997] compared pregnan-
cy outcomes among 497 women undergoing elective repeat cesarean delivery 
to 492 who attempted trial of labor and 989 women with routine vaginal deliv-
ery.	They	found	that	rates	of	suspected	and	confirmed	neonatal	sepsis	were	sig-
nificantly	lower	in	the	elective	repeat	cesarean	delivery	group,	although	abso-
lute numbers of cases were very small (9, 26 and 26 cases of suspected sepsis 
in elective repeat cesarean delivery, trial of labor and vaginal delivery, respec-
tively;	and	0,	4	and	1	cases	of	confirmed	sepsis	in	elective	repeat	cesarean	de-
livery, trial of labor and vaginal delivery, respectively).
Factors that might increase late-onset GBS disease rates  
in HIV-exposed neonates
Since 2009, the WHO recommends HIV-positive mothers to practice exclusive 
breastfeeding for their infants in combination with antiretroviral therapy (ART) 
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for mother or infant. However, compared to HIV-negative women, HIV-positive 
women have been shown to preferentially choose exclusive replacement feed-
ing or mixed feeding, or stop breastfeeding early, because of fear of HIV trans-
mission through breast milk. This is a consequence of previous WHO guide-
lines recommending total avoidance of breastfeeding and/or because many 
advocates of programs for prevention of mother-to-child transmission recom-
mend early weaning [Aishat UO 2015; Lunney et al., 2008; Kuhn et al., 2010; 
Slater, Stringer, and Stringer 2010; Haile 2015; Sadoh WE 2008; Adejuyigbe et 
al., 2008]. Lack of breastfeeding might hamper passive protection of the neo-
nate	against	GBS	neonatal	disease	as	GBS	specific	IgA,	present	in	breast	milk,	
could	offer	GBS-specific	protection	[Weisman	and	Dobson	1991].	Furthermore,	
HIV-infected mothers might have reduced IgA in breast milk, as has been shown 
to be the case for saliva [Challacombe and Sweet 1997]. These altered infant 
feeding	practices	are	likely	to	have	more	effect	on	the	incidence	of	LOD,	consid-
ering the fact that most infants with EOD are already septic at birth or become 
septic shortly after birth. Concordantly, clinical studies have shown that lack of 
breastfeeding is a risk factor for neonatal LOD and meningitis [Schanler, Shul-
man, and Lau 1999; Hylander, Strobino, and Dhanireddy 1998].
Factors that might increase EOD and LOD GBS disease rates  
in HIV-exposed neonates
Low	maternal	GBS-specific	antibody	concentrations	have	been	shown	to	be	cor-
related with susceptibility of neonates for GBS EOD and LOD [Baker and Kasper 
1976; Baker, Edwards, and Kasper 1981; Baker et al., 2014]. Some important ob-
servations show that these protective antibodies are reduced in HIV-exposed 
neonates	 and	 HIV-infected	 mothers.	 Significantly	 lower	 GBS-specific	 anti-
body concentrations were measured in maternal/cord blood from HIV-infect-
ed mothers and neonates born from HIV-infected mothers [Dangor, Kwatra, et 
al., 2015; Le Doare et al., 2015]. Furthermore, a reduced transplacental trans-
fer	of	GBS-specific	antibodies	has	been	shown	in	HIV-infected	mothers	[Dangor,	
Kwatra, et al., 2015; Le Doare et al., 2015]. In addition, the neonatal anti-GBS 
antibodies	remained	significantly	lower	at	16	weeks	[Le	Doare	et al., 2015]. Le 
Doare	and	co-workers	demonstrated	a	significantly	lower	antibody-mediated	
C3b/iC3b deposition on all investigated GBS serotypes (Ia, Ib, II, III and V) in 
HIV-infected women and neonates born to HIV-infected women, suggesting a 
reduced	opsonophagocytotic	immune	effector	function	[Le	Doare	et al., 2015]. 
A recent phase 2 GBS vaccination trial (with a trivalent vaccine consisting of 
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conjugated capsular polysaccharides of GBS serotypes Ia, Ib and III) in African 
HIV-positive and HIV-negative pregnant women showed that the vaccine was 
less immunogenic in HIV-infected women, irrespective of their CD4 count [Hey-
derman et al., 2016].
Other perturbations of the immune system of HIV-infected women (even in 
the absence of overt immune dysfunction) might also play an important role. 
HIV-infected women were shown to have reduced transplacental transfer of he-
matopoietic cytokines. This may result in lower thymic output of CD4+ cells in 
their infants and a delay in immune cell maturation [Epalza et al., 2010]. Fur-
thermore, intrauterine exposure to HIV or its soluble products appears to cause 
a disturbed thymic function in HIV-uninfected newborns [Clerici et al., 2000].
ART, used to prevent mother-to-child transmission of HIV, might play a role 
as well. Nucleoside reverse transcriptase inhibitors (NRTIs) crossing the placen-
ta could cause mitochondrial dysfunction in HIV-exposed uninfected infants, 
explaining a decrease in neutrophils, total lymphocytes, CD4+ and CD8+ cells 
counts [Epalza et al., 2010]. 
Factors that might increase or decrease early-onset  
GBS disease rates in HIV-exposed neonates: meta-analysis  
of the risk for rectovaginal GBS carriage in HIV-infected women.
Because rectovaginal GBS carriage is a major risk factor for early-onset neona-
tal GBS disease, we also assessed the risk for rectovaginal GBS carriage in HIV- 
infected women.
Our meta-analysis, based on 13 studies, did not show an association be-
tween HIV infection and rectovaginal GBS carriage, but most of the studies suf-
fered from major limitations and we consider the currently available evidence 
weak and call for further study. 
Few studies had adequate statistical power and few were designed to as-
sess the association between HIV infection and rectovaginal GBS carriage. Most 
studies were at medium or high risk of bias related to representativeness of 
study groups, comparability of study groups, and/or outcome assessment. 
Heterogeneity was considerable. Technical biases, such as the specimen col-
lection and culture methods are likely to contribute substantially to this hetero-
geneity.	For	example,	 rectovaginal	 sampling	has	been	shown	 to	yield	signifi-
cantly higher recovery rates compared to vaginal sampling alone [El Aila et al., 
2010; Dillon et al., 1982]. Furthermore, the use of a selective enrichment broth 
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has been shown to improve GBS detection substantially [Baker et al., 1977; El 
Aila et al., 2010]. However, rectovaginal sampling and the use of a selective en-
richment	broth,	both	recommended	by	the	CDC,	were	used	by	only	five	studies.	
Also,	the	different	study	populations	and	eligibility	criteria	are	likely	to	contrib-
ute to the observed heterogeneity.
Some important possible confounding factors were not taken into account. 
For instance, none of the studies corrected for bacterial vaginosis (BV), a dis-
turbance of the vaginal microbiome characterised by the deprivation of lacto-
bacilli and the presence of anaerobes such as Gardnerella vaginalis and Atopo-
bium vaginae. BV has been shown to be a risk factor for the acquisition of HIV 
[Atashili et al., 2008] but also to be negatively associated with vaginal GBS car-
riage [Cools et al., 2016; Hillier et al., 1992], possibly masking an association be-
tween HIV and GBS. 
Furthermore, as described above, the use of antibiotic prophylaxis in HIV 
positive women, recommended by the WHO [WHO 2006], might be responsible 
for lower GBS rectovaginal carriage rates in HIV-infected pregnant women but 
was only taken into account in few studies. Also, risk factors for early-onset GBS 
disease such as urinary tract infections and intrapartum fever have been report-
ed to be more prevalent in HIV-infected women but were considered only by 
Cutland and coworkers [2012].
As the risk for EOD increases with heavier vaginal GBS colonization at the 
onset of labor or rupture of membranes [Verani and Schrag 2010], future stud-
ies	should	also	include	quantitative	molecular	tests	such	as	GBS-specific	qPCR	
to determine the vaginal GBS load in relation to the HIV status. Furthermore, 
including the assessment of GBS serotype/genotype distribution in HIV-posi-
tive and –negative women will document whether more virulent GBS strains are 
present in HIV-positive women.
In conclusion, the evidence that HIV-exposed infants are at increased risk for 
late-onset GBS neonatal disease is accumulating and public health interven-
tion is urgently needed. A compromised immune system, a lesser tendency to 
breastfeed but higher tendency for cesarean section and the use of prophylac-
tic	antibiotics	in	HIV-positive	women	might	partly	explain	these	findings.	While	
we	did	not	find	evidence	for	an	increased	risk	of	rectovaginal	GBS	colonization	
in	HIV-infected	women,	most	studies	conducted	to	date	suffered	major	limita-
tions. Further well-designed studies incorporating sensitive, quantitative (and 
serotype	specific)	GBS	detection	methods	may	further	clarify	the	relation	be-
tween HIV-positivity and GBS carriage. 
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Supplementary Tables
Selection 
1 Representativeness of the exposed group
a Truly representative of the average women (neonates) in the community *
b Somewhat representative of the average women (neonates) in the community *
c Selected group of women (neonates)
d No description of the sampling strategy
2 Representativeness of the non-exposed group
a Drawn from the same community as the exposed group *
b	 Drawn	from	a	different	source
c No description of the derivation of the non-exposed group
3 Sample size (total number of cases analyzed)
a	 Justified	and	satisfactory *
b	 Not	justified	or	not	satisfactory
4 Ascertainment of the HIV infection (exposure)
a Validated assay performed for the study or through medical records *
b Self-reported without further documentation
Comparability 
The subjects in different comparison groups are comparable,  
based on the study design or analysis
a Controlling for confounding factors (logistic regression or propensity scoring) **
b	 Subjects	in	different	groups	are	comparable	 *
c No reporting on comparability between comparison groups and no control for confounding 
Outcome 
Assessment of the outcome (rectovaginal GBS carriage)
a	 Sampling,	culturing,	and	identification	according	to	CDC# guidelines **
b	 Culturing	and	identification	according	to	CDC	guidelines *
c	 Sampling,	culturing,	and	identification	not	adequately	performed/described
d No description
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Assessment of the outcome (GBS neonatal disease):
a	 Blood	samples,	cerebrospinal	fluid	(CSF),	or	other	normal	sterile	site;	 
	 	 BactAlert	and/or	GBS	specific	latex	agglutination	on	CSF
**
b Culture methods not described
Risk of bias
Selection 4 stars, low risk of bias; 2 or 3 stars, medium risk of bias; 0 or 1 star(s), high risk of bias
Comparability 2 stars, low risk of bias; 1 star, medium risk of bias; 0 stars, high risk of bias
Outcome 2 stars, low risk of bias; 1 star, medium risk of bias; 0 stars, high risk of bias
SUPPLEMENTARY TABLE 1 Quality appraisal tool: adjusted Newcastle-Ottawa  
   Quality Assessment Scale. 
  #CDC, Centers for Disease Control and Prevention,  
  Bethesda, Maryland.
SUPPLEMENTARY TABLE 2 (see next page)
Digest of included studies reporting HIV exposure  
of neonates and GBS neonatal disease. 
 » Author: a, Dangor, 2015, JID; b, Dangor, 2015, Plos ONE 
 » Country: B, Belgium; SA, South-Africa
 » Study design: CC, case-control; R, retrospective; XS, cross-sectional
 » Study setting and population: EOD, early-onset disease; I, inclusion criteria;  
LOD, late-onset disease; SSA, sub-Saharan Africa
 » Exposure assessment: CON, confirmatory test; RT, rapid test; S, serology;  
WB, Western blotting; PC, personal communication
 » Outcome assessment: EOD, early-onset disease; LOD, late-onset disease;  
d, days; PC, personal communication
1. Sampling and transport medium: B, blood sample; CSF, cerebrospinal fluid
2. Culture conditions: AER, aerobic conditions; BA, blood agar;  
BHIB, brain heart infusion broth; CA, chocolate agar 
3. Identification: BEA, growth on bile esculin agar; CAMP, Christie, Atkins,  
and Munch-Petersen test; CAT, catalase test; ESC, esculine hydrolase test;  
GS, Gram stain; LA, GBS specific latex agglutination
 » Correction confounding: PSM, propensity score matching
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Author, year Country Study design Study period Study setting and population HIV exposure assesment
Outcome assessment and EOS/LOS 
definition
Correction 
confounding 
Cutland, 2012 SA XS 2004–2007 Infants born at a public second-
ary-tertiary level of care hospital
Medical records, active voluntary 
HIV testing programme for pregnant 
women (in the community, >96% of 
pregnant women are tested (PC), in 
parent study, 99% were tested) 
EOS, 0–3 d; LOS, 4–28 d. Active surveil-
lance of neonatal/pediatric wards to
ID study neonates, abstraction informa-
tion related to neonatal sepsis from med-
ical records. 1. B, samples other sterile 
sites 2. B: BacT/Alert, other samples: rou-
tine methods 3. Routine methods
PSM
(EOS only)
Cutland, 2015 SA R 2004–2008 Infants born at a public second-
ary-tertiary level of care hospital
Medical records, HIV ELISA results 
from maternal blood tests (>96% of 
pregnant women accept testing (PC). 
Sensitivity analysis of incidence ac-
counted for GBS case-patients with 
unknown maternal HIV status 
GBS	disease,	0–90	d.	Cases	identified	
through screening of ward admissions 
and microbiological records within 24h 
of GBS ID.
1. B, CSF. 2. BacT/Alert 
None
Dangor, 2015a SA XS 2013 Tertiary-level care hospital serving 
black-African community of Soweto 
and surrounding areas. I, >= 2500 g. 
Medical records, pregnant women 
HIV tested by RT, CON ELISA
GBS disease, <90 d; EOS, < 7 d; LOS, 7–89 
d. GBS cultured from blood, CSF or nor-
mally sterile sites, or GBS in CSF by LA. 
1. B, CSF 2. B positive on BacT/Alert and 
CSF: BA or CA, BHIB (CSF), AER, CO2,	35°C,	
72h. 3. direct on CSF: LA, GS. Colonies ID: 
CAT, BEA, ESC, CAMP, GBALA (all PC)
None
Dangor, 2015b SA CC 2012–2014 Infants with GBS disease recruit-
ed from three secondary-tertiary 
care public hospitals; EOD controls 
from one public hospital; LOD con-
trols	identified	through	the	birth	
registries 
HIV testing of pregnant women rou-
tinely	performed	and	confirmed	us-
ing two independent RT 
GBS disease, <90 d; EOS, < 7 d; LOS, 7–89 
d. GBS cultured from blood, CSF or nor-
mally sterile sites, or GBS in CSF by LA. 
1. B, CSF 2. B positive on BacT/Alert and 
CSF: BA or CA, BHIB (CSF), AER, CO2,	35°C,	
72h. 3. direct on CSF: LA, GS. Colonies ID: 
CAT, BEA, ESC, CAMP, GBALA. 
None
Epalza, 2010 B R 2001–2008 Hospital with tertiary neonatal cen-
ter and HIV referral center in an ur-
ban setting. Most infants born from 
mothers of SSA origin living in poor 
socioeconomic conditions
Review of medical records, all preg-
nant women are tested for HIV (ELISA, 
CON WB)(PC)
EOS, 0–6 d; LOS, 7–90 d. 1. B, CSF (PC) 2. 
BacT/Alert (PC)
None
Frigati, 2014 SA R 2010–2011 Infants born at a primary and a ter-
tiary level of care hospital
Medical records GBS disease, 0–90 d; EOS, 0–6 d; LOS, 
7–90	d.	Cases	identified	throught	the	
hospital database. 1. B, CSF 2. BacT/Alert
None
SUPPLEMENTARY TABLE 2
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Author, year Country Study design Study period Study setting and population HIV exposure assesment
Outcome assessment and EOS/LOS 
definition
Correction 
confounding 
Cutland, 2012 SA XS 2004–2007 Infants born at a public second-
ary-tertiary level of care hospital
Medical records, active voluntary 
HIV testing programme for pregnant 
women (in the community, >96% of 
pregnant women are tested (PC), in 
parent study, 99% were tested) 
EOS, 0–3 d; LOS, 4–28 d. Active surveil-
lance of neonatal/pediatric wards to
ID study neonates, abstraction informa-
tion related to neonatal sepsis from med-
ical records. 1. B, samples other sterile 
sites 2. B: BacT/Alert, other samples: rou-
tine methods 3. Routine methods
PSM
(EOS only)
Cutland, 2015 SA R 2004–2008 Infants born at a public second-
ary-tertiary level of care hospital
Medical records, HIV ELISA results 
from maternal blood tests (>96% of 
pregnant women accept testing (PC). 
Sensitivity analysis of incidence ac-
counted for GBS case-patients with 
unknown maternal HIV status 
GBS	disease,	0–90	d.	Cases	identified	
through screening of ward admissions 
and microbiological records within 24h 
of GBS ID.
1. B, CSF. 2. BacT/Alert 
None
Dangor, 2015a SA XS 2013 Tertiary-level care hospital serving 
black-African community of Soweto 
and surrounding areas. I, >= 2500 g. 
Medical records, pregnant women 
HIV tested by RT, CON ELISA
GBS disease, <90 d; EOS, < 7 d; LOS, 7–89 
d. GBS cultured from blood, CSF or nor-
mally sterile sites, or GBS in CSF by LA. 
1. B, CSF 2. B positive on BacT/Alert and 
CSF: BA or CA, BHIB (CSF), AER, CO2,	35°C,	
72h. 3. direct on CSF: LA, GS. Colonies ID: 
CAT, BEA, ESC, CAMP, GBALA (all PC)
None
Dangor, 2015b SA CC 2012–2014 Infants with GBS disease recruit-
ed from three secondary-tertiary 
care public hospitals; EOD controls 
from one public hospital; LOD con-
trols	identified	through	the	birth	
registries 
HIV testing of pregnant women rou-
tinely	performed	and	confirmed	us-
ing two independent RT 
GBS disease, <90 d; EOS, < 7 d; LOS, 7–89 
d. GBS cultured from blood, CSF or nor-
mally sterile sites, or GBS in CSF by LA. 
1. B, CSF 2. B positive on BacT/Alert and 
CSF: BA or CA, BHIB (CSF), AER, CO2,	35°C,	
72h. 3. direct on CSF: LA, GS. Colonies ID: 
CAT, BEA, ESC, CAMP, GBALA. 
None
Epalza, 2010 B R 2001–2008 Hospital with tertiary neonatal cen-
ter and HIV referral center in an ur-
ban setting. Most infants born from 
mothers of SSA origin living in poor 
socioeconomic conditions
Review of medical records, all preg-
nant women are tested for HIV (ELISA, 
CON WB)(PC)
EOS, 0–6 d; LOS, 7–90 d. 1. B, CSF (PC) 2. 
BacT/Alert (PC)
None
Frigati, 2014 SA R 2010–2011 Infants born at a primary and a ter-
tiary level of care hospital
Medical records GBS disease, 0–90 d; EOS, 0–6 d; LOS, 
7–90	d.	Cases	identified	throught	the	
hospital database. 1. B, CSF 2. BacT/Alert
None
SUPPLEMENTARY TABLE 2
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Author, year Country Study design Study period Study setting and population Age (years) HIV exposure assesment Outcome assesment
Correction 
confounding 
Cutland, 2012 SA XS 2004–2007 Pregnant women presenting in la-
bor at a secondary-tertiary level of 
care hospital
Mdn, 26; R, 12–51 Medical records, active 
voluntary HIV testing 
programme for pregnant 
women (in the community, 
>96% accept testing (PC))
1. LV 2. A; HBA ± C (10 µg/
mL) and NA (15 µg/mL); 
TH+G (8 µg/mL) and NA (15 
µg/mL), HBA. 3. GPBHC: 
CAMP, ESC, LA. 
PSM
Dangor, 
2015a
SA XS 2013 Pregnant women delivering at a 
tertiary-level care hospital serving 
black-African community of Sowe-
to and surrounding areas.
R, 18.2–42.7 Medical records, pregnant 
women HIV tested by RT, 
CON ELISA
1. LV, R. 2. A w/o charcoal; 
CHA;	37	°C;	18–24-(48)h;	
AER. 3. GBS-like colonies: 
CAMP; ESC, CAT, LA
None
Djigma, 2011 BF XS 2009 Non-pregnant women seeking gy-
naecological assistance
HIV+: Mdn, 33.0; 
R, 28–44; HIV-
: Mdn, 35.0; R, 
27–45 
Questionnaire 1. V. 2.	CA;	37	°C;	24h	3. 
mini-galleries
None
Ernest, 2015 T XS 2011–2012 Pregnant women (GA, 28–42 w) 
attending consultant and teaching 
hospital, E,: ab within 2 w before 
recruitment 
M 25.6 ± 0.31; R, 
14–39
Questionnaire 1. LV, PA 2.	SBA,	37	°C,	CO2, 
24 h. GPBHC, CAT neg-
ative, SC SBA + SXT and 
BAC discs. 3. Confirmation	
CAMP, LA 
None 
SUPPLEMENTARY TABLE 3 
Digest of studies reporting HIV infection of women  
and rectovaginal GBS carriage.
 » Author: a, Dangor, 2015, JID
 » Country: Br, Brazil; BF, Burkina Faso; DRC, Democratic Republic Congo;  
K, Kenya; M, Malawi; S, Spain; SA, South-Africa; T, Tanzania; US, United States;  
Z, Zimbabwe; 
 » Study design: R, retrospective; XS, cross-sectional
 » Age: M, mean; Mdn, median; R, range
 » Study setting and population: E, exclusion criteria; GA, gestation age;  
I, inclusion criteria; w, weeks 
 » Exposure assessment: HEU, HIV-exposed uninfected; 2X, positive samples  
repeated with same method; CON, confirmatory test; RT, rapid test; S, serology;  
WB, Western blotting; PC, personal communication 
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Author, year Country Study design Study period Study setting and population Age (years) HIV exposure assesment Outcome assesment
Correction 
confounding 
Cutland, 2012 SA XS 2004–2007 Pregnant women presenting in la-
bor at a secondary-tertiary level of 
care hospital
Mdn, 26; R, 12–51 Medical records, active 
voluntary HIV testing 
programme for pregnant 
women (in the community, 
>96% accept testing (PC))
1. LV 2. A; HBA ± C (10 µg/
mL) and NA (15 µg/mL); 
TH+G (8 µg/mL) and NA (15 
µg/mL), HBA. 3. GPBHC: 
CAMP, ESC, LA. 
PSM
Dangor, 
2015a
SA XS 2013 Pregnant women delivering at a 
tertiary-level care hospital serving 
black-African community of Sowe-
to and surrounding areas.
R, 18.2–42.7 Medical records, pregnant 
women HIV tested by RT, 
CON ELISA
1. LV, R. 2. A w/o charcoal; 
CHA;	37	°C;	18–24-(48)h;	
AER. 3. GBS-like colonies: 
CAMP; ESC, CAT, LA
None
Djigma, 2011 BF XS 2009 Non-pregnant women seeking gy-
naecological assistance
HIV+: Mdn, 33.0; 
R, 28–44; HIV-
: Mdn, 35.0; R, 
27–45 
Questionnaire 1. V. 2.	CA;	37	°C;	24h	3. 
mini-galleries
None
Ernest, 2015 T XS 2011–2012 Pregnant women (GA, 28–42 w) 
attending consultant and teaching 
hospital, E,: ab within 2 w before 
recruitment 
M 25.6 ± 0.31; R, 
14–39
Questionnaire 1. LV, PA 2.	SBA,	37	°C,	CO2, 
24 h. GPBHC, CAT neg-
ative, SC SBA + SXT and 
BAC discs. 3. Confirmation	
CAMP, LA 
None 
 » Outcome assessment: 
1. Sampling and transport medium: A, anal swab; B, blood sample; CSF, 
cerebrospinal fluid; HV, high vaginal swab; LV, low vaginal swab; PA, perianal 
swab; R, rectal swab; RV, rectovaginal swabs; V, vaginal swab;
2. Culture conditions: A, Amies transport medium; AER, aerobic conditions; BA, 
blood agar; BAC, bacitracin; BHIB, brain heart infusion broth; C, colistin; CA, 
chocolate agar; CA+SB, Columbia agar + 5% sheep blood; CAN, colistin nalidixic 
acid agar; CHA, CHROMagar StrepB; CEF CLED, cefoxitine CLED plates; G, 
gentamycin; HBA, 5% horse blood agar; NA, nalidixic acid; S, Stuart’s transport 
medium; SB, sheep blood; SBA, 5% sheep blood agar; SC, subcultures; TH, Todd 
Hewitt broth; TSA-HB, tryptic soy agar + 5% human blood; (-48h), if no growth 
after 24h, another day was incubated 
3. Identification: BEA, growth on bile esculin agar; CAMP, Christie, Atkins, and  
Munch-Petersen test; CAT, catalase test; ESC, esculine test; GS, Gram stain; (GP)
BHC, (Gram-positive) β-haemolytic colonies; HAEM, haemolytic activity; HIP, 
hippurate test; LA, latex agglutination; PC, personal communication
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El Beitune, 
2006
Br XS 2002–2004 Pregnant women (GA, 35–37 w), 
singleton gestation; E, hepatitis B, 
hepatitis C, syphilis, previous his-
tory of a newborn with GBS EOD.
R, 16–43 2 ELISAs, CON WB 1. LV, A 2. TH + 8 mg/ml G 
and 15 mg/ml NA (trans-
port),	+250	ul	SB,	35	°C,	
18 h; BA + G and NA (idem 
conc),	35	°C,	48h.	3. (GP)
BHC, LA 
None
Gray, 2011 M XS 2008–2010 Pregnant women (GA, 3th trimes-
ter) recruited from the labor ward 
of hospital 
>= 16; M, 25.2 
± 5.9 
2 RT (Detemine™, Uni-
Gold™), discordant results: 
3rd RT (SD-Bioline)
1. LV, R 2. TH+ 15 ug/ml NA 
and 10 ug/ml C; 18–24 h. 3. 
Phenotypic characteristics, 
CAMP, LA
LR
Joachim, 2011 T XS 2008–2009  Pregnant women (GA, >= 37 w) at-
tending antenatal clinics of a ter-
tiary facility which handles refer-
rals from peripheral and upcountry 
hospitals for routine antenatal 
visits; E, ab within 2 weeks prior to 
recruitment
M, 26.6 ± 5.1; R, 
16–44
RT (SD-Bioline HIV 1/2), if 
negative: HIV status neg-
ative, if reactive: CON 2nd 
RT (Determine™). HIV sta-
tus positive if both tests 
positive 
1. HV, R 2. TH (transport), 
TH + NA (15 mg/L) and G 
(8	mg/L),	37°C,	5%	CO2, 
24 h-(48h), SC on SBA. 3. 
Presumptive ID: GS, CAT, 
HAEM, HIP, CAMP, LA; Con-
firmation,	LA.
None
Mavenyengwa, 
2010
Z XS 2003–2005 Pregnant women (GA, ± 20 w) at-
tending antenatal clinic and re-
cruited consecutively at three cen-
tres (rural, an urban, and a mixed 
rural-urban).
R, 16–45 RT (HIV Ag/Ab Combo). CON 
WB. Interpretation accord-
ing to American Red Cross 
guidelines.
1. LV, R 2. S, CAN agar base 
with SB, and in TH+C (10 
mg/L) and NA 15 mg/L, 
37°C,	24	h-(48),	looking	for	
b-haemolytic or nonhemo-
lytic streptococcal colo-
nies typical of GBS. TH was 
sub-cultured onto CAN 
blood agar plates before 
24	h	incubation	at	37	°C.	
None
Mitima, 2014 DRC XS 2012–2013 Pregnant women, (GA, 3th trimes-
ter), attending prenatal care in 12 
healthcare centers. Women mostly 
of low socio-economic status, ur-
ban	population.	E,	women	with	fis-
tulae, women currently on ab.
10%, <18; 66%, 
R, 18–35; 24% 
>35 
Medical records; RT (De-
termine), CON 2nd RT (Uni-
gold or	Double	Check	Gold).	
Positive if 2 RT positive.
1. V 2. A, BA + NA (15 mg/
mL) and C (10 µg/mL); 
37°C,	CO2, 48 h 3. BHC: GS, 
CAT, HIP, CAMP.
None
Sebitloane, 
2011
SA XS 2 years Pregnant women (GA, >= 36 w) 
in whom vaginal delivery was 
anticipated
>= 18 RT (DetermineTM HIV1/2), 
CON 2nd RT (SmartCheck). 
1. V 2. A, CEF CLED, BAC CA, 
and laked blood CEF
None
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El Beitune, 
2006
Br XS 2002–2004 Pregnant women (GA, 35–37 w), 
singleton gestation; E, hepatitis B, 
hepatitis C, syphilis, previous his-
tory of a newborn with GBS EOD.
R, 16–43 2 ELISAs, CON WB 1. LV, A 2. TH + 8 mg/ml G 
and 15 mg/ml NA (trans-
port),	+250	ul	SB,	35	°C,	
18 h; BA + G and NA (idem 
conc),	35	°C,	48h.	3. (GP)
BHC, LA 
None
Gray, 2011 M XS 2008–2010 Pregnant women (GA, 3th trimes-
ter) recruited from the labor ward 
of hospital 
>= 16; M, 25.2 
± 5.9 
2 RT (Detemine™, Uni-
Gold™), discordant results: 
3rd RT (SD-Bioline)
1. LV, R 2. TH+ 15 ug/ml NA 
and 10 ug/ml C; 18–24 h. 3. 
Phenotypic characteristics, 
CAMP, LA
LR
Joachim, 2011 T XS 2008–2009  Pregnant women (GA, >= 37 w) at-
tending antenatal clinics of a ter-
tiary facility which handles refer-
rals from peripheral and upcountry 
hospitals for routine antenatal 
visits; E, ab within 2 weeks prior to 
recruitment
M, 26.6 ± 5.1; R, 
16–44
RT (SD-Bioline HIV 1/2), if 
negative: HIV status neg-
ative, if reactive: CON 2nd 
RT (Determine™). HIV sta-
tus positive if both tests 
positive 
1. HV, R 2. TH (transport), 
TH + NA (15 mg/L) and G 
(8	mg/L),	37°C,	5%	CO2, 
24 h-(48h), SC on SBA. 3. 
Presumptive ID: GS, CAT, 
HAEM, HIP, CAMP, LA; Con-
firmation,	LA.
None
Mavenyengwa, 
2010
Z XS 2003–2005 Pregnant women (GA, ± 20 w) at-
tending antenatal clinic and re-
cruited consecutively at three cen-
tres (rural, an urban, and a mixed 
rural-urban).
R, 16–45 RT (HIV Ag/Ab Combo). CON 
WB. Interpretation accord-
ing to American Red Cross 
guidelines.
1. LV, R 2. S, CAN agar base 
with SB, and in TH+C (10 
mg/L) and NA 15 mg/L, 
37°C,	24	h-(48),	looking	for	
b-haemolytic or nonhemo-
lytic streptococcal colo-
nies typical of GBS. TH was 
sub-cultured onto CAN 
blood agar plates before 
24	h	incubation	at	37	°C.	
None
Mitima, 2014 DRC XS 2012–2013 Pregnant women, (GA, 3th trimes-
ter), attending prenatal care in 12 
healthcare centers. Women mostly 
of low socio-economic status, ur-
ban	population.	E,	women	with	fis-
tulae, women currently on ab.
10%, <18; 66%, 
R, 18–35; 24% 
>35 
Medical records; RT (De-
termine), CON 2nd RT (Uni-
gold or	Double	Check	Gold).	
Positive if 2 RT positive.
1. V 2. A, BA + NA (15 mg/
mL) and C (10 µg/mL); 
37°C,	CO2, 48 h 3. BHC: GS, 
CAT, HIP, CAMP.
None
Sebitloane, 
2011
SA XS 2 years Pregnant women (GA, >= 36 w) 
in whom vaginal delivery was 
anticipated
>= 18 RT (DetermineTM HIV1/2), 
CON 2nd RT (SmartCheck). 
1. V 2. A, CEF CLED, BAC CA, 
and laked blood CEF
None
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Shah, 2011 US R 1997–2007 Ethically diverse pregnant women 
attending prenatal care in an urban 
public hospital
HIV+: M, 29.5 ± 
5.8; HIV-: M, 28.0 
± 6.3
HIV status abstracted from 
medical records, HIV test 
not mentioned.
Medical	records.:	defined	
as having a positive rec-
tovaginal swab recovered 
within 5 weeks of delivery 
or GBS bacteriuria at any 
point during index preg-
nancy, as per the 2002 
guidelines CDC
LR
Temmerman, 
1992
K XS 1989–1990 Pregnant women with clinical 
signs and symptoms of sponta-
neous abortion (GA, < 20 w) and 
pregnant women (GA, >20 w) vis-
iting a non-private referral univer-
sity hospital. E, women on ab 24h 
before visit, women with induced 
or clinically septic abortion or with 
axillary	temp	>38°C,	severe	ane-
mia, shock.
M, 25.9 EIA (2X), CON WB 1. HV 2. CAN CA+SB None
Ulla, 1993 S XS 1986–1991 Female sex workers recruited at a 
family planning center
M, 25; R, 18–50 ELISA, CON WB 1. V 2. TSA-HB None
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Shah, 2011 US R 1997–2007 Ethically diverse pregnant women 
attending prenatal care in an urban 
public hospital
HIV+: M, 29.5 ± 
5.8; HIV-: M, 28.0 
± 6.3
HIV status abstracted from 
medical records, HIV test 
not mentioned.
Medical	records.:	defined	
as having a positive rec-
tovaginal swab recovered 
within 5 weeks of delivery 
or GBS bacteriuria at any 
point during index preg-
nancy, as per the 2002 
guidelines CDC
LR
Temmerman, 
1992
K XS 1989–1990 Pregnant women with clinical 
signs and symptoms of sponta-
neous abortion (GA, < 20 w) and 
pregnant women (GA, >20 w) vis-
iting a non-private referral univer-
sity hospital. E, women on ab 24h 
before visit, women with induced 
or clinically septic abortion or with 
axillary	temp	>38°C,	severe	ane-
mia, shock.
M, 25.9 EIA (2X), CON WB 1. HV 2. CAN CA+SB None
Ulla, 1993 S XS 1986–1991 Female sex workers recruited at a 
family planning center
M, 25; R, 18–50 ELISA, CON WB 1. V 2. TSA-HB None
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Study Selection Comparability Outcome
Representativeness 
exposed group
Representativeness 
non-exposed group
Total number  
cases analyzed
Ascertainment HIV  
infection/ exposure
HIV infection in women and rectovaginal GBS carriage
Cutland, 2012 * * * * ** *
Dangor, 2015a * * * *
Djigma, 2011 *
Ernest, 2015 * * *
El Beitune, 2006 * * **
Gray, 2011 * * * * ** **
Joachim, 2011 * * * * **
Mavenyengwa, 2010 * * **
Mitima, 2014 * * *
Sebitloane, 2011 * * * *
Shah, 2011 * ** **
Temmerman, 1992 * *
Ulla, 1993 * *
HIV exposure neonates and GBS neonatal disease
Cutland, 2012 * * * * ** **
Cutland, 2015 * * * * * **
Dangor, 2015a * * * * * *
Dangor, 2015b * * * * ** **
Epalza, 2010 * * * * *
Frigati, 2014 * * * * **
SUPPLEMENTARY TABLE 4 Critical appraisal of the included studies. 
  a, Dangor, 2015, JID; b, Dangor, 2015 PONE
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Study Selection Comparability Outcome
Representativeness 
exposed group
Representativeness 
non-exposed group
Total number  
cases analyzed
Ascertainment HIV  
infection/ exposure
HIV infection in women and rectovaginal GBS carriage
Cutland, 2012 * * * * ** *
Dangor, 2015a * * * *
Djigma, 2011 *
Ernest, 2015 * * *
El Beitune, 2006 * * **
Gray, 2011 * * * * ** **
Joachim, 2011 * * * * **
Mavenyengwa, 2010 * * **
Mitima, 2014 * * *
Sebitloane, 2011 * * * *
Shah, 2011 * ** **
Temmerman, 1992 * *
Ulla, 1993 * *
HIV exposure neonates and GBS neonatal disease
Cutland, 2012 * * * * ** **
Cutland, 2015 * * * * * **
Dangor, 2015a * * * * * *
Dangor, 2015b * * * * ** **
Epalza, 2010 * * * * *
Frigati, 2014 * * * * **
SUPPLEMENTARY TABLE 4 Critical appraisal of the included studies. 
  a, Dangor, 2015, JID; b, Dangor, 2015 PONE
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9.1 Introduction 
Streptococcus agalactiae (Group B Streptococcus, GBS) is a commensal bacteri-
um with an unique ability to colonize the vagina of adult women asymptomat-
ically but causing acute disease in neonates. In this population, it is worldwide 
the leading cause of sepsis and meningitis, commonly named neonatal disease 
[Melin, 2011]. Neonatal disease causes one million neonatal deaths each year, 
and over 99% occur in low- and middle-income countries [Lawn et al., 2005]. 
Early-onset	neonatal	disease	(EOD),	occurs	in	the	first	week	of	life,	but	in	over	
90% of cases, signs are evident at birth or within 12 hours after birth and pre-
sentation is typically with pneumonia/sepsis [Heath et al., 2016]. In EOD, verti-
cal transmission of GBS takes place in utero when GBS ascends from the vagina 
and causes an intra-amniotic infection after rupture of the membranes, or intra-
partum when the neonate passes the birth canal [Simonsen et al., 2014; Hornik 
et al., 2012]. Late-onset disease (LOD), mostly presenting as meningitis, occurs 
between week 1 and month 3 of life, and transmission is less well-understood 
but thought to be caused by GBS acquired vertically or horizontally [Schuchat 
et al., 1998]. 
To	prevent	GBS	disease	 in	 infants,	huge	efforts	have	been	made	since	the	
late 1980s based on two strategies, i.e. intrapartum antibiotic prophylaxis (IAP) 
and vaccination [Melin et al.,	2013].	Women	at	target	for	IAP	are	identified	on	a	
risk-based screening or by a late-gestation culture-based screening [Verani et 
al., 2010]. Although IAP has reduced EOD in high-income countries [Schrag et 
al.,	2000],	it	has	no	effect	on	LOD	or	adverse	perinatal	outcomes	related	to	GBS	
such as chorioamnionitis [Galask et al.,	1984;	Yancey et al., 1994], spontaneous 
abortion [Temmerman et al., 1992; McDonald et al., 2000], stillbirth [Nan et al., 
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2015], premature labour [Allen et al., 1999], premature rupture of membranes 
[Matorras et al., 1989], premature delivery [Regan et al., 1996], and puerperal 
sepsis [Acosta et al., 2014; Koenig et al., 2009].
Vaccination of pregnant women represents an attractive alternative to pro-
tect neonates against EOD, LOD and GBS-related adverse perinatal outcomes 
[Heath et al., 2016; Melin et al., 2013]. Most GBS vaccines under development 
aim at eliciting maternal serum immunoglobuline G (IgG) against capsular poly-
saccharides (CPS) that protect the fetus or neonate after crossing the placenta 
[Kasper et al., 1996; Heath et al., 2016]. However, as transplacental IgG is only 
sufficiently	from	week	32	of	gestation	onwards	[Boyer et al., 1984], premature 
neonates – at high risk for EOD – might not be protected by a systemic vaccine 
[Hordnes et al.,	1996].	Vaginal	mucosal	immunity	to	GBS	is	an	important	first-
line defense against EOD and some GBS-related adverse perinatal outcomes, as 
colonization	of	the	vaginal	epithelium	by	GBS	is	the	first	step	in	pathogenesis	
[Simonsen et al., 2014]. Therefore, an optimal vaccine should also induce muco-
sal immunity [Shen et al., 2000].
However, the human vaginal mucosal immune response to GBS colonization 
of the vaginal tract remains to be elucidated. Gaining insight into this is essen-
tial for our understanding of the biological factors favoring colonization and 
persistence of GBS in the complex environment of the vaginal microbiome. Fur-
thermore, knowledge of protective vaginal mucosal cytokines in response to 
GBS	could	provide	a	template	for	the	design	or	refinement	of	more	appropriate	
and	effective	vaccines	[Morel et al., 2010].
To our knowledge, the cytokine responses to GBS have only been character-
ized using in vitro cell-culture studies and murine models.
In this study, we describe mucosal cytokine patterns associated with hu-
man vaginal GBS colonization in populations at the highest need for prevention 
measures to counter the extremely high burden of GBS EOD, LOD and GBS-re-
lated adverse perinatal outcomes.
9.2 Materials and methods
 Study design and population A total of 430 women were recruited during 2010–
2011 at three study sites, i.e. the International Centre for Reproductive Health 
Kenya (ICRHK), Mombasa, Kenya (170 women); the Wits Reproductive Health 
and HIV Institute (WrHI), Johannesburg, Republic of South Africa (RSA) (200 
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women); and the non-governmental organisation Rinda Ubuzima (RU), Kigali, 
Rwanda	(60	women)	(Table	10).	The	women	were	recruited	into	6	predefined	
study groups: a reference group of 219 women (adult, non-pregnant, HIV-nega-
tive women at average risk of HIV), 60 pregnant women (up to 14 weeks of ges-
tational age as determined by abdominal ultrasound at recruitment), 60 adoles-
cent girls (16–17 years), 31 HIV-negative women engaging in vaginal practices 
(usage of cloth, lemon juice, detergents to clean, dry or tighten the vagina on a 
regular basis), 30 female sex workers (FSW), and 30 HIV-positive women (on an-
tiretroviral treatment for at least 6 months, asymptomatic and with a CD4 count 
of more than 350 cells/µl). Women in the reference group and pregnant wom-
en were recruited from family planning clinics, ‘women’s groups’ and antenatal 
clinics in Mombasa County and Johannesburg. Adolescents were recruited at 
youth centres and youth-friendly family planning services in Mombasa Coun-
ty and Johannesburg. Women engaging in vaginal practices were recruited in 
Johannesburg only. FSW and HIV-positive women were recruited in Kigali from 
the sex worker community, using community mobilizers and from public HIV 
treatment clinics, respectively. 
This	study	reports	on	a	cross-sectional	analysis	of	the	first	study	visit	of	a	lon-
gitudinal parent study presented in detail previously [Jespers et al., 2014]. After 
screening	and	consenting,	this	first	study	visit	was	scheduled	soon	after	the	last	
day (day 9 ± 2 days) of the menstrual period. 
Study site Study group n Prevalence of vaginal GBS (95% CI)
Mombasa, Kenya Reference group 110 20.2 (13.7–28.7)
Mombasa, Kenya Pregnant women 30 14.3 (5.7–31.5)
Mombasa, Kenya Adolescents 30 3.6 (0.6–17.7)
Kigali, Rwanda FSW 30 20.0 (9.5–37.3)
Kigali, Rwanda HIV+ women 30 0.0 (0.0–11.4)
Johannesburg, SA Reference group 109 23.2 (16.2–31.9)
Johannesburg, SA Pregnant women 30 10.0 (3.5–25.6)
Johannesburg, SA Adolescents 30 0.0 (0.0–11.4)
Johannesburg, SA Vaginal practices 31 25.8 (13.7–43.2)
TABLE 10 Study population and vaginal GBS carriage rates. 
FSW, female sex workers
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 Ethical committee Written information and consent forms in the local lan-
guage were provided to the women or Legally Authorized Representatives for 
their review. After the interview, the participants and, in case they were of mi-
nor age (age below 18 in Kenya and South Africa and below 21 in Rwanda), the 
parents	or	guardians	were	asked	to	confirm	their	willingness	to	participate	in	
the study by signing (or thumb-printing in case they were illiterate) the con-
sent form. The protocol was approved by the Kenyatta National Hospital Ethi-
cal Review Committee, Kenya; the Human Research Ethics Committee (Medical), 
University of the Witwatersrand, RSA; the Rwanda National Ethics Committee, 
Rwanda; the Institutional Review Boards of the Institute of Tropical Medicine 
in Antwerp, of Ghent University, and of the University Teaching Hospital in Ant-
werp, Belgium. In addition, the study was approved by the National Council on 
Science and Technology in Kenya; the RSA Department of Health; and the Na-
tional AIDS Control Commission in Rwanda. The study is registered at the Trial 
Registration at the National Health Research Ethics Council South Africa with 
the number DOH2709103223. 
 Collection of samples	 Two	sterile	Copan	flocked®	swabs	(CopanDiagnostics,	
Inc., Murrieta, CA) were brought into the vaginal vault by the study clinician, ro-
tated against the vaginal wall at the midportion of the vault, gently dipped in 
the posterior fornix and carefully removed to prevent contamination with the 
microbes of the vulva and introitus. The swab heads were collected into two 1.5 
ml	cryovials,	labeled	and	immediately	frozen	at	-80	°C	until	shipment.	
For cervicovaginal lavage (CVL) samples, 10 ml normal saline at room tem-
perature	was	flushed	using	a	sterile	pipette	over	the	cervix	and	the	lateral	vag-
inal	walls.	This	fluid	was	aspirated	from	the	posterior	fornix	using	the	same	pi-
pette and collected in a 15 ml Falcon tube and immediately transported in a 
cooled	box	(2–8°C)	to	the	laboratory	for	processing.	At	the	laboratory,	CVL	pro-
cessing was started within one hour after sample collection. CVLs were centri-
fuged	at	1,000g	for	10	minutes	at	4°C	and	the	supernatant	stored	at	-80°C	until	
shipment.
 Shipment of samples Cryovials with the vaginal swab heads and CVLs were 
placed	in	a	dry	shipper,	which	was	filled	with	liquid	nitrogen	according	to	the	
manufacturer’s instructions. The dry shippers were sent to the central laborato-
ry at the Institute of Tropical Medicine (ITM) in Antwerp, Belgium, using a tem-
perature-monitor to guarantee maintenance of the cold chain.
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 Extraction and purification of DNA For the quantitative PCR (qPCR) assays, 
DNA extraction from the two Copan swabs of each subject was performed by 
thawing the swabs at room temperature for 30 minutes. After adding 1200 µL 
of diluted PBS, each swab was gently vortexed for 15 seconds, and 1 mL of each 
swab	suspension	was	pooled	into	a	final	volume	of	2	mL.	An	aliquot	of	250	µL 
was extracted using the Abbott m24sp automated extraction platform (Abbott, 
Maidenhead, UK), according to the manufacterer’s instructions, and 200 µl of 
eluted	DNA	was	stored	at	-80	°C.
 GBS-specific qPCR To detect and quantify GBS in vaginal swab DNA extracts, a 
GBS-specific	qPCR	was	carried	out	as	described	previously	[Cools et al., 2016]. 
Briefly,	the	qPCR	reactions	were	performed	in	a	final	volume	of	10	µl, contain-
ing 5 µl	of	LightCycler	480®	SYBR	Green	I	Master	(Roche	Applied	Science,	Basel,	
Switzerland), 0.5 µM of both forward Sip1 (5’-ATCCTGAGACAACACTGACA-3’) 
and reverse primer Sip2 (5’-TTGCTGGTGTTTCTATTTTCA-3’), 0.3 µM of probe 
(5’- 6FAM-ATCAGAAGAGTCATACTGCCACTTC–TAMRA-3’) (Eurogentec, Liège, Bel-
gium) and 2 µl of DNA extract or 2 µl of HPLC water (as negative template con-
trol).	Cycling	conditions	were	as	follows:	95	°C	for	5	min;	40	cycles	of	95	°C	for	
10	s,	58	°C	for	15	s	and	72	°C	for	20	s.	Amplification,	detection	and	quantifica-
tion	were	carried	out	using	the	LightCycler480	platform	and	the	LightCycler®	
480 Software Version 1.5 (Roche, Basel, Switzerland). Concentrations were ex-
pressed as bacteria/ml and log transformed.
 Quantification of cytokines and elafin	 Quantification	of	 the	concentrations	
of the cytokines IL-1α, IL-1β, IL-6, IL-8 and IL-12, MIP-1β, interferon (IFN)-γ–in-
duced protein (IP-10), granulocyte-macrophage colony-stimulating factor (GM-
CSF), granulocyte colony-stimulating factor (G-CSF) in CVL samples was done 
using the Bio-Plex™ human cytokine assay kit (Bio-Rad Laboratories NV-SA, 
Nazareth,	Belgium),	elafin	was	measured	by	ELISA	kits	from	R&D	Systems	(Min-
neapolis, MN), and IL-1RA was measured using the Meso Scale Discovery (MSD) 
multiplex platform and Sector Imager 2400 (MSD, Gaithersburg, MD). All mea-
surements were performed according to the manufacturer’s instructions as de-
scribed previously [Kyongo et al., 2015]. Concentrations of immune markers 
were expressed as pg/mL and log transformed.
 Data analysis Women with a positive qPCR result for GBS were consid-
ered	GBS	carriers.	Correlations	of	the	concentrations	of	GBS	and	the	different	
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cytokines/elafin	were	investigated	by	calculating	the	Spearman	correlation	co-
efficients,	with	p-values	<	0.05	indicating	significance.
A multivariate analysis of variance (MANOVA) was performed to simultane-
ously	 compare	 the	means	of	 all	 cytokines	and	elafin	between	 the	GBS	 carri-
ers	and	the	non-carriers.	Tests	for	mean	differences	between	these	two	groups	
were	based	on	Hotelling’s	Trace	statistic.	If	a	statistically	significant	difference	
was indicated, analysis of variance (ANOVA) was carried out for cytokines or 
elafin	separately.	All	analyses	were	performed	using	SPSS	software	version	22	
(SPSS Inc.).
9.3 Results
A total of 595 women were screened and 430 were enrolled in the study. De-
tails on screening, screening failure and enrolment have been reported previ-
ously [Jespers et al., 2014]. Of the 430 women enrolled, 424 women were an-
alysed by qPCR for vaginal GBS colonization. Overall, 69 of the 424 women 
(16.3%) were found positive for vaginal GBS carriage. The prevalences in the 
different	study	groups	are	presented	in	Table	10.	Details	on	associations	of	GBS	
carriage and sociodemographic characteristics, reproductive health, sexual be-
haviour, vaginal practices, cervicovaginal signs and symptoms, and genital tract 
infections have been presented previously [Cools et al., 2016].
MANOVA	analysis	showed	that	there	were	statistically	significant	differences	
in the immune parameters in the CVLs of the women carrying GBS versus the 
women not carrying GBS vaginally (F (11,412) = 2,240, p<0.05). The results of 
the	different	ANOVAs	are	presented	 in	Table	11.	Women	colonized	with	GBS	
had higher cervicovaginal concentrations of IL-8 (log10 concentration 2.41 pg/
mL versus 2.14 pg/mL), IL-12 (log10 concentration 0.26 pg/mL versus 0.13 pg/
mL) and IP-10 (log10 concentration 2.81 pg/mL versus 2.53 pg/mL) compared to 
non-colonized women. 
The Spearman correlations – only providing a measure of linear associations 
and not suited to show logaritmic or other non-linear assocations – between 
the	concentrations	of	the	different	cytokines/elafin	and	GBS	are	shown	in	Ta-
ble	12.	GBS	loads	were	significantly	positively	correlated	with	concentrations	
of IL-8 (rs = 0.161), IP-10 (rs = 0.134), IL-12 (rs = 0.130), IL-1 (rs = 0.101) and IL-6 
(rs = 0.097).
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GBS positive (n=69) GBS negative (n=355) ANOVA
mean SD mean SD F p
IL-1α 1.41 0.500 1.39 0.641 0.064 0.801
IL-1β 1.19 0.788 0.99 0.753 3.726 0.054
IL-1Ra 4.73 0.472 4.71 0.542 0.065 0.799
IL-6 1.05 0.658 0.91 0.613 2.733 0.099
IL-8 2.41 0.658 2.14 0.547 12.967 <0.001
IL-12 0.26 0.303 0.13 0.371 8.213 0.004
Elafin 5.22 0.437 5.10 0.535 3.126 0.078
G-CSF 2.07 0.621 1.98 0.641 1.237 0.267
GM-CSF 0.36 0.400 0.30 0.410 1.514 0.219
IP-10 2.81 0.606 2.53 0.727 8.882 0.003
MIP-1β 1.01 0.667 0.87 0.579 3.423 0.065
TABLE 11 Mean log10 concentrations (pg/mL) of the different cytokines and elafin  
 in the GBS carrier group versus the non-carrier group.  
 ANOVAs are presented with their F value and p value.  
 Bold: significant at the 0.05 level.
IL-1β 0.101                    
GM-CSF 0.083 0.197                  
IL-1α 0.014 0.532 0.196                
IL-6 0.097 0.701 0.202 0.209              
IL-8 0.161 0.743 0.257 0.434 0.602            
IL-12 0.130 0.569 0.238 0.310 0.514 0.561          
G-CSF 0.064 0.646 0.189 0.224 0.799 0.560 0.476        
IP-10 0.134 0.150 0.247 0.184 0.221 0.365 0.277 0.300      
MIP-1β 0.076 0.558 0.159 0.049 0.668 0.546 0.550 0.568 0.248    
Elafin 0.069 0.073 0.102 0.219 -0.008 0.187 0.102 0.174 0.391 -0.037  
IL-1RA 0.024 0.331 0.172 0.402 0.088 0.361 0.380 0.152 0.205 0.080 0.295
  GBS IL-1β GM-CSF IL-1α IL-6 IL-8 IL-12 G-CSF IP-10 MIP-1β Elafin
TABLE 12 Spearman correlation of the cytokines and GBS. 
 Bold, p<0.05; grey; GBS, Group B Streptococcus; IL-1β, Interleukin-1β; GM-CSF,  
 granulocyte- macro phage colony-stimulating factor; IL-1α, Interleukin-1α; IL-6,  
 Interleukin-6; IL-8, Interleukin-8; IL-12, Interleukin-12; G-CSF, Granulocyte colony- 
 stimulating factor; MIP-1β, Macrophage inflammatory protein-1β; elafin; IL-1RA,  
 Interleukin-1 receptor antagonist.
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9.4 Discussion
We assessed the immune correlates of vaginal GBS colonization and found that 
concentrations of IL-8, IL-12 and IP-10 in CVLs of women who were vaginal-
ly	colonized	with	GBS	were	significantly	elevated	compared	to	non-colonized	
women, and these concentrations correlated with vaginal GBS concentrations 
as determined by qPCR. 
IL-8 was elevated in GBS carriers and correlated with GBS loads
IL-8 is a potent chemotactic and activating factor for neutrophils, which re-
spond to pathogens through phagocytosis, production and release of reactive 
oxygen species and antimicrobial peptides. Epithelial cells of the female repro-
ductive tract (FRT), in addition to providing a physical barrier for protection, are 
immunologically active cells and act as key initiators of innate and adaptive im-
munity by secreting cytokines such as IL-8 [Agrawal et al., 2009]. There is gen-
eral	consensus	that	the	number	of	neutrophils	in	the	different	FRT	tissues	is	de-
pendent on IL-8 [Weissenbacher et al., 2014]. Although IL-8 has been shown to 
be the major chemoattractant secreted by epithelial cells of the FRT, GM-CSF 
has been shown to work synergetically with IL-8 in the chemoattraction of neu-
trophils [Shen et al., 2004]. 
Numerous in vitro studies have shown that GBS induced IL-8 transcription 
or IL-8 expression after stimulation of human vaginal epithelial cells, lung epi-
thelial cells, cord/neonatal/adult blood mononuclear cells, neutrophils, mono-
cytes, macrophages, placental trophoblasts, decidual cells and brain endotheli-
al cells [Patras et al., 2013; Doran et al., 2002; Berner et al., 2002; Griesinger et 
al., 2001; Dudley et al., 1997; Kwak et al., 2000; Doran et al., 2003; Mikamo et 
al., 2004; Albanyan et al., 2000; De Francesco et al., 2008; Berner et al., 2002; 
Sagar et al.,	2013].	IL-8	production	has	been	shown	to	differ	significantly	after	
stimulation	with	different	GBS	serotypes	and	genotyes	and	to	elicit	significant-
ly more IL-8 from adult monocytes compared to cord monocytes [Mikamo et al., 
2004; De Francesco et al., 2008; Rowen et al., 1995].
Functionally, GBS-induced IL-8 has been shown to induce neutrophil migra-
tion across human brain microvascular endothelial cells [Doran et al., 2003]. 
GBS serotype III-induced secretion of IL-8 by neutrophils did not result in in-
gestion of GBS nor did it trigger superoxide production [Albanyan et al., 2000].
Despite these in vitro	findings,	 the	only	clinical	study	carried	out	 thus	 far	
documented that IL-8 was not elevated in the maternal and fetal plasma of 
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women (recto)vaginally colonized with GBS compared to non-carriers [Mitch-
ell et al., 2013]. 
Our	 study	 confirms	 the	 above-mentioned	 in vitro	 findings.	 Although	 the	
cross-sectional study design of our study does not allow mechanistic infer-
ences regarding GBS colonization and the observed cytokine patterns, the fact 
that IL-8 is readily released by many cell types upon stimulation by GBS, not in 
the least by vaginal epithelial cells [Patras et al.,	2013],	justifies	us	to	hypothe-
size/speculate that the presence of GBS in the cervicovaginal mucosa of these 
women induced IL-8, rather than that GBS was present because of elevated lev-
els of IL-8.
In	 summary,	 although	our	 finding,	 i.e.	 that	GBS	 colonization	 is	 associated	
with	elevated	IL-8	transcription,	seems	to	contradict	the	findings	of	the	only	
other cross-sectional clinical study [Mitchell et al., 2013] carried out thus far, 
they are in agreement with the general notion that the epithelial cells of the 
FRT act as key initiators of innate and adaptive immunity by secreting cytokines 
such as IL-8 [Agrawal et al., 2009], and with numerous in vitro studies indicating 
IL-8	transcription	and	expression	by	different	cell	types	upon	challenge	with	
GBS (see above for relevant references).
In our study, following elevated IL-8 concentrations in the CVLs of the GBS 
carriers, increased neutrophil levels could be expected. However, GBS carriage 
was asymptomatically and not associated with the presence of neutrophils 
[Cools et al.,	 2016].	 Possible,	 although	 significantly	 elevated,	 IL-8	 concentra-
tions in GBS carriers were not high enough to chemoattract neutrophils, as it 
has	been	shown	that	chemotaxis	is	strongly	influenced	by	the	concentration	of	
IL-8 [Lin et al., 2004].
IL-12 and IP-10 were elevated in GBS carriers  
and both correlated with GBS loads
Women	vaginally	colonized	with	GBS	had	significantly	higher	cervicovaginal	
concentrations of IL-12 compared to non-colonized women. Furthermore, in 
GBS	carriers,	 IL-12	concentrations	were	modestly	but	significantly	correlated	
with the GBS concentrations.
IL-12	 is	a	pro-inflammatory	cytokine	 that	 induces	 the	production	of	 IFN-γ 
and	favours	the	differentiation	of	T	helper	1	(TH1) cells [Trinchieri et al., 2003].
In vitro studies have shown that GBS induced IL-12 production in murine 
macrophages, human neonatal lymphocytes, T-cells and NK cells [Peoples et 
al., 2009; Kwak et al., 2000; Derrico et al., 1996]. In human epithelial cells, this 
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production	 differed	 significantly	 upon	 stimulation	 with	 different	 serotypes	
[Mikamo et al., 2004]. Interestingly, GBS-induced IL-12 and IFN-γ production 
by mixed mononuclear cells from cord blood was found to be signifantly less 
compared to production by mixed mononuclear cells from adults [La Pine et 
al., 2003; Martins et al., 2002]. This TH1	type	cytokine	deficiency	was	suggest-
ed to contribute to the enhanced susceptibility of neonates to GBS [La Pine et 
al., 2003].
Different	animal	models	have	documented	the	importance	of	 IL-12	in	pro-
tection of the neonate against GBS infections. In a murine model of neonatal 
GBS sepsis, IL-12 was found to be elevated in the plasma of GBS-infected pups, 
and	pretreatment	with	antibodies	that	neutralized	IL-12	resulted	in	significant-
ly greater mortality and GBS bacteremia [Mancuso et al., 1997]. In contrast, pro-
phylactic	or	therapeutical	administration	of	recombinant	IL-12	was	significant-
ly associated with a lower mortality and a decreased bloodstream replication of 
GBS.	These	beneficial	effects	of	IL-12	were	at	least	partially	explained	by	IL-12	
mediated induction of IFN-γ. 
Likewise, in a murine GBS-induced arthritis model, prophylactic adminis-
tration	of	IL-12	to	infected	mice	was	shown	to	have	beneficial	effects,	mostly	
attributable to the IL-12-induced IFN-γ [Puliti et al., 2002]. In a murine model, 
where GBS was infected peritoneally, the mRNA of IL-12 and IFN-γ, but not of 
TH2 associated cytokines IL-4 and IL-5, was upregulated in spleen cells [Rosati 
et al., 1998].
In our study, the mean log10 concentration of IP-10 in the CVLs of GBS colonized 
women	(2.81	pg/mL)	was	significantly	higher	compared	to	uncolonized	women	
(2.53	pg/mL)	and	these	concentrations	correlated	in	a	significant	manner	with	
the GBS concentrations. 
IP-10 is a pleiotropic cytokine induced by IFN-γ, the TH1 cytokine signature, 
and is capable of exerting potent biological functions in infectious diseases 
[Liu et al., 2011; Holdren et al., 2014]. IP-10 chemoattracts monocytes/macro-
phages, dendritic cells, NK cells, cytotoxic T cells and TH1	cells	towards	inflamed	
and infected sites [Liu et al., 2011; Holdren et al., 2014; Bonecchi et al., 1998; 
Lebre et al., 2005]. 
Only few studies investigated IP-10 in the context of GBS infection. Murine 
macrophages did not produce IP-10 after stimulation with heat-killed GBS [Fan 
et al., 2007]. Interestingly, IP-10 has been shown to be a sensitive early marker 
of late-onset bacterial sepsis and a good predictor of serious bacterial infection 
in general in infants < 4 months of age [Ng et al., 2007; Chen et al., 2011]. 
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Vaginal GBS colonization is associated  
with a TH1-associated cytokine environment
Our observations of elevated concentrations of IL-12 and IP-10 in CVLs of GBS 
colonized women point to a cytokine environment associated with a TH1 re-
sponse, as IL-12 is the main inducer of such a response, and IP-10 is induced by 
IFN-γ,	the	main	effector	cytokine	of	TH1 cells and itself induced by IL-12 [Abbas 
et al., 1996].
Our cross-sectional study design does not allow to infere whether this 
TH1-associated cytokine pattern preceeds or follows vaginal GBS colonization. 
However, there are numerous indications suggesting that a GBS infection induc-
es a TH1 response. First, all above-mentioned cell-culture and mouse models do 
conclude that IL-12 (and IFN-γ) followed GBS infection. Second, other studies 
demonstrated a TH1 response following GBS infection. Total splenocytes from 
mice	infected	with	GBS	produced	a	type	1	proinflammatory	response	inducing	
CD4+	T	cells	 to	differentiate	 into	TH1 cells, which produced large amounts of 
IFN-γ [Clarke et al., 2016]. Similarly, in a mouse model of GBS neonatal sepsis, 
IFN-γ was produced by splenocytes after GBS challenge, and administration of 
recombinant IFN-γ partially restored impaired host defense [Cusumano et al., 
1996]. Concordantly, in vitro and clinical studies reported TH1 (and TH17) re-
sponses against pneumococcal and group A streptococcal infections [Olliver et 
al., 2011; Mortensen et al., 2015]. Interestingly, IFN-γ was found to inhibit the 
intracellular survival of GBS in human umbilical vein endothelial cells, although 
no	cause/effect	relationship	could	be	assessed	[Lione et al., 2014]. 
Taken together, a vast literature of in vitro and animal studies, suggests that 
GBS induces a TH1 reponse that confers protection and the asymptomatic vagi-
nal GBS colonization of the women in our study was associated with a mucosal 
TH1-type cytokine pattern, probably protective and following colonization.
The cervicovaginal mucosal TH1-cytokine environment during vaginal GBS colo-
nization	might	profoundly	influence	the	isotype	of	naturally	acquired	antibod-
ies by isotype switching. Indeed, rectovaginal colonization with GBS has been 
associated	with	significantly	elevated	levels	of	cervicovaginal	and	systemic	IgA	
and IgG [Hordnes et al., 1996], and human naïve B cells have the potential to 
switch	to	any	Ig	isotype	production	under	influence	of	cytokines.	For	instance,	
TH1-related cytokines are suggested to induce IgG1, IgG2 and IgG3 isotypes 
[Abbas et al., 1996; Sousa et al., 1998; Mortensen et al., 2015], which are the 
only isotypes (together with IgG4) that can cross the placenta [Guttormsen et 
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al., 2008; Palmeira et al., 2012; Vidarsson et al., 2014], and maternal/cord serum 
IgG have been linked with neonatal protection against GBS disease [Baker et al., 
1976]. Furthermore, IgG1, IgG2, and IgG3 (but not IgG4) are opsonizing antibod-
ies, important for protection against invasive GBS infections. Also, Ig switching 
towards the production of IgA antibodies, which might be important for GBS im-
munity at mucosal sites, is induced by TGF-β but inhibited by TH1 cytokine IFN-γ 
[Macpherson et al., 2008; Trinchieri et al., 2003].
The development of vaccins is one of the main strategies to prevent GBS dis-
ease [Melin et al., 2013]. One of the most important strategies for the develop-
ment	of	effective	new	vaccines	is	the	selection	and	usage	of	a	suitable	adjuvant.	
Immunologic adjuvants are essential for enhancing vaccine potency by im-
provement of the humoral and/or cell-mediated immune response to vaccine 
antigens [Lee S and Nguyen 2015]. Most GBS vaccine studies so far have used 
conjugate vaccins without an adjuvant [Heath et al., 2011]. One study demon-
strated that aluminium hydroxide as an adjuvant did not enhance the immune 
response to a GBS serotype III conjugated vaccine [Paoletti et al., 2001].
Because	IL-12	directs	the	differentiation	of	TH cells to the TH1 phenotype, its 
use as a vaccine adjuvant to promote TH1 responses is of great interest [Romani 
et al.,	1997].	IL-12	has	been	shown	to	enhance	the	efficacy	of	systemic	vaccines	
against bacterial pathogens such as Bordetella pertussis and Listeria monocyto-
genes [Miller et al., 1997; Mahon et al., 1996]. Interestingly, administration of IL-
12 as adjuvant together with tetanus toxoid (TT) at the nasal mucosa not only 
induced	sharp	increases	in	TT-specific	serum	IgG	and	IgA,	but	was	also	shown	
to enhance mucosal IgA [Boyaka et al., 1999], pointing to IL-12 as a promising 
mucosal vaccine adjuvant [Stevceva et al., 2006]. As our results seem to point 
to	a	protecting	effect	of	IL-12	in	controlling	mucosal	colonization	of	GBS,	IL-12	
might be considered as an adjuvans in GBS vaccination.
Our	findings	are	limited	by	the	cross-sectional	design	of	our	study,	but	has	ad-
vantages compared to animal studies. Animal models have undoubtedly im-
proved our understanding of the immune response against GBS, but only a few 
murine models studied the vaginal mucosal immune response against GBS [Pa-
tras et al., 2015; Patras et al., 2013; Carey et al., 2014]. However, like many oth-
er pathogens, strains of S. agalactiae isolated from human infections appear 
to be adapted to their human host [Lindahl et al., 2005], reducing the value 
of animal models. For instance, most human GBS isolates have important vir-
ulence factors such as surface proteins ScpB, Lmb, and IgA-binding beta pro-
tein, that are not present in strains isolated from bovine mastitis. Moreover, the 
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C5a peptidase of GBS may degrade human C5a but not mouse C5a [Lindahl et 
al., 2005]. Importantly, the composition of murine vaginal microbial communi-
ty	differs	substantially	from	that	of	the	human	vagina	[Barfod et al., 2013], nor-
mally dominated by lactobacilli. Furthermore, the murine vagina has a neutral 
pH	and	not	the	characteristic	low	pH	of	the	human	vagina	[Yano et al., 2011], 
shown to be important in GBS adherence to epithelial cells [Tamura et al., 1994].
In conclusion, in populations at the highest need for better prevention mea-
sures to control rectovaginal GBS colonization and GBS neonatal disease, as-
ymptomatic vaginal colonization was associated with elevated CVL levels of 
IL-8 and Th1-associated cytokines IL-12 and IP-10. This might have important 
consequences in our understanding of the mucosal immune reactions against 
GBS	and	for	current	and	future	vaccination	efforts.
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Summary and  
future perspectives
— CHAPTER 10
10.1 Objective 1 
To assess the prevalence of vaginal GBS  
and E. coli carriage	in	different	populations	 
from sub-Saharan Africa
Background
Sub-Saharan Africa (SSA) has the highest rates of neonatal sepsis mortality 
worldwide. However, epidemiological data on GBS and E. coli vaginal carriage 
– the main risk factors for early-onset sepsis (EOS) – are very limited, although 
they are necessary to design and implement EOS prevention strategies [Capan, 
2012;	Stoll	and	Schuchat	1998].	Therefore,	the	first	objective	of	this	thesis	was	
to assess the prevalence of vaginal GBS and E. coli	in	different	populations	from	
SSA.
How did we study this?
A total of 430 women from Mombasa (Kenya), Kigali (Rwanda) and Johannes-
burg (South Africa (SA)) were recruited during 2010–2011 (Table 13). To cap-
ture	different	relevant	populations	groups,	these	women	were	recruited	into	
different	predefined	study	groups:	
 » A group of reference women (adult, non-pregnant, HIV-negative women at av-
erage risk of HIV)
 » Pregnant women (up to 14 weeks of gestational age as determined by abdomi-
nal ultrasound at recruitment)
 » Adolescents (16–17 years)
 » Female sex workers (self-acknowledged)
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 » HIV-positive women (on antiretroviral treatment for at least 6 months, asymp-
tomatic and with a CD4 count of more than 350 cells/µl)
 » Women engaging in vaginal practices (HIV-negative women who use cloth, 
lemon juice, or detergents to clean, dry or tighten the vagina on a regular basis)
Vaginal carriage of GBS and E. coli was assessed by collecting vaginal swabs and 
detecting GBS and E. coli using quantitative polymerase-chain reaction (qPCR) 
in vaginal swab DNA extracts.
TABLE 13 Vaginal GBS and E. coli carriage rates.
Group City, Country n
GBS prevalence % 
(95% CI)
E. coli prevalence % 
(95% CI)
Reference group Mombasa, Kenya 110 20.2 (13.7–28.7) 25.0 (17.8–33.9)
Johannesburg, SA 109 23.2 (16.2–31.9) 27.1 (19.6–36.2)
Pregnant women Mombasa, Kenya 30 14.3 (5.7–31.5) 14.3 (5.7–31.5)
Johannesburg, SA 30 10.0 (3.5–25.6) 33.3 (19.2–51.2)
Adolescents Mombasa, Kenya 30 3.6 (0.6–17.7) 28.6 (15.3–47.1)
Johannesburg, SA 30 0.0 (0.0–11.4) 13.3 (5.3–29.7)
FSW Kigali, Rwanda 30 20.0 (9.5–37.3) 70.0 (52.1–83.3)
HIV+ women Kigali, Rwanda 30 0.0 (0.0–11.4) 20.0 (9.5–37.3)
Vaginal practices Johannesburg, SA 31 25.8 (13.7–43.2) 30.0 (16.7–47.9)
 
What were our major findings?
Vaginal GBS carriage rates
 » Vaginal carriage rates in reference groups from Kenya and SA were 20.2% (95% 
CI, 13.7–28.7%) and 23.1% (95% CI, 16.2–31.9%).
 » The pregnant women in our study population had vaginal GBS carriage rates 
of 14.3% and 10.0% in Kenya and SA, respectively. In chapter 7, we discuss 
the observed lower prevalences compared to most other studies in SSA (see 
Table 14). 
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TABLE 14 Studies reporting (recto)vaginal GBS carriage rates in SSA.
Country Year n Population % GBS Sample Detection Reference
Nigeria 1980 588 P, L 19 V SB+C [Onile, 1980]
Nigeria 1983 225 P 20 V SB+C [Dawodu, 1983]
Zimbabwe 1990 89 P 31 V SB+C [Nathoo, 1990]
Togo 1991 106 P 4 V, R SB+C [David-Prince, 1991]
Gambia 1994 136 P 22 V, R SB+C [Suara, 1994]
Malawi 2005 97 P 16.5 V, R SA [Dzowela, 2005]
Mozambique 2008 113 P 1.8 V, R SB+C [de Steenwinkel, 2008]
Tanzania 2009 300 P 23.0 V, R SB+C [Joachim, 2009]
Zimbabwe 2010 780 P 47, 24, 21# V, R SB+C [Mavenyengwa, 2010]
Malawi 2011 1840 P, HIV+ and HIV- 21.2 V, R SB+C [Gray, 2011]
South Africa 2014 661, 621, 595, 521$ P 33.0, 32.7, 28.7, 28.4$ V, R SA [Kwatra, 2014]
DR Congo 2015 509 P 20.2 V SA [Mitima, 2014]
L, women in labor; NP, non-pregnant women; P, pregnant women; V, vaginal swab;  
R, rectal swab; SB+C, selective broth and culturing; SA, selective agar; #week 20, 26,  
and delivery, respectively; $week 20–25, week 26–30, week 31–35, and week 37+, 
respectively.
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TABLE 14 Studies reporting (recto)vaginal GBS carriage rates in SSA.
Country Year n Population % GBS Sample Detection Reference
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Malawi 2005 97 P 16.5 V, R SA [Dzowela, 2005]
Mozambique 2008 113 P 1.8 V, R SB+C [de Steenwinkel, 2008]
Tanzania 2009 300 P 23.0 V, R SB+C [Joachim, 2009]
Zimbabwe 2010 780 P 47, 24, 21# V, R SB+C [Mavenyengwa, 2010]
Malawi 2011 1840 P, HIV+ and HIV- 21.2 V, R SB+C [Gray, 2011]
South Africa 2014 661, 621, 595, 521$ P 33.0, 32.7, 28.7, 28.4$ V, R SA [Kwatra, 2014]
DR Congo 2015 509 P 20.2 V SA [Mitima, 2014]
L, women in labor; NP, non-pregnant women; P, pregnant women; V, vaginal swab;  
R, rectal swab; SB+C, selective broth and culturing; SA, selective agar; #week 20, 26,  
and delivery, respectively; $week 20–25, week 26–30, week 31–35, and week 37+, 
respectively.
 » Adolescents in our study were found to have low GBS carriage rates: 3.6% of 
the Kenyan and 0% of the SA adolescents carried GBS vaginally. Other stud-
ies	report	conflicting	associations	between	age	and	vaginal	GBS	carriage	and	
are discussed in chapter 7.
 » Women engaging in vaginal practices had higher prevalences of vaginal GBS 
carriage and will be discussed in objective 3.
 » In the group of HIV positive women, we did not observe any GBS carriers. 
This group will be discussed in objective 4.
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Vaginal E. coli carriage rates
 » The group of reference women from Kenya and SA had vaginal E. coli carriage 
rates of 25.0% and 27.1%, respectively. In chapter 7, we performed a system-
atic review on global epidemiology of rectovaginal E. coli carriage. Vaginal E. 
coli carriage rates in our references groups were somewhat lower than pooled 
prevalences from Africa (36.0%), but higher than pooled prevalences in Asia 
(5.3%), Europe (13.4%), North America (12.7%) and South America (19.7%). 
 » Compared to their reference groups, pregnant women in our Kenyan and SA 
population had lower (14.3%) and higher (33.3%) prevalences of vaginal E. 
coli carriage, respectively.
 » The FSW study group in Kigali had a very high prevalence of E. coli carriage, i.e. 
70%, and will be discussed further (objective 3).
What do our findings mean?
 » Vaginal carriage rates of GBS are prevalent among pregnant women from Ken-
ya and SA but lower compared to populations from high-income countries. Con-
sidering the lack of implementation of IAP in these countries, other preven-
tion measures to reduce vaginal GBS carriage in pregnant women are urgently 
needed.
 » E. coli is the leading pathogen in EOS among preterm neonates [Stoll, 2011] 
and SSA has the highest rates of preterm births worldwide, with rates as high 
as 14.3% and 17.5% in Eastern and Southern Africa, respectively [Beck et al., 
2010]. Therefore, the high vaginal E. coli carriage prevalences in our pregnant 
populations urgently warrant for prevention measures to reduce these carriage 
rates during pregnancy to reduce transmission hence E. coli EOS.
163
10.2 Objective 2  
To assess the GBS serotype distribution  
in	different	population	of	SSA
Background
Prevention measure to reduce neonatal GBS disease are based on two main 
strategies: intrapartum antibiotic prophylaxis and vaccination, discussed in 
chapter 3. Most GBS vaccines under development aim at eliciting protective 
antibodies against capsular polysaccharides (CPS), of which ten antigenically 
distinct CPS are known [Melin, 2013]. Vaccines under development are sero-
type-specific	but	might	not	be	effective	in	SSA	populations	because	of	different	
serotype distribution [Johri et al., 2006]. Only a few studies have documented 
on GBS serotype distributions of vaginal isolates in SSA. Therefore, the second 
objective	of	this	thesis	was	to	assess	the	GBS	serotype	distribution	in	different	
population of SSA.
How did we study this?
Of all women in our study, we collected vaginal swabs and inoculated these 
on TMBplus culture plates, after 24–72h of anaerobic incubation, all biological 
material	was	harvested,	frozen	at	–	80	°C	and	shipped	to	the	Institute	of	Trop-
ical Medicine, Antwerp, Belgium. Of all women found positive for vaginal GBS 
carriage as assessed by qPCR (see objective 1), we inoculated Limbroth culture 
bottles with the harvested and frozen biological material. We performed multi-
plex PCR directly on DNA extracts of these Limbroth cultures in order to deter-
mine to capsular serotype. 
What were our major findings?
 » In Kenya and SA, the most prevalent serotypes were Ia (27.3% and 34.5%, 
respectively), V (27.3% and 34.5%, respectively), and III (22.7% and 13.8%, 
respectively) (Table 15).
 » In Rwanda, we found Ia (83.3%) and II (16.7%) to be most prevalent, but abso-
lute	numbers	were	too	small	to	make	significant	conclusions.
 » Overal GBS serotypes Ia, II, III, IV, V, VI, VII and VIII were prevalent.
 » GBS serotypes Ib and IX were not prevelant.
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In	 chapter	7,	we	discuss	different	 factors,	 such	as	 the	use	of	molecular	 tech-
niques,	that	might	account	for	observed	differences	in	our	population	and	other	
populations from SSA.
TABLE 15 Studies reporting GBS serotype distribution of (recto)vaginal isolates in SSA.
Country Year Population Ia Ib II III IV V VI VII VIII IX NT Reference
The Gambia 1994 P 19 28 6 3 38 [Suara, 1994]$
Malawi 2011 P, HIV+, HIV- 18.2 6.2 10.3 39.0 0.3 23.9 0.8 0.8 1.5 [Gray, 2011]
SA 2011 P 30.1 6.7 11.3 37.3 3.7 10.2
[Madzivhandila, 
2011]
SA 2014 P 36.2–41.4 3.5–4.6 7.2–7.5 31.3–34.9 2.0–4.0 10.3–15.6 0.0–3.3 [Kwatra, 2014]
Kenya 2015 P, NP 27.3 22.7 27.3 13.6 4.5 4.5 [Cools, 2016]
Rwanda 2015 NP 83.3 16.7 [Cools, 2016]
SA 2015 P, NP 34.5 10.3 13.8 31.0 6.9 3.4 [Cools, 2016]
P, pregnant; NP, non-pregnant; $determined serotypes I-VI  
(no differentiation between Ia and Ib); N/A, not applicable (review)
TABLE 16 GBS serotype distribution of (recto)vaginal isolates in Europa and the US.
Region Year Ia Ib II III IV V VI VII VIII IX NT Reference
Europe 2010 18.2 12.4 14.4 28.1 3.7 14.9 0.6 0.6 0.6 [Ippolito, 2010]
US 2010 26.8 8.1 10.9 24.8 1.0 15.0 0.3 0.0 0.2 [Ippolito, 2010]
Data from a systematic review
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In	 chapter	7,	we	discuss	different	 factors,	 such	as	 the	use	of	molecular	 tech-
niques,	that	might	account	for	observed	differences	in	our	population	and	other	
populations from SSA.
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SA 2015 P, NP 34.5 10.3 13.8 31.0 6.9 3.4 [Cools, 2016]
P, pregnant; NP, non-pregnant; $determined serotypes I-VI  
(no differentiation between Ia and Ib); N/A, not applicable (review)
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Region Year Ia Ib II III IV V VI VII VIII IX NT Reference
Europe 2010 18.2 12.4 14.4 28.1 3.7 14.9 0.6 0.6 0.6 [Ippolito, 2010]
US 2010 26.8 8.1 10.9 24.8 1.0 15.0 0.3 0.0 0.2 [Ippolito, 2010]
Data from a systematic review
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What do our findings mean?
 » Currently, vaccines in clinical trials phase II target serotypes Ia, Ib, and III (tri-
valent vaccine) or serotype III (monovalent vaccine). Assuming equal transmis-
sion	rates	of	GBS	serotypes	from	mother	to	fetus/neonate	and	100%	efficacy	of	
vaccines, in our Kenyan population, immunoprophylaxis with the trivalent and 
monovalent vaccine would not be protective in 50.0% and 77.3% of cases, re-
spectively. These percentages are even higher in our SA study population, i.e. 
55.2% and 89.7%.
 » Compared populations from Europe and the US (Table 16), we found relatively 
high	prevalences	of	serotypes	IV,	VI,	VII	(shown	for	this	first	time	in	SSA)	and	VIII	
in the Kenyan and SA population (VI, 13.6%; VII, 4.5%; VIII 4.5% in Kenya, and 
IV, 13.8%; VI, 6.9%; VIII, 3.4% in SA), but did not detect any serotype Ib, with 
prevalences of 8.1% and 12.4% in the US and Europe, respectively [Ippolito et 
al., 2010]. This might warrant development of protein based vaccines that are 
not	serotype	specific	and	cover	all	GBS	strains.
10.3 Objective 3  
To determine risk factors for vaginal GBS  
and E. coli carriage in populations from SSA 
Background
Efforts	to	prevent	EOS,	i.e.	IAP	and	development	of	vaccines,	have	been	focus-
ing mainly on GBS and high-income countries [Melin, 2013]. Vaccines are still 
under development and both IAP and vaccination strategies have their draw-
backs,	discussed	in	chapter	3.	IAP	is	not	effective	against	E. coli EOS, LOS, and 
other adverse perinatal outcomes related to GBS [Regan et al., 1996; Ohlsson et 
al., 2014]. Furthermore, to our knowledge, national guidelines for IAP are lack-
ing	in	SSA	countries,	and	might	be	difficult	to	implement.	In	a	large	randomized	
controlled trial, the use of the wide-spectrum microbicide chlorhexidine as an 
alternative	prevention	measure	has	been	shown	to	have	no	effect	on	the	verti-
cally transmission of GBS (55% and 54% transmission rate in the chlorhexidine 
and control group, respectively) [Cutland et al., 2009]. 
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Therefore, the third objective of this thesis was to identify risk factors for vag-
inal GBS and E. coli carriage that can be implemented in public health recom-
mendations or interventions to reduce neonatal sepsis.
How did we study this?
Risk factors for GBS and E. coli	 carriage	were	 identified	using	 logistic	 regres-
sion analysis. The variables investigated were sociodemographic factors, sex-
ual behavior, reproductive history, vaginal practices, vaginal signs and symp-
toms, and microbial characteristics other than GBS and E. coli (see Tables 4 and 
5 in Chaper 7).
What were our major findings?
Independent risk factors for vaginal GBS carriage
 » Recent vaginal intercourse (AOR, 2.63; 95% CI, 1.35–5.15; p=0.005) Women 
who	had	recent	vaginal	sex,	defined	as	the	morning	or	evening	before	the	study	
visit, were more than twice as likely to carry GBS vaginally than women who 
did	not.	Other	papers	reporting	conflicting	results	on	the	relationship	between	
vaginal GBS carriage and sexual behavior, and the argumentation why we think 
that vaginal intercourse only induces a brief temporal colonization of the vagi-
na are discussed in chapter 7.
 » Vaginal washing (AOR, 2.26; 95% CI, 1.16–4.37; p=0.016) Women engaging 
in the practice of washing inside the vagina were more than twice as likely to be 
colonized with GBS compared to women not washing inside the vagina.
Independent risk factors vaginal E. coli carriage
 » working as a FSW (AOR, 7.83; 95% CI, 2.88–21.30; p<0.001) Women who 
were self-acknowledged sex workers were nearly eight times as likely to carry E. 
coli vaginally. We could not explain this high prevalence in this study group by 
any of the sexual behavioral or other parameters assessed. In chapter 7, we dis-
cuss why we hypothesize that unreported anal intercourse is not unlikely to, at 
least partly, explain these observations. 
 » cervical ectopy (AOR, 1.64; 95% CI, 1.01–2.68; p=0.046) Twenty two percent 
of women without cervical ectopy were E. coli carriers as opposed to 35.2% of 
women with cervical ectopy. 
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Vaginal carriage of GBS and E. coli were positively associated
Importantly, we found that the two major causes of EOS, i.e. GBS and E. coli, 
were independent risk factors for one another (AOR, 2.05; 95% CI, 1.09–3.83; 
p=0.025).
Vaginal carriage of GBS and/or E. coli were independently associated with dis-
turbances of the vaginal microbiome and C. albicans. Vaginal pH was not asso-
ciated with vaginal presence of GBS 
 » GBS was negatively associated with bacterial vaginosis as assessed by Nugent 
score (AOR, 0.43; 95% CI, 0.21–0.88; p=0.022). 
 » E. coli was positively associated with an intermediate Nugent score (AOR, 2.61; 
95% CI, 1.15–5.94; p=0.023)
 » GBS was independently and positively associated with the vaginal Candida al-
bicans as assessed by qPCR (AOR, 3.25; 95% CI, 1.50–7.06; p=0.003).
 » GBS was not associated with vaginal pH.
Studies	confirming	or	not	confirming	these	findings	are	discussed	in	chapter	7.
What do these findings mean?
 » In	populations	suffering	from	the	highest	burden	of	neonatal	sepsis	and	intra-
partum maternal sepsis, prevention of maternal GBS and E. coli carriage might 
be accomplished by advocating behavioral changes such as abstinence of sexu-
al intercourse and vaginal washing during late pregnancy, e.g. via counseling in 
family planning facilities.
 » Inclusion of vaginal carriage of C. albicans, E. coli and GBS and of the presence of 
cervical ectopy in a risk- and/or screening-based administration of IAP should 
be explored. 
 » The screening for E. coli itself also merits further investigation because of its 
role as a major EOS causative agent for which currently no prevention measures 
are taken, nor in low-income, nor in high-income countries [Stoll et al., 2011]. In 
this context, the presence of cervical ectopy – a risk factor for vaginal E. coli car-
riage – should be further investigated.
 » We found a higher vaginal pH and absence of lactobacilli not related to high-
er carriage rates of GBS, which contradicts other report [Leclair et al., 2010; Le 
Doare and Heath 2013; Kubota et al., 2002].
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10.4 Objective 4  
To determine to which extent HIV infection  
in women is associated with rectovaginal  
GBS carriage by means of systematic review  
and meta-analysis
Background
SSA	remains	the	most	heavily	HIV	affected	region	with	67%	of	the	global	bur-
den [Kilmarx, 2009]. HIV infection in women has been associated with in-
creased rates of genital tract infections [Vandepitte et al., 2012; Umeh et al., 
2010; Weiss et al., 2001]. Therefore, we wanted to assess to which extent HIV 
women in our study population were at risk for vaginal GBS colonization. 
In our study population of HIV positive women, we found that none of these 
women	was	vaginally	colonized	with	GBS.	This	was	a	significant	finding	in	uni-
variate analysis, but not after correcting for antibiotic use. Indeed, most of the 
HIV positive women (26/30) received prophylactic cotrimoxazole - largely ef-
fective against GBS [Joachim et al., 2009]- and which is a probable explana-
tion for our observations of the lack of GBS positive women in our HIV-positive 
group but leaving us with unresolved issues. Therefore, our fourth objective 
was to clarify to which extent HIV infection in women is associated with rec-
tovaginal GBS carriage by means of systematic review and meta-analysis.
How did we perform this systematic review and meta-analysis?
We searched the MEDLINE, Web of Science, and EMBASE databases for bib-
liographic references using all combinations of search terms listed in columns 
A and B below.
A B
Streptococcus agalactiae, S. agalactiae, Group B 
Streptococcus, GBS, Group B streptococci, early-onset 
disease, early-onset sepsis, late-onset disease, late-
onset sepsis, neonatal sepsis, neonatal septicemia, 
neonatal pneumonia, neonatal meningitis
Human	immunodeficiency	virus,	
HIV, HIV-1, AIDS
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We included studies that assessed the association between rectovaginal GBS 
colonization and HIV-status in adult women. We only included studies that re-
ported	a	sample	size	and	a	measure	of	effect	for	the	associations	assessed,	or	
did provide the data to calculate the latter. 
Studies were scored for quality and risk of bias using a study quality apprais-
al tool, based on the Newcastle-Ottawa Scale [Wells et al., 2013]. We compared 
the odds of rectovaginal GBS carriage in HIV-positive to HIV-negative women, 
using unadjusted counts. 
What were our major findings?
 » Based on thirteen studies, representing a total of 10,105 women, we found no 
significant	association	between	HIV	infection	status	and	rectovaginal	GBS	car-
riage (OR 1.09; 95% CI 0.82–1.44; p=0.55).
 » Most studies had a medium or high risk of bias for study group selection, 
showed lack of adequate statistical power, and did not sample and culture ac-
cording to CDC guidelines for GBS detection. 
 » Heterogeneity among the studies was substantial (I2 = 68.7%), publication 
bias was not unlikely and important possible confounding factors, such as anti-
biotic prophylaxis and bacterial vaginosis, were not taking into account in most 
studies.
What do these findings mean?
 » Most	of	 the	studies	suffered	from	major	 limitations	and	we	consider	the	cur-
rently available evidence weak and call for further study. 
 » Well-designed studies are urgently needed to clarify the relation between 
HIV-positivity and GBS carriership, the most important risk factor for GBS EOS. 
 » These	studies	should	 incorporate	quantitative	and	serotype-specific	 (molecu-
lar) GBS detection methods to clarify if HIV-status is related to vaginal GBS load 
(the risk for EOS increases with heavier vaginal GBS colonization [Verani et al., 
2010]) and to more virulent serotypes.
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10.5 Objective 5  
To determine if neonates born from HIV-infected  
women are at increased risk for GBS EOS and LOS  
by means of systematic review and meta-analysis
Background
Infants born to HIV-infected mothers have increased rates of infectious morbid-
ity and mortality compared to non-exposed infants, even if they remain HIV-un-
infected [Madhi et al., 2011; Epalza et al.,	2010].	Since	the	first	study	reporting	
an increased risk of GBS neonatal sepsis in HIV-exposed neonates [Epalza et al., 
2010],	evidence	for	this	association	has	been	accumulating.	Therefore,	the	fifth	
objective of this thesis was to assess to which extent neonates born to HIV-in-
fected mothers were at increased risk for GBS neonatal disease by means of 
systematic review and meta-analysis.
How did we perform this systematic review and meta-analysis?
We followed the same strategy as summarized in objective 4, exept that for this 
meta-analyses, we compared the odds of GBS neonatal sepsis, GBS EOS and GBS 
LOS in HIV-exposed neonates compared to HIV-unexposed neonates. Neonatal 
HIV-exposure	was	defined	as	neonates	who	were	born	to	HIV-infected	mothers,	
regardless of the neonatal HIV-status at birth.
What were our major findings?
 » Based on outcomes from 64608 births from HIV-infected mothers and 187443 
births from HIV-uninfected mothers, HIV-exposed neonates were more likely 
to have neonatal GBS disease compared to unexposed neonates (OR, 2.39; CI, 
1.31–4.38; p=0.005).
 » When analyzing cases of GBS EOS and GBS LOS separately, this increased risk 
pertained to LOS only. (EOS; OR, 1.31; 95% CI, 0.84–2.04; p=0.240; LOS; OR, 
4.43; 95% CI, 1.81–10.85; p=0.001).
We integrated several factors associated with HIV infection in pregnant wom-
en or mothers into a model that might explain why infants born to HIV-infect-
ed mothers were at increased risk for GBS LOS but not GBS EOS. In the case of 
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GBS EOS, the factors that might increase or decrease the risk for GBS EOS might 
balance out, while in the case of GBS LOS, the net result may be an enhanced 
risk. The model is explained and argued in detail in Chapter 8, and takes into 
account the following parameters, summarized below, that might decrease/in-
crease EOS/LOS (Figure 11):
Factors that might decrease EOS GBS rates in HIV-exposed neonates
 » antibiotic prophylaxis (co-trimoxazole) is widely used in HIV-positive preg-
nant	women	as	recommended	by	the	WHO	[WHO,	2006],	and	is	largely	effec-
tive against GBS [Joachim et al., 2009], consequently likely to be responsible 
for lower GBS rectovaginal carriage rates in HIV-infected pregnant women, and 
consequently might reduce the risk for the GBS EOS but not for the GBS LOS
 » elective caesarean section	 defined	as	a	caesarean	delivery	before	labor	and	
before rupture of membranes, is increasingly used in HIV-infected women be-
cause of proven reduced risk of mother-to-child transmission of HIV [Jamieson 
et al., 2007], and might reduce the risk for EOS as GBS is thought to be mainly 
transmitted in utero after rupture of the membranes.
Factors that might increase LOS GBS disease in HIV-exposed neonates
 » breastfeeding might not be the preferred choice of infant feeding or might 
be stopped early by HIV-positive mothers, because of fear of HIV transmission 
through breast milk, which might lead to a hampered passive antibody-mediat-
ed	protection,	likely	to	have	more	effect	on	the	incidence	of	LOS,	considering	
the fact that most EOS cases are already septic at birth or become septic short-
ly after birth. 
Factors that might increase EOS and LOS GBS rates in HIV-exposed neonates
 » immune dysfunction and perturbations contributed to HIV infection has 
been shown in HIV-exposed neonates and HIV-infected mothers. Protective an-
tibodies are reduced in both mother and neonates (even at 16 weeks) [Dangor 
et al., 2015; Le Doare et al., 2015], and transplacental transfer of protective anti-
bodies and hematopoietic cytokines is reduced in HIV-infected mothers [Epalza 
et al., 2010; Dangor et al., 2015; Le Doare et al., 2015], lower antibody-mediated 
complement	fixation	in	HIV-infected	mothers	[Le	Doare et al., 2015].
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FIGURE 13
 » antiretroviral therapy is used to prevent mother-to-child transmission of HIV, 
but nucleoside reverse transcriptase inhibitors crossing the placenta might be 
responsible for decreased immune cell counts in HIV-exposed uninfected in-
fected infants [Epalza et al., 2010].
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Factors that might increase or decrease GBS EOS rates in HIV-exposed neonates
 » rectovaginal GBS carriage is the single most important risk factor for GBS EOS, 
if not, a prerequisite. The extent to which HIV infection is associated with rec-
tovaginal GBS carriage, is discussed in detail in chapter 8 and summarized in 
objective 4.
What do these findings mean?
 » The evidence that HIV-exposed infants are at increased risk for GBS LOS is con-
vincing and accumulating. 
 » Public health interventions, especially in SSA, where the burden of HIV and neo-
natal sepsis is the highest, are urgently needed. 
10.6 Objective 6  
To characterize the vaginal mucosal cytokine pattern  
associated with asymptomatic vaginal GBS carriage
Background
Most current GBS vaccines aim to protect the fetus or neonate against neona-
tal GBS disease by immunoglobuline G (IgG) transferred transplacentally from 
maternal serum [Kasper et al., 1996; Heath et al., 2016]. However, fetal IgG con-
centrations increase with gestational age [Boyer et al., 1984] and might not be 
high enough to protect premature newborns, at high risk for EOS [Hordnes et al., 
1996]. 
Vaginal	mucosal	immunity	to	GBS	is	an	important	first-line	defense	against	
GBS EOS and some GBS-related adverse perinatal outcomes, as vaginal coloni-
zation	is	the	first	step	in	pathogenesis	[Simonsen et al., 2014]. Therefore, an op-
timal vaccine should also induce vaginal mucosal immunity [Shen et al., 2000].
However, the human vaginal mucosal immune response to GBS colonization 
of the vaginal tract remains to be elucidated. Cytokine responses to GBS have 
only been characterized using in vitro cell-culture studies and murine models. 
Therefore, or sixth objective was to characterize the vaginal mucosal cyto-
kine pattern associated with vaginal GBS colonization in populations at the 
highest need for better prevention measures against neonatal GBS disease.
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How did we study this?
Cervicovaginal lavage (CVL) samples were obtained from the women in our 
study.	 In	 these	 CVLs,	 the	 concentrations	 of	 different	 cytokines	 (interleukin	
(IL)-1α, IL-1RA, IL-1β, IL-6, IL-8 and IL-12, MIP-1β, interferon (IFN)-γ–induced 
protein (IP-10), granulocyte-macrophage colony-stimulating factor (GM-CSF), 
granulocyte	 colony-stimulating	 factor	 (G-CSF))	 and	elafin	were	measured	by	
means	of	ELISA.	Differences	in	cytokine	patterns	were	analyzed	by	means	of	
MANOVA and ANOVA, and linear correlations between concentrations of GBS in 
carriers	and	the	different	immune	parameters	were	assessed	by	calculating	the	
Spearman correlations.
What were our major findings?
 » IL-8 was elevated in GBS carriers and correlated with GBS loads
IL-8 is a potent chemotactic and activating factor for neutrophils, essential in 
the responce to pathogens. Epithelial cells of the female reproductive tract act 
as key initiators of innate and adaptive immunity by secreting cytokines such 
as IL-8 [Agrawal et al., 2009] and there is general consensus that IL-8 is the ma-
jor	chemoattractant	for	neutrophils	in	the	different	FRT	tissues	[Weissenbach-
er et al., 2014]. Numerous in vitro studies have shown that GBS induced IL-8 
transcription	or	IL-8	expression	after	stimulation	of	different	human	cell	types.	
These studies are discussed in chapter 9.
 » IL-12 and IP-10 were elevated in GBS carriers  
and both correlated with GBS loads
IL-12	is	a	pro-inflammatory	cytokine	that	induces	the	production	of	IFN-γ and 
favours	the	differentiation	of	T	helper	1	(TH1) cells [Trinchieri et al., 2003]. IP-10 
is a pleiotropic cytokine induced by IFN-γ, the TH1 response cytokine signature, 
and chemoattracts monocytes/macrophages, dendritic cells, NK cells, cytotoxic 
T cells and TH1	cells	towards	inflamed	and	infected	sites	[Liu et al., 2011]. 
In vitro	studies	have	shown	that	GBS	induced	IL-12	production	in	different	
human cell types and animal models have documented the importance of IL-12 
in the protection of the neonate against GBS infections. These studies are dis-
cussed in chapter 9.
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What do these findings mean?
 » This	 first	 clinical	 study	 characterizing	 the	 vaginal	mucosal	 cytokine	patterns	
associated	 with	 GBS	 colonization,	 confirms	 findings	 of	 in vitro cell models 
and murine models that document elevated levels of IL-8 and IL-12 after GBS 
challenge. 
 » Our observations of elevated concentrations of IL-12 and IP-10 point to a local 
TH1-associated cytokine environment in asymptomatically vaginally colonized 
with GBS. 
 » This TH1-cytokine environment during vaginal GBS colonization might pro-
foundly	influence	the	isotype	distribution	of	naturally	acquired	antibodies	by	
isotype switching. TH1-related cytokines are important to induce IgG1, IgG2 and 
IgG3 isotypes that can cross the placenta, but inhibit IgA antibodies important 
for	mucosal	immunity.	These	findings	may	be	important	for	the	development	of	
vaccination strategies.
 » IL-12 might be considered as an adjuvans in GBS vaccines, as our results seem 
to	point	to	a	protecting	effect	of	IL-12	in	controlling	mucosal	colonization	of	
GBS and the use of IL-12 as a vaccine adjuvant to promote TH1 responses is of 
great interest [Romani et al., 1997].
10.7 Future perspectives
One million neonates die each year because of neonatal sepsis, and Sub-Saha-
ran	Africa	(SSA)	suffers	from	the	highest	rates	worldwide	[Capan	et al., 2012; 
Stoll et al. 1998; Lawn et al.,	2005].	Early-onset	sepsis	(EOS)	occurs	in	the	first	
week of life while late-onset sepsis (LOS) occurs between week 1 and month 3 
of life [Schuchat et al., 1998]. 
EOS poses unique opportunities for prevention because transfer of a single 
species from the maternal genitourinary tract to the neonate before/during de-
livery is a prerequisite. 
In high-income countries, the leading causes of EOS are Group B Streptococ-
cus (GBS, Streptococcus agalactiae) and Escherichia coli.
Efforts	to	prevent	EOS	in	high-income	countries	have	been	focusing	on	GBS	
only, based on two strategies: the culture-based or risk-based intrapartum anti-
biotic prophylaxis (IAP) and the development of GBS vaccines.
Although the highest rates of neonatal sepsis occur in SSA, there is very lim-
ited epidemiological data on (recto)vaginal carriage rates of GBS and E. coli 
in SSA. These data are necessary to design and implement EOS prevention 
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strategies. In our study population, pregnant women from Kenya and South- 
Africa had vaginal GBS carriage rates of 14.3% and 10.0%, respectively; and 
vaginal E. coli carriage rates of 14.3% and 33.3%, respectively. 
Further research should identify not only document further carriage rates for 
GBS and E. coli	in	different	populations	of	SSA,	but	also	identify	pathogens	re-
sponsible for EOS and LOS. Indeed, in contrast to high-income countries where 
it is well documented that GBS is the most common cause of EOS, while E. coli 
is the most common cause of mortality related to EOS; in SSA, - although GBS 
and E. coli are regarded as major pathogens causing EOS -, there is a lack on 
data on etiological agents. A limited number of studies report that GBS is a ma-
jor cause of EOS but is preceded by E. coli, Klebsiella pneumoniae and Staphylo-
coccus areus [Newton and English 2007; Zaidi et al., 2009]. Future research re-
garding (recto)vaginal organisms and EOS should include these organisms in 
the study protocols. 
Furthermore, the limited number of studies carried out in SSA are hospi-
tal-based. According to UNICEF, most of deliveries in SSA take place at home 
and only half of the pregnant women in SSA in 2015 had skilled attendance at 
birth. Therefore, the target population for future studies on neonatal sepsis in 
SSA should also include pregnant women delivering at home.
IAP has reduced GBS EOS in high-income countries [Schrag, 2000], but it has 
had	no	effect	on	EOS	caused	by	other	pathogens,	GBS	LOS,	and	other	adverse	
perinatal outcomes related to GBS.
In	SSA	settings,	an	IAP	strategy	could	be	considered,	although	in	modified	
form compared to the IAP implemented in many high-income countries. Explor-
ing the possibilities for including not only GBS, but also or only E. coli, K. pneu-
moniae and/or S. aureus should be considered, as the latter pathogens may be 
more important than GBS. 
Studies should document transmission (rates) of E. coli, K. pneumoniae and/
or S. aureus from the maternal vagina and/or rectum to the neonate. These 
studies should use typing techniques, and transmission should not be merely 
based on the detection of the same pathogen in mother and neonate. Longi-
tudinal studies should clarify if a late-gestational (i.e., the time point in preg-
nancy of screening for GBS in high-income countries) positive screening of a E. 
coli, K. pneumoniae or S. aureus is predictive for (recto)vaginal carriage of the 
same pathogen at birth. Furthermore, vaginal sampling, rectal sampling and 
rectovaginal sampling, should be compared to identify optimal sampling tech-
nique	–	if	any	–	for	these	different	pathogens.
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We have shown that vaginal carriage of E. coli, GBS and Candida are posi-
tively	associated,	which	might	offer	unique	opportunities	by	screening	for	the	
three organisms, as a culture-based and risk-based screening would be inter-
twined. For example, a screening positive for E. coli and Candida but negative 
for GBS, would still imply increased odds for GBS carriage.
For IAP strategies to be feasible in resource-limited settings, administration 
of antibiotics other than the intravenous route should be considered.
Vaccination of pregnant women represents an attractive alternative to protect 
neonates against GBS EOS, LOS and GBS-related adverse perinatal outcomes 
[Heath, 2016; Melin, 2013]. Most GBS vaccines under development aim at elic-
iting protective antibodies against capsular polysaccharides (CPS), of which ten 
antigenically	distinct	CPS	are	known	and	offer	only	a	serotype	specific	protec-
tion. Hence, a vaccine suitable for American or European populations may not 
be suitable for populations in SSA. For this reason, data on GBS serotype distri-
butions	in	different	populations	in	SSA	are	urgently	needed.	We	found	that	GBS	
serotypes Ia, V and III were most prevalent, as in most high-income countries, 
whereas serotypes VI, VII and VIII were more prevalent in our study population 
and we did not detect serotype Ib, prevalent in high-income countries. Immuno-
prophylaxis with phase II GBS vaccines would not protect the majority of wom-
en against carriage in our study population. 
All GBS vaccines under current development aim at eliciting maternal serum 
antibodies that protect the fetus or neonate after crossing the placenta [Kasper, 
1996; Heath, 2016]. However, an optimal vaccine should also induce mucosal 
immunity	[Shen,	2000	],	as	transplacental	IgG	is	insufficiently	early	in	gestata-
tion [Hordnes, 1996].
We aimed at elucidating the human vaginal mucosal immune response to 
vaginal GBS colonization because knowledge of protective vaginal mucosal cy-
tokines	in	response	to	GBS	could	provide	a	template	for	the	design	or	refine-
ment	of	more	appropriate	and	effective	vaccines	[Morel	and	Turner	2010].
Our	study	was	the	first	clinical	study	characterizing	the	vaginal	mucosal	cy-
tokine	patterns	associated	with	GBS	colonization,	and	we	confirmed	findings	of	
in vitro cell models and murine models that document elevated levels of IL-8 
and IL-12 after GBS challenge. Our observations of elevated concentrations of 
IL-12 and IP-10 point to a local TH1-associated cytokine environment in wom-
en asymptomatically vaginally colonized with GBS. As our results point to a pro-
tecting	effect	of	IL-12	in	controlling	mucosal	colonization	of	GBS,	IL-12	might	
be considered as an adjuvans in GBS vaccination. 
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In future GBS vaccination trials in SSA, two infections might profoundly in-
fluence	vaccine	efficacy	and	immunogenicity.	Helminths,	multicellular	parasitic	
worms that are highly endemic in SSA, have been shown to confound vaccine ef-
ficacy	[Urban	et al., 2007]. Helminths are potent inducers of a TH2 response and 
it	has	been	shown	that	worm	antigens	induce	amplification	of	the	TH2	response	
to bystander antigens [Elias et al., 2007]. Future trials assessing GBS vaccine ef-
ficacy	in	countries	endemic	for	these	helminthes	should	take	this	into	consider-
ation	and	might	consider	to	overcome	the	possible	effects	of	immunomodula-
tion by helminthes by the use of adjuvants [Elias et al., 2007]. Another infection 
highly	affecting	SSA	is	HIV.	Recently,	it	has	been	shown	in	phase	II	trails	that	GBS	
vaccines were less immunogenic in HIV-infected women compared to HIV-un-
infected women.
Vaccination	trials	so	far	assessed	the	serum	concentration	of	CPS	specific	an-
tibodies.	However,	knowledge	on	the	effect	of	these	vaccines	on	the	concentra-
tion of antibodies and GBS at the vaginal mucosa would allow us to further un-
derstand the mucosal immune response induced by current vaccines. 
Furthermore, vaccination at rectal, vaginal or oral mucosa might be explored 
given	the	possible	protective	benefits	early	in	gestation,	as	GBS	has	also	been	
associated with spontaneous abortion and stillbirth.
In settings where future implementation of IAP and/or vaccination for the pre-
vention of GBS EOS is unlikely and were prevention measure for other EOS re-
lated pathogens such as E. coli are more urgently needed, risk factors for (recto)
vaginal GBS and/or E. coli	carriage	that	are	easily	modifiable	might	be	consid-
ered in prevention strategies that aim to change behavior. Such risk factors 
identified	in	our	study	include	practices	of	intravaginal	washing/douching/dry-
ing, recent sexual intercourse and possibly anal intercourse. Further research 
should explore of behavioral change, e.g. through counselling in family plan-
ning clinics, youth/adolescent centers or health care centers, - if found feasi-
ble - could reduce the (recto)vaginal carriage rate of GBS and/or E. coli in late 
pregnancy. 
We could not assess the role of HIV as a possible risk factor for (recto)vaginal 
carriage of GBS and/or E. coli in our clinical study because nearly all HIV-infect-
ed women were on antibiotic prophylaxis. We therefore conducted a systematic 
review and meta-analysis on the association between HIV-infected women and 
(recto)vaginal GBS carriage; and on the association between neonatal HIV-ex-
posure and GBS EOS / LOS. 
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We did not found an association between HIV infection and rectovaginal car-
riage of GBS, but studies included were poor. Well-designed studies that asses 
the association between HIV-infection in women and (recto)vaginal carriage of 
not only GBS, but also other major pathogens related to neonatal sepsis should 
be performed, and preferable document (recto)vaginal loads. 
We found convincing evidence that HIV exposure of neonates is associat-
ed with higher odds of GBS LOS but not GBS EOS. Health workers in the clini-
cal practice should be aware of these increased risks and health policy mak-
ers should advocate for a better follow-up of neonates born to HIV-infected 
mothers.
The	model	explaining	our	findings	on	the	influence	of	neonatal	HIV	exposure	
and GBS neonatal sepsis integrates breastfeeding, mode of delivery, antibiot-
ic prophylaxis and reduced immune status; and should be further explored to 
identify opportunities to reduce the risk for GBS LOS. Furthermore, given our 
findings	for	GBS,	the	relation	between	HIV-exposure	of	neonates	of	LOS	due	to	
other pathogens than GBS, should be further investigated.
Most studies that investigate GBS and/or E. coli in relation to adverse pregnancy 
outcomes use culture-based techniques for the detection of GBS and/or E. coli 
in (recto)vaginal samples, as do most hospitals were screening-based IAP is im-
plemented to prevent GBS EOS. However, in general, molecular techniques such 
as qPCR and deep-sequencing are increasingly used in a clinical or research set-
ting to detected infections or to study (vaginal) microbiota. Regarding research 
on the vaginal microbiome, deep-sequencing studies are increasingly pub-
lished. These deep-sequencing studies are usually performed to describe the 
vaginal	microbiome	in	different	populations,	but	caution	is	warranted	as	these	
often lack the resolution to detect E. coli and GBS. 
For research, qPCR, possibly in a multiplex format including GBS, E. coli, S. 
aureus, and/or K. pneumoniae	might	be	the	most	cost-effective	technique	for	
studying these species in relation to adverse pregnancy outcomes. 
However,	for	obtaining	data	on	antibiotic	sensitivities	of	the	different	patho-
gens, and for typing studies that document transmission, isolated strains are 
still needed, necessitating culturing. Furthermore, typing of isolates will allow 
to document if certain ‘pathotypes’ of E. coli (and other pathogens) associat-
ed with the cervicovaginal mucosa and/or downstream pathological anatomical 
locations	(such	as	chorion,	amnion,	amniotic	fluid)	exist,	as	is	the	case	for	e.g.	E. 
coli related to urinary tract infections.
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In resource-limited settings, the use of Gram-stained vaginal smears for the 
detection of Gram-positive streptococci (including GBS), Gram-positive staphy-
lococci (including S. aureus), Gram-negative rods (include E. coli and K. pneumo-
niae) and Candida	could	offer	possibilities	to	be	used	in	research	and/or	clinical	
setting.
Regarding adverse pregnancy outcomes, research has mostly focused on EOS. 
However, stillbirth is one of the most common causes of pregnancy loss world-
wide, and in spite of advances in perinatal medicine, an estimated 3.2 million 
cases occur each year [McClure and Goldenberg 2009]. Few studies have shown 
GBS and E. coli as causative organisms in stillbirth. Future longitudinal studies 
should include investigation on the role of infections in stillbirths. 
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